var title_f38_61_39888="Normal male breast";
var content_f38_61_39888=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal male breast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 250px; height: 425px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral MLO views of a normal male breast showing small amount of fatty breast tissue.",
"    <div class=\"footnotes\">",
"     MLO: mediolateral oblique.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_61_39888=[""].join("\n");
var outline_f38_61_39888=null;
var title_f38_61_39889="Patient information: Pulmonary hypertension in adults (The Basics)";
var content_f38_61_39889=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/12/17601\">",
"         Patient information: Heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/5/92\">",
"         Patient information: Heart transplant (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Pulmonary hypertension in adults (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/pulmonary-hypertension-in-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H26908317\">",
"      <span class=\"h1\">",
"       What is pulmonary hypertension?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Pulmonary hypertension is a condition that causes high blood pressure in the blood vessels that carry blood to the lungs. When this happens, the heart has to work harder. This causes people to have trouble breathing and to feel very tired.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26908332\">",
"      <span class=\"h1\">",
"       What are the symptoms of pulmonary hypertension?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The early symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble breathing when moving around",
"       </li>",
"       <li>",
"        Feeling very tired",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Over time, you might get other symptoms, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Swelling of the legs and feet",
"       </li>",
"       <li>",
"        Chest pain",
"       </li>",
"       <li>",
"        Fainting",
"       </li>",
"       <li>",
"        Not feeling hungry",
"       </li>",
"       <li>",
"        Belly pain",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Rare symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Cough",
"       </li>",
"       <li>",
"        Spitting up blood",
"       </li>",
"       <li>",
"        A hoarse voice",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26908347\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The tests depend on your symptoms and any other health problems you might have. You might get 1 or both of the following tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Echocardiogram &ndash; This test uses sound waves to create pictures of your heart.",
"       </li>",
"       <li>",
"        Pulmonary artery catheterization &ndash; This test measures the pressure in the blood vessels that go to your lungs. Your doctor will advance a thin, flexible tube (called a &ldquo;catheter&rdquo;) into a blood vessel in your groin, neck, or shoulder area. The catheter goes to the blood vessels in your heart.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You might also need other tests to find what might be causing your pulmonary hypertension. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A chest X-ray or CT scan (a special kind of X-ray)",
"       </li>",
"       <li>",
"        An ECG &ndash; This test measures your heart&rsquo;s electrical activity",
"       </li>",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Tests to check how well you lungs are working",
"       </li>",
"       <li>",
"        A sleep study &ndash; This test checks your breathing, oxygen level, and other body functions while you are sleeping overnight. These tests can sometimes be done at home, but they are often done in a sleep lab.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26908364\">",
"      <span class=\"h1\">",
"       How is pulmonary hypertension treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include a number of different medicines. Some are injected into the skin or through a tube called an &ldquo;IV.&rdquo; Others are given as pills and include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Diuretics such as",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/14/12518?source=see_link\">",
"         furosemide",
"        </a>",
"        (brand name: Lasix&reg;) &ndash; These medicines help control swelling in the legs and feet.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/2/33830?source=see_link\">",
"         Warfarin",
"        </a>",
"        (brand names Coumadin&reg;, Jantoven&reg;) &ndash; This helps prevent blood clots in the lungs.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor might also have you use extra oxygen, which comes in a metal or plastic cylinder that you can take around with you. The oxygen flows through a tube into two plastic tubes that you put in your nostrils.",
"     </p>",
"     <p>",
"      Some people with pulmonary hypertension are too tired to be very active. But if you can do some activity, walking or other light exercises can be helpful. Check with your doctor before you begin exercising.",
"     </p>",
"     <p>",
"      People with very serious symptoms might need surgery. One option is a special type of heart surgery to make a hole in the heart to ease its workload. The other is a lung transplant or a heart-lung transplant. A transplant is a type of surgery in which a doctor replaces a diseased organ with a healthy one.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26908379\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Pulmonary hypertension is a serious illness. Some cases can&rsquo;t be treated, and for those that can, there is no cure. The disease gets worse over time and is likely to make it hard for you to do everyday things, like bathing and dressing. But medicines and oxygen might make you feel better and live longer. You will need to see your doctor often to check if you need to change the dose of the medicines you take.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26908394\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/12/17601?source=see_link\">",
"       Patient information: Heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/5/92?source=see_link\">",
"       Patient information: Heart transplant (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/61/39889?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17227 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-F5F47B5EFB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_61_39889=[""].join("\n");
var outline_f38_61_39889=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26908317\">",
"      What is pulmonary hypertension?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26908332\">",
"      What are the symptoms of pulmonary hypertension?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26908347\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26908364\">",
"      How is pulmonary hypertension treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26908379\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26908394\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/5/92?source=related_link\">",
"      Patient information: Heart transplant (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_61_39890="Low sodium diet";
var content_f38_61_39890=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Low sodium diet (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/61/39890/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/61/39890/contributors\" id=\"au4766\">",
"       Norman M Kaplan, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/61/39890/contributors\" id=\"au6051\">",
"       Barbara Olendzki, RD, MPH, LDN",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/61/39890/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/61/39890/contributors\" id=\"se5420\">",
"       George L Bakris, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/61/39890/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/61/39890/contributors\" id=\"de7812\">",
"       John P Forman, MD, MSc",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/61/39890?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      LOW SODIUM DIET OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Sodium is an element that is found in many foods as well as water. The body requires a small amount of sodium in the diet to control blood pressure and blood volume. However, most people consume many times the amount of sodium needed. A low sodium diet contains fewer than 2.3 grams (2300 milligrams) of sodium each day. People with certain medical conditions such as high blood pressure, kidney disease, and heart problems can benefit from a diet that is low in sodium.",
"    </p>",
"    <p>",
"     This topic will review how to read food labels, how to choose foods that are low in sodium, and how to live with less salt.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHY SHOULD I REDUCE SODIUM IN MY DIET?",
"     </span>",
"    </p>",
"    <p>",
"     Reducing sodium intake lowers blood pressure in people with high and borderline high blood pressure. Reducing sodium can also help to prevent the collection of fluid in the lower legs or abdomen. People with chronic kidney disease must control sodium intake to prevent volume overload, which increases blood pressure and causes swelling. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/5/13398?source=see_link\">",
"      \"Patient information: Chronic kidney disease (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Decreasing sodium can also assist people who have heart failure. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=see_link\">",
"      \"Patient information: Heart failure (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Switching from a higher sodium diet to a lower sodium diet can modestly reduce blood pressure in people who have normal blood pressure. When the sodium intake is lowered from 4000 mg to 2000 mg per day, blood pressure falls by 2 to 3 mmHg. This reduction may be as great as 10 mmHg over several years and can substantially lower the risk of heart disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Benefits",
"     </span>",
"     &nbsp;&mdash;&nbsp;In addition to directly reducing blood pressure, a lower sodium intake may also enhance the effectiveness of high blood pressure medications and other non-drug treatments, such as weight loss. A lower sodium intake has also been associated with other health benefits, including a reduced risk of dying from a stroke, reversal of heart enlargement, and a reduced risk of kidney stones and osteoporosis. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/53/28499?source=see_link\">",
"      \"Patient information: Kidney stones in adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=see_link\">",
"      \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      WHERE IS SODIUM FOUND?",
"     </span>",
"    </p>",
"    <p>",
"     The main source of sodium in the diet is the salt added to packaged and processed foods, and in foods from restaurants. Processed foods include prepared frozen meals, canned foods, pickled foods, snack foods, lunch meats, cheese, condiments, sauces, dressings, breads, cereals, and soda (including diet soda) just to name a few. Sodium found in processed food accounts for about 80 percent of a person's daily sodium intake in a typical Western diet, and can quickly add up, even without the use of the salt shaker.",
"    </p>",
"    <p>",
"     In addition, many people add more salt to foods; just one teaspoon of table salt contains about 2300 milligrams of sodium, which is more than many people need for the entire day. Most fresh foods (fresh unprocessed meats, fish, vegetables and fruit) have a low sodium content, and can be substituted for foods that are high in sodium.",
"    </p>",
"    <p>",
"     Terms like \"low sodium\" and \"reduced sodium\" can be confusing. The following table provides a guide to what these terms mean (",
"     <a class=\"graphic graphic_table graphicRef61514 \" href=\"mobipreview.htm?1/41/1691\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Guidelines",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several professional organizations have issued evidence-based guidelines for reducing sodium intake. Most clinicians agree that people with high blood pressure should consume less than 2300 milligrams (2.3 grams) of sodium per day. People with other conditions may be advised to consume even less (1500 to 1800 mg per day).",
"    </p>",
"    <p>",
"     The sodium content of packaged, processed, and prepared foods can usually be determined by reading food labels (",
"     <a class=\"graphic graphic_figure graphicRef56605 \" href=\"mobipreview.htm?31/34/32293\">",
"      figure 1",
"     </a>",
"     ) or consulting a reference book. Many websites provide nutrient data (eg,",
"     <a class=\"external\" href=\"file://www.nutrition.gov/\">",
"      www.nutrition.gov",
"     </a>",
"     ), and low sodium cookbooks are also available.",
"    </p>",
"    <p>",
"     It is important to remember that the amount of sodium listed is for a particular serving size; eating more or less than the listed serving size changes the amount of sodium consumed.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      HOW DO I CUT DOWN ON SODIUM?",
"     </span>",
"    </p>",
"    <p>",
"     Although it is difficult to abruptly cut back on the amount of sodium in the diet, most people find that they do not miss the sodium if they cut back gradually. Fresh herbs, spice blends without sodium, citrus and flavored vinegar make tasty alternatives to the salt shaker. Salt is an acquired taste and taste buds can be retrained in less than one to two weeks, if people stick with the lower sodium diet.",
"    </p>",
"    <p>",
"     It may be helpful to keep a detailed food record and add up sodium intake. Within a short period of time (less than a week), the main sources of sodium can be identified and daily intake can be calculated.",
"    </p>",
"    <p>",
"     Suggestions to decrease sodium include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Put away the salt shaker and reduce or eliminate salt in cooking. Experiment with spices, garlic, onions or lemon instead.",
"      </li>",
"      <li>",
"       Look for low sodium products such as spice blends, tomato products, and tuna.",
"      </li>",
"      <li>",
"       Make a list of healthy low sodium foods to substitute. Many groceries now supply this information for their stores.",
"      </li>",
"      <li>",
"       When dining out, request the food be prepared without salt, have dressings or sauces on the side, and avoid bacon bits, cheese, and croutons at the salad bar.",
"      </li>",
"      <li>",
"       Do not add salt to food while cooking or before eating. Teach family members to taste food before adding salt.",
"      </li>",
"      <li>",
"       Avoid eating at fast food restaurants. If this is not possible, choose restaurants that offer fruits or vegetables without sauces or dressings. Ask that no salt be used to prepare food, when possible.",
"      </li>",
"      <li>",
"       Do not use salt substitutes (especially those high in potassium) unless a healthcare provider approves. Herb and spice combinations that are salt-free are widely available and can be used to flavor foods.",
"      </li>",
"      <li>",
"       Water softeners remove calcium and add sodium to drinking water. Do not drink softened water. When purchasing bottled water, check the label to ensure that it does not contain sodium.",
"      </li>",
"      <li>",
"       Look at labels for over the counter medications. Avoid products that contain sodium carbonate or sodium bicarbonate. Sodium bicarbonate is baking soda.",
"      </li>",
"      <li>",
"       Fresh fruits and vegetables are generally low in sodium. In addition, a diet rich in fruits and vegetables provides additional benefits in lowering blood pressure. The DASH diet (Dietary Approaches to Stop Hypertension) is a well known intervention to treat high blood pressure. The DASH diet requires the person to eat four to five servings of fruit, four to five servings of vegetables, and two to three servings of low-fat dairy, and all foods must contain less than 25 percent total fat per serving.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Foods to choose",
"     </span>",
"     &nbsp;&mdash;&nbsp;The following are examples of foods that are generally low in sodium. Check the label to determine the amount of sodium as amounts can vary from one brand to another.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Breads &mdash; Whole grain breads, English muffins, bagels, corn and flour tortillas, most muffins",
"      </li>",
"      <li>",
"       Cereals &mdash; Many cooked low salt (read the label to determine sodium content) hot cereals (not instant) such as oatmeal, cream of wheat, rice, or farina, puffed wheat, puffed rice, shredded wheat",
"      </li>",
"      <li>",
"       Crackers and snack foods &mdash; All unsalted crackers and snack foods, unsalted peanut butter, unsalted nuts or seeds, unsalted popcorn",
"      </li>",
"      <li>",
"       Pasta, rice, and potatoes &mdash; Any type of pasta (cooked in unsalted water), potatoes, white or brown rice",
"      </li>",
"      <li>",
"       Dried peas and beans &mdash; Any cooked dried beans or peas (without seasoning packet), or low salt canned beans and peas",
"      </li>",
"      <li>",
"       Meats and protein &mdash; Fresh or frozen beef, poultry, and fish; low sodium canned tuna and salmon; eggs or egg substitutes",
"      </li>",
"      <li>",
"       Fruits and vegetables &mdash; Any fresh, frozen, or canned fruit, any fresh or frozen vegetables without sauce, canned vegetables without salt, low-salt tomato",
"       <span class=\"nowrap\">",
"        sauce/paste",
"       </span>",
"      </li>",
"      <li>",
"       Dairy products &mdash; Milk, cream, sour cream, non-dairy creamer, yogurt, low-sodium cottage cheese, low sodium cheese, ricotta and mozzarella cheese",
"      </li>",
"      <li>",
"       Fats and oils &mdash; Plant oils (olive, canola, corn, peanut), unsalted butter or margarine",
"      </li>",
"      <li>",
"       Soups &mdash; Salt-free soups and low-sodium bouillon cubes, unsalted broth, homemade soup without added salt",
"      </li>",
"      <li>",
"       Desserts &mdash; Gelatin, sherbet, pudding, ice cream, salt-free baked goods, sugar, honey, jam, jelly, marmalade, syrup",
"      </li>",
"      <li>",
"       Beverages &mdash; Coffee, tea, soft drinks, fruit flavored drinks, low salt tomato juice, any fruit juice",
"      </li>",
"      <li>",
"       Condiments &mdash; Fresh and dried herbs; lemon juice; low-salt mustard (not commercially available but can be made at home), vinegar, Tabasco sauce; low- or no-salt ketchup; seasoning blends that do not contain salt",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Foods to avoid",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many foods, especially those that are processed, have a high sodium content. Items that can be substituted for high sodium foods are listed in the following table (",
"     <a class=\"graphic graphic_table graphicRef74448 \" href=\"mobipreview.htm?1/55/1916\">",
"      table 2",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Breads &mdash; Biscuits, prepared mixes (pancake, muffin, corn bread), instant hot cereals, many boxed cold cereals, self-rising flour",
"      </li>",
"      <li>",
"       Crackers and snack foods &mdash; Salted crackers and snack items (chips, pretzels, popcorn), regular peanut butter, prepared",
"       <span class=\"nowrap\">",
"        dips/spreads,",
"       </span>",
"       salted nuts or seeds",
"      </li>",
"      <li>",
"       Pasta, rice, and potatoes &mdash; Macaroni and cheese mix; rice, noodle, or spaghetti mixes; canned spaghetti; frozen lasagna; instant potatoes; seasoned potato mixes",
"      </li>",
"      <li>",
"       Beans and peas &mdash; Beans or peas prepared with ham, bacon, salt pork, or bacon grease; all canned beans",
"      </li>",
"      <li>",
"       Meats and proteins &mdash; Salted, smoked, canned, spiced, and cured meat, poultry or fish; bacon; ham; sausage; lunch meats; hot dogs; breaded frozen meat, fish, or poultry; frozen dinners; pizza",
"      </li>",
"      <li>",
"       Fruits and vegetables &mdash; Regular canned vegetables and vegetable juices, regular tomato sauce and tomato paste, olives, pickles, relishes, sauerkraut, frozen vegetables in butter or sauces, crystallized and glazed fruit, maraschino cherries, fruit dried with sodium sulfite",
"      </li>",
"      <li>",
"       Dairy products &mdash; Buttermilk, Dutch processed chocolate milk, processed cheese slices and spreads, cottage cheese, aged or natural cheese",
"      </li>",
"      <li>",
"       Fats and oils &mdash; Prepared salad dressings, bacon, salt pork, fat back, salted butter or margarine",
"      </li>",
"      <li>",
"       Soups &mdash; Regular canned or prepared soups, stews, broths, or bouillon; packaged and frozen soups",
"      </li>",
"      <li>",
"       Desserts &mdash; Packaged baked goods",
"      </li>",
"      <li>",
"       Beverages &mdash; Softened water; carbonated beverages with sodium or salt added; regular tomato juice (V-8); ask about alcoholic beverages",
"      </li>",
"      <li>",
"       Condiments &mdash; Table salt, lite salt, bouillon cubes, meat extract, taco seasoning, Worcestershire sauce, tartar sauce, ketchup, chili sauce, cooking sherry and wine, onion salt, mustard, garlic salt, soy sauce, tamari, meat flavoring or tenderizer, steak and barbecue sauce, seasoned salt, monosodium glutamate (MSG), Dutch processed cocoa",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804456616\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20923919\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/19/41266?source=see_link\">",
"      Patient information: Low-sodium diet (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/35/28212?source=see_link\">",
"      Patient information: Chronic kidney disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/42/21155?source=see_link\">",
"      Patient information: Swelling (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/37/30290?source=see_link\">",
"      Patient information: High blood pressure in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/40/36483?source=see_link\">",
"      Patient information: Diabetes and diet (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/41/36499?source=see_link\">",
"      Patient information: Medicines for heart failure (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/1/25619?source=see_link\">",
"      Patient information: Hemodialysis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/22/11619?source=see_link\">",
"      Patient information: Preparing for hemodialysis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/43/16051?source=see_link\">",
"      Patient information: Peritoneal dialysis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/2/18467?source=see_link\">",
"      Patient information: Dialysis and diet (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/57/27539?source=see_link\">",
"      Patient information: High blood pressure emergencies (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/55/43889?source=see_link\">",
"      Patient information: Diabetes insipidus (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/4/11331?source=see_link\">",
"      Patient information: When your lungs fill with fluid (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/62/9188?source=see_link\">",
"      Patient information: Medicines for chronic kidney disease (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20924090\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/5/13398?source=see_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=see_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/53/28499?source=see_link\">",
"      Patient information: Kidney stones in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=see_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42679?source=see_link\">",
"      Diet in the treatment and prevention of hypertension",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24120?source=see_link\">",
"      Salt intake, salt restriction, and essential hypertension",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Medline Plus",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/002415.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/002415.htm",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.heart.org/HEARTORG/Conditions/HighBloodPressure/PreventionTreatmentofHighBloodPressure/Shaking-the-Salt-Habit_UCM_303241_Article.jsp\">",
"      www.heart.org/HEARTORG/Conditions/HighBloodPressure/PreventionTreatmentofHighBloodPressure/Shaking-the-Salt-Habit_UCM_303241_Article.jsp",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Kidney Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.kidney.org/atoz/atozItem.cfm?id=175\">",
"      www.kidney.org/atoz/atozItem.cfm?id=175",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?38/61/39890/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/61/39890?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39890/abstract/1\">",
"      He FJ, MacGregor GA. How far should salt intake be reduced? Hypertension 2003; 42:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39890/abstract/2\">",
"      Appel LJ, Espeland MA, Easter L, et al. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Intern Med 2001; 161:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39890/abstract/3\">",
"      He FJ, MacGregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev 2004; :CD004937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39890/abstract/4\">",
"      Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f38_61_39890=[""].join("\n");
var outline_f38_61_39890=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           LOW SODIUM DIET OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHY SHOULD I REDUCE SODIUM IN MY DIET?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           WHERE IS SODIUM FOUND?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           HOW DO I CUT DOWN ON SODIUM?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/34/32293\" title=\"figure 1\">",
"           Nutrition label sodium PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/41/1691\" title=\"table 1\">",
"           Sodium terms PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/55/1916\" title=\"table 2\">",
"           High low sodium foods PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f38_61_39891="Papaverine: Pediatric drug information";
var content_f38_61_39891=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"37\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Papaverine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?37/2/37923?source=see_link\">",
"    see \"Papaverine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/20/7492?source=see_link\">",
"    see \"Papaverine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antimigraine Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vasodilator",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12675523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Peripheral arterial catheter patency: Full-term neonates: Add 30 mg preservative-free papaverine to an admixture of 250 mL NS or",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS with heparin 1 unit/mL; infuse via peripheral arterial catheter at &le;1 mL/hour (see Heparin). A double-blind, placebo-controlled trial of 141 neonates (median GA: 27 weeks; median birth weight: 910-952 g) demonstrated prolonged functionality of peripherally inserted arterial catheters (Griffin, 2005).",
"     <b>",
"      Note:",
"     </b>",
"     Due to the risk of IVH, the use of papaverine in preterm neonates &lt;3 weeks is not recommended (Griffin, 2005); further studies are needed.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/2/37923?source=see_link\">",
"      see \"Papaverine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Arterial spasm: I.M., I.V.: 1.5 mg/kg 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peripheral arterial catheter patency: Add 30 mg papaverine to an admixture of 250 mL NS or",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS with heparin 1 unit/mL (Heulitt, 1993); infuse via peripheral arterial catheter; some centers report infusions at &le;1 mL/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Migraine prophylaxis: Children and Adolescents 6-15 years: Oral: Initial: 5 mg/kg/day given once daily; range: 5-10 mg/kg/day divided into 2-3 doses/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 75-300 mg 3-5 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral, sustained release: 150-300 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V.: 30-120 mg every 3 hours as needed",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F206334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 30 mg/mL (2 mL, 10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F206320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer after or with meals, milk or antacids to decrease nausea; swallow sustained release capsule whole, do not crush or chew",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Rapid I.V. administration may result in arrhythmias and fatal apnea; administer slow I.V. over 1-2 minutes",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F206377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with LR.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Iohexol 64.7%, iopamidol 61%, iothalamate sodium 60%, phentolamine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ioxaglate meglumine 39.3%, ioxaglate sodium 19.6%.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1054684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect from heat or freezing; do not refrigerate injection; solutions should be clear to pale yellow; precipitates with LR",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of peripheral and cerebral ischemia associated with arterial spasm; investigationally for prophylaxis of migraine headache; intracavernosal injection for impotence",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7280343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Papaverine may be confused with pamidronate",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F206376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias (with rapid I.V. use), flushing, mild hypertension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, malaise, sedation, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distress, anorexia, constipation, diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cirrhosis, hepatic hypersensitivity, hepatitis (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea (with rapid I.V. use)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to papaverine or any component; complete atrioventricular block; Parkinson's disease",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with glaucoma; administer I.V. slowly and with caution since arrhythmias and apnea may occur with rapid I.V. use; should",
"     <b>",
"      not",
"     </b>",
"     be used in neonates due to the increased risk of drug-induced cerebral vasodilation and possibility of an intracranial bleed",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F206329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F206331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13801078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have not been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver enzymes; intraocular pressure in glaucoma patients",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Smooth muscle spasmolytic producing a generalized smooth muscle relaxation including vasodilatation, GI sphincter relaxation, bronchiolar muscle relaxation, and potentially a depressed myocardium",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Oral: Rapid",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapid in the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: &sim;54%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 30-120 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily as metabolites in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/20/7492?source=see_link\">",
"      see \"Papaverine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dizziness, flushing, headache; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1054696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Evidence of therapeutic value of systemic use for relief of peripheral and cerebral ischemia related to arterial spasm is lacking",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Further studies are needed to determine the benefit of adding papaverine (60 mg/500 mL) to arterial catheter infusions containing NS or",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS and heparin 1 unit/mL. One investigation showed a lower risk of arterial catheter failure and longer duration of arterial catheter function in patients 7 months to 5.5 years of age who received papaverine in their arterial catheter solutions; these results should be verified by additional studies before the addition of papaverine to arterial catheter solutions can be recommended.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Griffin MP and Siadaty MS, \"Papaverine Prolongs Patency of Peripheral Arterial Catheters in Neonates,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2005, 146(1):62-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/61/39891/abstract-text/15644824/pubmed\" id=\"15644824\" target=\"_blank\">",
"        15644824",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heulitt MJ, Farrington EA, O'Shea TM, et al, &ldquo;Double-Blind, Randomized, Controlled Trial of Papaverine-Containing Infusions to Prevent Failure of Arterial Catheters in Pediatric Patients,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1993, 21(6):825-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/61/39891/abstract-text/ 8504648 /pubmed\" id=\" 8504648 \" target=\"_blank\">",
"        8504648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sillanp&auml;&auml; M and Koponen M, &ldquo;Papaverine in the Prophylaxis of Migraine and Other Vascular Headache in Children,&rdquo;",
"      <i>",
"       Acta Paediatr Scand",
"      </i>",
"      , 1978, 67(2):209-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/61/39891/abstract-text/343489/pubmed\" id=\"343489\" target=\"_blank\">",
"        343489",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12678 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-41.78.124.10-D68EE5DB58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_61_39891=[""].join("\n");
var outline_f38_61_39891=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054688\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12675523\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054681\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206334\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206320\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054691\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206377\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054684\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054690\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7280343\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206376\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054695\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054680\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299820\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206329\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206331\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13801078\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054687\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054679\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054693\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054694\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054686\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054696\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12678\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12678|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/2/37923?source=related_link\">",
"      Papaverine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/20/7492?source=related_link\">",
"      Papaverine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_61_39892="Pramoxine and hydrocortisone: Drug information";
var content_f38_61_39892=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pramoxine and hydrocortisone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/24/22916?source=see_link\">",
"    see \"Pramoxine and hydrocortisone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Analpram E&trade;;",
"     </li>",
"     <li>",
"      Analpram HC&reg;;",
"     </li>",
"     <li>",
"      Epifoam&reg;;",
"     </li>",
"     <li>",
"      Pramosone E&trade;;",
"     </li>",
"     <li>",
"      Pramosone&reg;;",
"     </li>",
"     <li>",
"      ProCort&reg;;",
"     </li>",
"     <li>",
"      ProctoFoam&reg; HC;",
"     </li>",
"     <li>",
"      Zypram&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F212421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pramox&reg; HC;",
"     </li>",
"     <li>",
"      Proctofoam&trade;-HC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F212433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anesthetic/Corticosteroid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F212424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inflammatory conditions:",
"     </b>",
"     Topical/rectal: Apply to affected areas 3-4 times/day. If clinical improvement is not seen within 2-3 weeks after initiating treatment or if condition worsens, product should be discontinued.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F212425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F212408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Aerosol, foam, rectal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ProctoFoam&reg; HC: Pramoxine hydrochloride 1% and hydrocortisone acetate 1% (10 g)",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Aerosol, foam, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epifoam&reg;: Pramoxine hydrochloride 1% and hydrocortisone acetate 1% (10 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: Pramoxine hydrochloride 1% and hydrocortisone acetate 1% (30 g); pramoxine hydrochloride 1% and hydrocortisone acetate 2.5% (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Analpram Advanced&trade; Kit: Pramoxine hydrochloride 1% and hydrocortisone acetate 2.5% (1s) [kit includes Analpram HC&reg; cream (4 g x 30), diosmiplex (Vasculera&trade;) tablets, AloeClean&trade; wipes, and applicators]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Analpram Advanced&trade; Kit: Pramoxine hydrochloride 1% and hydrocortisone acetate 2.5% (1s) [kit includes Analpram HC&reg; cream (30 g), diosmiplex (Vasculera&trade;) tablets, AloeClean&trade; wipes, and applicator]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Analpram E&trade;: Pramoxine hydrochloride 1% and hydrocortisone acetate 2.5% (4 g, 30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Analpram HC&reg;: Pramoxine hydrochloride 1% and hydrocortisone acetate 1% (4 g, 30 g); pramoxine hydrochloride 1% and hydrocortisone acetate 2.5% (4 g, 30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pramosone&reg;: Pramoxine hydrochloride 1% and hydrocortisone acetate 1% (30 g, 60 g); pramoxine hydrochloride 1% and hydrocortisone acetate 2.5% (30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pramosone E&trade;: Pramoxine hydrochloride 1% and hydrocortisone acetate 2.5% (30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ProCort&reg;: Pramoxine hydrochloride 1.15% and hydrocortisone acetate 1.85% (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zypram&trade;: Pramoxine hydrochloride 1% and hydrocortisone acetate 2.35% (30 g) [contains benzyl alcohol, propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Analpram-HC&reg;: Pramoxine hydrochloride 1% and hydrocortisone acetate 2.5% (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pramosone&reg;: Pramoxine hydrochloride 1% and hydrocortisone acetate 1% (60 mL, 120 mL, 240 mL); pramoxine hydrochloride 1% and hydrocortisone acetate 2.5% (60 mL, 120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pramosone&reg;: Pramoxine hydrochloride 1% and hydrocortisone acetate 1% (30 g); pramoxine hydrochloride 1% and hydrocortisone acetate 2.5% (30 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F212396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Cream",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F212411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical cream, lotion, ointment: Apply a thin film to clean, dry skin and rub in gently.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rectal foam: Use the applicator provided by manufacturer; the aerosol container should not be placed in the rectum; for local application the foam can be placed on a tissue first and then gently rubbed into affected area.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F212410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F212440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pramosone&reg; may be confused with predniSONE",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F212431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F212414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pramoxine, hydrocortisone, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F212399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: Systemic absorption of topical corticosteroids may cause hypothalamic-pituitary-adrenal (HPA) axis suppression (reversible) particularly in younger children. HPA axis suppression may lead to adrenal crisis. Risk is increased when used over large surface areas, for prolonged periods, or with occlusive dressings.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use may result in fungal or bacterial superinfection; discontinue if dermatological infection persists despite appropriate antimicrobial therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sensitization: Topical use has been associated with local sensitization (redness, irritation); discontinue if sensitization is noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F212430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F212403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F212405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F212416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies. Rectal use of pramoxine and hydrocortisone for the treatment of hemorrhoids in the third trimester of pregnancy was not shown to affect birth weight (Ebrahimi, 2011). Also refer to Hydrocortisone (Topical)  monograph.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13383353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to Hydrocortisone (Topical)  monograph.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F212415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Analpram-HC Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-1% (30 g): $127.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-2.5% (30 g): $127.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Analpram-HC Singles Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-1% (4 g): $10.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-2.5% (4 g): $10.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Hydrocortisone Ace-Pramoxine Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-1% (30 g): $83.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-1% (4 g): $5.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Pramosone E External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-2.5% (28.4 g): $90.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Pramosone External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-1% (28.4 g): $95.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-2.5% (28.4 g): $95.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (ProCort Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.85-1.15% (60 g): $199.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Epifoam External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-1% (10 g): $54.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Proctofoam HC Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-1% (10 g): $88.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Novacort External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-1-1% (29 g): $116.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Analpram Advanced Combination)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-1% (1): $127.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Analpram E Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-1 &amp; 1% (1): $120.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Hydrocortisone Ace-Pramoxine Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-1 &amp; 1% (1): $80.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Analpram-HC Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-2.5% (59 mL): $127.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Pramosone External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-1% (118 mL): $186.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-2.5% (59 mL): $119.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Pramosone External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-1% (28.4 g): $93.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-2.5% (28.4 g): $93.29",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F212417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Epifoam (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Prasone (TW);",
"     </li>",
"     <li>",
"      Proctofoam (GB);",
"     </li>",
"     <li>",
"      Proctofoam HC (IL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13383354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F212413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ebrahimi N, Vohra S, Gedeon C, et al, \"The Fetal Safety of Hydrocortisone-Pramoxine (Proctofoam-HC) for the Treatment of Hemorrhoids in Late Pregnancy,\"",
"      <i>",
"       J Obstet Gynaecol Can",
"      </i>",
"      , 2011, 33(2):153-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/61/39892/abstract-text/21352635/pubmed\" id=\"21352635\" target=\"_blank\">",
"        21352635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/61/39892/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10068 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7ADB670DEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_61_39892=[""].join("\n");
var outline_f38_61_39892=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212420\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212421\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212433\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212424\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212425\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212408\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212396\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212411\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212410\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212440\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212431\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212414\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212399\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212430\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212403\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212405\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212416\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13383353\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212415\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212417\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13383354\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212413\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10068\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10068|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/24/22916?source=related_link\">",
"      Pramoxine and hydrocortisone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_61_39893="Overview of vasectomy";
var content_f38_61_39893=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of vasectomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/61/39893/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/61/39893/contributors\">",
"     Theodore J Ongaro, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/61/39893/contributors\">",
"     Christopher J Cutie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/61/39893/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/61/39893/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/61/39893/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/61/39893/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/61/39893/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 23, 2009.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasectomy is the most effective available mode of male contraception. The procedure involves interruption or occlusion of the vas deferens, and is typically performed in an outpatient setting under local anesthesia.",
"   </p>",
"   <p>",
"    Worldwide, in 2004 almost 43 million men had undergone vasectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/1\">",
"     1",
"    </a>",
"    ]. Slightly more than one half million vasectomies were performed in the United States (US) in 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/2\">",
"     2",
"    </a>",
"    ]. Approximately 79 percent of vasectomies in the US were performed by urologists, 13 percent by family practitioners, and 8 percent by general surgeons. Procedure costs range from $350 to $1,000, which is below costs associated with long-term pharmacologic contraception or female sterilization procedures.",
"   </p>",
"   <p>",
"    The most common sterilization procedure for women, tubal ligation, requires entering the peritoneal cavity to access the fallopian tubes, and is usually performed under general anesthesia. Compared to tubal ligation, vasectomy is safer, less costly, and has a significantly shorter post-procedure recovery time. Nonetheless, worldwide, tubal ligation is performed five times more often than vasectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/3\">",
"     3",
"    </a>",
"    ]. This suggests lower acceptance of vasectomy, which may be attributed to a variety of reasons, including misperceptions of the procedure and its side effects.",
"   </p>",
"   <p>",
"    Reported rates of successful infertility for vasectomy exceed 98 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], though data are limited by lack of long-term follow-up. Most studies report outcomes only within two years of the procedure, and might not account for subsequent failures due to later recanalization.",
"   </p>",
"   <p>",
"    This topic will present an overview of vasectomy, and will discuss patient selection, and preoperative and postoperative considerations for the primary physician. The technique of vasectomy is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44712?source=see_link\">",
"     \"Vasectomy and other vasal occlusion techniques for male contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough preoperative discussion is important, as is true for any surgical procedure, and should review the risks, complications, and long-term effects associated with vasectomy.",
"   </p>",
"   <p>",
"    The primary clinician should discuss the procedure with the patient prior to arranging the referral. This initial discussion should provide information about the nature of the procedure and alternative contraceptive options, and address patient expectations and questions.",
"   </p>",
"   <p>",
"    The discussion between patient and referring clinician should review:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contraception method(s) used, and patient understanding of alternatives",
"     </li>",
"     <li>",
"      Patient understanding that the procedure results in permanent sterility",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Social/family",
"      </span>",
"      status: whether in stable relationship, number and ages of children (if any), acceptance of procedure by partner, future family intent",
"     </li>",
"     <li>",
"      Patient understanding of the need for interim contraception for a minimum of three months, and semen analysis prior to assuming sterility",
"     </li>",
"     <li>",
"      Need for ongoing use of condoms to protect against sexually transmitted infections if not in a committed monogamous relationship",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW OF PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasectomy is typically performed with local anesthesia in the physician's clinic or in an outpatient surgical center. Vasectomy is not thought to have appreciable effects on sperm production or seminiferous tubule function. This has been confirmed by intratesticular biopsy up to 15 years post-vasectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Conventional vasectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional vasectomy approach involves bilateral small scrotal incisions to visualize and mobilize the vas deferens. A portion of the vas is removed and the resulting end or ends are occluded by electrocautery fulguration and",
"    <span class=\"nowrap\">",
"     sutures/clips.",
"    </span>",
"   </p>",
"   <p>",
"    This",
"    technique now accounts for only a small proportion of vasectomies performed in the US (18 percent in 1995) but remains the most common technique used in other regions of the world [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44712?source=see_link&amp;anchor=H12#H12\">",
"     \"Vasectomy and other vasal occlusion techniques for male contraception\", section on 'Vasectomy procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     No-scalpel vasectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the no-scalpel technique, a minimal skin puncture is made instead of incisions. This technique has reported lower rates of bleeding and infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44712?source=see_link&amp;anchor=H12#H12\">",
"     \"Vasectomy and other vasal occlusion techniques for male contraception\", section on 'Vasectomy procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Percutaneous vasal occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous methods can be used for injecting chemicals directly into the vas deferens to effect temporary (polymer) or permanent (sclerosing agents) occlusion. Vasal occlusion and vasal injection techniques have been described, but are not in general use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44712?source=see_link&amp;anchor=H2#H2\">",
"     \"Vasectomy and other vasal occlusion techniques for male contraception\", section on 'Methods'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important determinant of postoperative complications is operator experience. Surgeons performing more than 50 vasectomies in a year had one-third the complication rate of those performing fewer than 10 procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bleeding",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hematoma formation",
"     </li>",
"     <li>",
"      Infection",
"     </li>",
"     <li>",
"      Sperm granuloma",
"     </li>",
"     <li>",
"      Post-vasectomy pain syndrome (eg, chronic congestive epididymitis, sperm granuloma, nerve entrapment)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These complications are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44712?source=see_link&amp;anchor=H21#H21\">",
"     \"Vasectomy and other vasal occlusion techniques for male contraception\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Follow-up to confirm sterility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should follow up with the surgeon three months following vasectomy to confirm sterility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. The patient should have had at least 20 ejaculates since the time of vasectomy. The time to achieve azoospermia declines with increasing patient age, and increasing number of ejaculations after vasectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44712?source=see_link&amp;anchor=H27#H27\">",
"     \"Vasectomy and other vasal occlusion techniques for male contraception\", section on 'Follow up to confirm sterility'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Vasectomy failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;If motile sperm are confirmed on two samples one month apart, it is likely the vasectomy has failed. The patient should be advised to have a second procedure and use alternative contraception. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44712?source=see_link&amp;anchor=H26#H26\">",
"     \"Vasectomy and other vasal occlusion techniques for male contraception\", section on 'Vasectomy failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ASSOCIATED MORBIDITY CONCERNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns have been raised over potential links between vasectomy and a variety of unproven health consequences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;A link between vasectomy and atherosclerosis was suggested by a study in monkeys, but this study was later reinterpreted to show no association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/14\">",
"     14",
"    </a>",
"    ]. Several studies in humans have found no increased risk of cardiovascular disease following vasectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prostate cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Earlier studies suggested that there was an increased incidence of prostate cancer in men who had undergone vasectomy up to 20 years earlier. Two systematic reviews of five cohort studies and 9 to 10 case-control studies published before 2000 found that vasectomy was not associated with an increased risk of prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/4,18\">",
"     4,18",
"    </a>",
"    ]. A subsequent large case-control study, including over 900 men with prostate cancer, also found no association between prostate cancer and vasectomy, even after more than 25 years post procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small increased rate of prostate cancer following vasectomy, however, was found in a meta-analysis that included five cohort studies and 17 case-control studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/20\">",
"     20",
"    </a>",
"    ]. There was a 20 percent increase in calculated relative risk for prostate cancer 30 years after vasectomy (RR 1.23, 95% CI 1.11-1.37). The study could not conclude a causal relationship between vasectomy and prostate cancer, or exclude bias. Patients who undergo vasectomy are more likely to be followed by urologists, and are more likely to be screened for prostate cancer as they age.",
"   </p>",
"   <p>",
"    The American Urological Association no longer recommends informing patients of a possible risk for cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Testicular cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large cohort studies have found no increased risk of testicular cancer among vasectomized men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Again, any association between the two is likely to be the result of detection bias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Immune dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasectomy disrupts the",
"    <span class=\"nowrap\">",
"     blood/testis",
"    </span>",
"    barrier, resulting in anti-sperm antibodies in 60 to 80 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/25\">",
"     25",
"    </a>",
"    ]. There is no association between anti-sperm antibodies and other immune-complex mediated diseases, such as lupus erythematosus, scleroderma, or rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/15\">",
"     15",
"    </a>",
"    ]. A large observational study of men who underwent vasectomy an average of thirteen years previously, compared with non-vasectomized men, found no evidence that vasectomy was associated with increased risk for asthma, diabetes mellitus, thyrotoxicosis, multiple sclerosis, myasthenia gravis, inflammatory bowel disease, testicular atrophy, ankylosing spondylitis, or rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Kidney stones",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association has been found between vasectomy and increased risk for kidney stones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. A case control study found a twofold risk for kidney stones in men younger than age 46 (RR 1.9, 95% CI 1.2-3.1) but not for men aged 46 years or older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/27\">",
"     27",
"    </a>",
"    ]. The physiologic mechanism for this increased risk is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     VASECTOMY REVERSAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although vasectomy should be performed only for patients desiring permanent sterility, decisions regarding fertility may change throughout the reproductive years. Vasectomy can be reversed with microsurgical techniques. Vasectomy reversal involves reanastomosis (vasovasostomy) of the reproductive tract, ideally at the site of the previous ligation of the vas deferens. Successful vasectomy reversal has been reported in fifty to seventy percent of men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Rates decline with increasing time between vasectomy and reversal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients must be adequately counseled, and vasectomy should be undertaken only in men who intend to have permanent sterility.",
"   </p>",
"   <p>",
"    Multiple studies have examined the relationship between patient characteristics and the likelihood of a future request for vasectomy reversal. The strongest predictive factor for a vasectomy reversal is a change in marital status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/29\">",
"     29",
"    </a>",
"    ]. Men without children, and men who were older than 30 years at the time of vasectomy, were less likely to request a reversal in the future [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/32\">",
"     32",
"    </a>",
"    ]. There was no correlation between a patient's religion, number of marriages, or occupation, and the probability of a future request for reversal.",
"   </p>",
"   <p>",
"    Key determinant of success and patency of reversal are the method of vasectomy and the duration of obstruction. An effort has been made to prevent irreversible damage at the time of vasectomy. This has led to the development of the open-ended vasectomy. The leaked sperm cause an immune response that may result in a sperm granuloma but reduces the risk of concomitant tubular damage. Sealing the testicular side of the cut end of the vas may result in epididymal damage, and decreased vasectomy reversal success.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large retrospective study found patency rates (sperm present in ejaculate) of &gt;95 percent, and a pregnancy rate of approximately 75 percent, for men who underwent vasectomy less than 3 years prior to reversal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39893/abstract/31\">",
"       31",
"      </a>",
"      ]. Both rates decreased in a linear fashion as the duration of obstruction increased. A patency rate of 71 percent and pregnancy rate of 30 percent was reported for men who underwent vasovasostomy 15 years after vasectomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/25/36242?source=see_link\">",
"       \"Patient information: Vasectomy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/2/29730?source=see_link\">",
"       \"Patient information: Vasectomy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vasectomy is the most effective available mode of male contraception, with infertility rates exceeding 98 percent. Vasectomy is safer, less costly, and has a shorter recovery time than tubal ligation, though is not performed as frequently. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A semen analysis should be collected three or four months following vasectomy, and the patient should have had at least 20 ejaculates since the time of vasectomy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Follow-up to confirm sterility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no firm evidence that vasectomy causes an increase in cardiovascular disease, cancer of the prostate or testes, or immune disorders. There may be an increase in kidney stone formation. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Associated morbidity concerns'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients must understand and accept that vasectomy is a permanent sterilization procedure. Despite counseling, some patients will desire future fertility. Successful reversal is reported in 50 to 70 percent of procedures. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Vasectomy reversal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vasectomy reversal (vasovasostomy) is more successful when performed with shorter time interval of vas obstruction, and is more successful following open-ended vasectomies, in which the testicular end of the vas is fulgurated but not ligated or clipped. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Vasectomy reversal'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/1\">",
"      Peterson HB, Curtis KM. Clinical practice. Long-acting methods of contraception. N Engl J Med 2005; 353:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/2\">",
"      Barone MA, Hutchinson PL, Johnson CH, et al. Vasectomy in the United States, 2002. J Urol 2006; 176:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/3\">",
"      Awsare NS, Krishnan J, Boustead GB, et al. Complications of vasectomy. Ann R Coll Surg Engl 2005; 87:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/4\">",
"      Schwingl PJ, Guess HA. Safety and effectiveness of vasectomy. Fertil Steril 2000; 73:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/5\">",
"      Jamieson DJ, Costello C, Trussell J, et al. The risk of pregnancy after vasectomy. Obstet Gynecol 2004; 103:848.",
"     </a>",
"    </li>",
"    <li>",
"     Sandlow, JI, Winfield, HN, Goldstein, M. Surgery of the scrotum and seminal vesicles. In: Campbell-Walsh Urology, 9th ed, Wein, A, Kavoussi, L, Novick, A, et al (Eds), Saunders, Philadelphia 2000. p.1098.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/7\">",
"      Aradhya KW, Best K, Sokal DC. Recent developments in vasectomy. BMJ 2005; 330:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/8\">",
"      Dassow P, Bennett JM. Vasectomy: an update. Am Fam Physician 2006; 74:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/9\">",
"      Li SQ, Goldstein M, Zhu J, Huber D. The no-scalpel vasectomy. J Urol 1991; 145:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/10\">",
"      Kendrick JS, Gonzales B, Huber DH, et al. Complications of vasectomies in the United States. J Fam Pract 1987; 25:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/11\">",
"      Griffin T, Tooher R, Nowakowski K, et al. How little is enough? The evidence for post-vasectomy testing. J Urol 2005; 174:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/12\">",
"      Hancock P, McLaughlin E, British Andrology Society. British Andrology Society guidelines for the assessment of post vasectomy semen samples (2002). J Clin Pathol 2002; 55:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/13\">",
"      Barone MA, Nazerali H, Cortes M, et al. A prospective study of time and number of ejaculations to azoospermia after vasectomy by ligation and excision. J Urol 2003; 170:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/14\">",
"      Clarkson TB, Alexander NJ, Morgan TM. Atherosclerosis of cynomolgus monkeys hyper- and hyporesponsive to dietary cholesterol. Lack of effect of vasectomy. Arteriosclerosis 1988; 8:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/15\">",
"      Massey FJ Jr, Bernstein GS, O'Fallon WM, et al. Vasectomy and health. Results from a large cohort study. JAMA 1984; 252:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/16\">",
"      Giovannucci E, Tosteson TD, Speizer FE, et al. A long-term study of mortality in men who have undergone vasectomy. N Engl J Med 1992; 326:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/17\">",
"      Coady SA, Sharrett AR, Zheng ZJ, et al. Vasectomy, inflammation, atherosclerosis and long-term followup for cardiovascular diseases: no associations in the atherosclerosis risk in communities study. J Urol 2002; 167:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/18\">",
"      Bernal-Delgado E, Latour-P&eacute;rez J, Pradas-Arnal F, G&oacute;mez-L&oacute;pez LI. The association between vasectomy and prostate cancer: a systematic review of the literature. Fertil Steril 1998; 70:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/19\">",
"      Cox B, Sneyd MJ, Paul C, et al. Vasectomy and risk of prostate cancer. JAMA 2002; 287:3110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/20\">",
"      Dennis LK, Dawson DV, Resnick MI. Vasectomy and the risk of prostate cancer: a meta-analysis examining vasectomy status, age at vasectomy, and time since vasectomy. Prostate Cancer Prostatic Dis 2002; 5:193.",
"     </a>",
"    </li>",
"    <li>",
"     www.auanet.org/about/policy/services.cfm#vasectomy. (Accessed on December 14, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/22\">",
"      M&oslash;ller H, Knudsen LB, Lynge E. Risk of testicular cancer after vasectomy: cohort study of over 73,000 men. BMJ 1994; 309:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/23\">",
"      Hewitt G, Logan CJ, Curry RC. Does vasectomy cause testicular cancer? Br J Urol 1993; 71:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/24\">",
"      Strader CH, Weiss NS, Daling JR. Vasectomy and the incidence of testicular cancer. Am J Epidemiol 1988; 128:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/25\">",
"      Aitken RJ, Parslow JM, Hargreave TB, Hendry WF. Influence of antisperm antibodies on human sperm function. Br J Urol 1988; 62:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/26\">",
"      Goldacre MJ, Wotton CJ, Seagroatt V, Yeates D. Immune-related disease before and after vasectomy: an epidemiological database study. Hum Reprod 2007; 22:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/27\">",
"      Kronmal RA, Krieger JN, Coxon V, et al. Vasectomy is associated with an increased risk for urolithiasis. Am J Kidney Dis 1997; 29:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/28\">",
"      Kronmal RA, Alderman E, Krieger JN, et al. Vasectomy and urolithiasis. Lancet 1988; 1:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/29\">",
"      Hendry WF. Vasectomy and vasectomy reversal. Br J Urol 1994; 73:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/30\">",
"      Sharlip ID. What is the best pregnancy rate that may be expected from vasectomy reversal? J Urol 1993; 149:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/31\">",
"      Belker AM, Thomas AJ Jr, Fuchs EF, et al. Results of 1,469 microsurgical vasectomy reversals by the Vasovasostomy Study Group. J Urol 1991; 145:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39893/abstract/32\">",
"      Potts JM, Pasqualotto FF, Nelson D, et al. Patient characteristics associated with vasectomy reversal. J Urol 1999; 161:1835.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8091 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-708A4DD6E0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_61_39893=[""].join("\n");
var outline_f38_61_39893=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW OF PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Conventional vasectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      No-scalpel vasectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Percutaneous vasal occlusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Follow-up to confirm sterility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Vasectomy failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ASSOCIATED MORBIDITY CONCERNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Testicular cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Immune dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Kidney stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      VASECTOMY REVERSAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/2/29730?source=related_link\">",
"      Patient information: Vasectomy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/25/36242?source=related_link\">",
"      Patient information: Vasectomy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/42/44712?source=related_link\">",
"      Vasectomy and other vasal occlusion techniques for male contraception",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_61_39894="Pathophysiology and prediction of chemotherapy-induced nausea and vomiting";
var content_f38_61_39894=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology and prediction of chemotherapy-induced nausea and vomiting",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/61/39894/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/61/39894/contributors\">",
"     Paul J Hesketh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/61/39894/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/61/39894/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/61/39894/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/61/39894/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/61/39894/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few side effects of cancer treatment are more feared by the patient than nausea and vomiting. Although nausea and emesis (vomiting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    retching) can also result from surgery, opiates, or radiotherapy, chemotherapy-induced nausea and vomiting (CINV) is potentially the most severe and most distressing. Although significant progress has been made with the development of a number of effective and well-tolerated antiemetic treatments, CINV remains an important adverse effect of treatment.",
"   </p>",
"   <p>",
"    The types of emesis, its pathophysiology, and factors predictive for the development of CINV will be reviewed here. The characteristics of the available antiemetic drugs, the management of CINV, and a general approach to the patient are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19208?source=see_link\">",
"     \"Characteristics of antiemetic drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16120?source=see_link\">",
"     \"Approach to the adult with nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF EMESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three distinct types of CINV have been defined: acute, delayed, and anticipatory. Recognizing the differences between these types of CINV has important implications for both prevention and management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Acute emesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute emesis is defined as emesis occurring during the first 24 hours after chemotherapy. In the absence of effective prophylaxis, it most commonly begins within one to two hours of chemotherapy and usually peaks in the first four to six hours. Acute emesis is the most widely studied manifestation of CINV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Delayed emesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emesis occurring more than 24 hours after chemotherapy is classified as delayed. It is best characterized following treatment with high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    . In the absence of antiemetic prophylaxis, delayed emesis after cisplatin peaks at approximately 48 to 72 hours after therapy, then gradually subsides over the next two to three days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/1\">",
"     1",
"    </a>",
"    ]. While the frequency and number of episodes of emesis may be less during the delayed period compared to acute emesis, the delayed form is less well controlled with current antiemetic medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/2\">",
"     2",
"    </a>",
"    ]. Delayed emesis occurs most frequently after cisplatin but can also occur following other agents, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , anthracyclines, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Anticipatory emesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticipatory emesis is a conditioned response in patients who have developed significant nausea and vomiting during previous cycles of chemotherapy. It can be elicited by a variety of stimuli and cognitive activities in association with subsequent cycles of chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/4\">",
"     4",
"    </a>",
"    ]. As antiemetic control during the initial cycle of chemotherapy has progressively improved, anticipatory emesis has become a less significant clinical problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considerable progress has been made in elucidating the mechanisms by which chemotherapy initiates the emetic reflex. This understanding includes both the anatomy and neurotransmitters involved in CINV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Neuroanatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several areas in the central and peripheral nervous systems and gastrointestinal tract are involved in CINV (",
"    <a class=\"graphic graphic_figure graphicRef70638 \" href=\"mobipreview.htm?31/29/32213\">",
"     figure 1",
"    </a>",
"    ). Two areas in the brainstem are thought to play critical roles in the emetic reflex: the vomiting center and the area postrema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The vomiting center is an anatomically indistinct collection of receptor and effector nuclei located in the medulla that coordinates the emetic reflex. This group of neurons has also been called the \"central pattern generator\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. It appears to coordinate the efferent respiratory, gastrointestinal, and autonomic activity associated with nausea and vomiting and functions as the final effector pathway through which a variety of afferent stimuli can activate emesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The area postrema (AP) is a circumventricular structure located at the caudal end of the fourth ventricle. The AP has commonly been called a \"chemoreceptor trigger zone\". It lies outside of the blood-brain barrier and is therefore accessible to emetic stimuli borne either in the blood or cerebrospinal fluid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/7\">",
"       7",
"      </a>",
"      ]. The area postrema appears to be an important source of afferent input to the vomiting center and is an important site for muscarinic (M1), dopamine (D2), serotonin (5-HT3), neurokinin -1(NK1), and histamine (H1) receptors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two other sources of afferent input to the vomiting center with CINV include higher brainstem and cortical structures, which may play a role in anticipatory emesis, and input from the gastrointestinal tract that is conveyed by the vagus and splanchnic nerves, whose afferents terminate in the brainstem in the nucleus tractus solitarius in close proximity to or within the area postrema itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/5,14\">",
"     5,14",
"    </a>",
"    ]. These two areas of the brainstem are referred to collectively as the dorsal vagal complex (",
"    <a class=\"graphic graphic_figure graphicRef70638 \" href=\"mobipreview.htm?31/29/32213\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neurotransmitters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although over 30 neurotransmitters have been associated with the peripheral and central nervous system sites involved in CINV, three neurotransmitters have the most clinical relevance, since therapeutic agents designed to antagonize their action have shown clinical benefit as antiemetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dopamine",
"     </li>",
"     <li>",
"      Serotonin (5-hydroxytryptamine)",
"     </li>",
"     <li>",
"      Substance P",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serotonin (5-HT) received significant attention during the 1980s in preclinical studies attempting to elucidate the mechanisms of CINV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/16\">",
"     16",
"    </a>",
"    ]. These studies led to the development of the type three 5-hydroxytryptamine (5-HT3) receptor antagonists during the early 1990s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/17\">",
"     17",
"    </a>",
"    ], and these drugs have become a mainstay of current antiemetic therapy for CINV. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Substance P became a focus for preclinical studies evaluating the emetic reflex beginning in the 1990s. Substance P binds to the type one neurokinin (NK1) receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/18\">",
"     18",
"    </a>",
"    ], and selective antagonists of the NK1 receptor are potent antiemetics in preclinical models using a variety of emetic stimuli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/19\">",
"     19",
"    </a>",
"    ]. Subsequent clinical trials in CINV led to the development of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    for patients receiving highly emetogenic chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=see_link&amp;anchor=H7#H7\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\", section on 'Neurokinin-1 receptor antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A precise understanding of the mechanisms by which chemotherapy induces emesis remains elusive. Two reviews summarize our current understanding of the pathophysiology of CINV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The following figure schematically illustrates potential sites at which chemotherapy is thought to exert its effects (",
"    <a class=\"graphic graphic_figure graphicRef70638 \" href=\"mobipreview.htm?31/29/32213\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Higher central nervous system (CNS) centers located in structures in the limbic forebrain, such as the amygdala may be a source of some types of emetic stimuli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/22\">",
"     22",
"    </a>",
"    ]. Some chemotherapy agents or their metabolites may interact directly or indirectly with receptors within the area postrema with subsequent activation of the vomiting center.",
"   </p>",
"   <p>",
"    In addition, studies in animal models indicate that the intestinal cell damage produced by chemotherapy initiates the release of 5-hydroxytryptamine (5-HT) and other neuroactive agents from enterochromaffin cells. These agents bind to the type three 5-HT receptor and other receptors on the vagal and splanchnic afferent fibers within the wall of the gastrointestinal tract. The stimulated vagal and splanchnic afferents project to the vomiting center and the area postrema, resulting in activation of the emetic reflex arc. It is also likely that released 5-HT binds directly to receptors in the area postrema.",
"   </p>",
"   <p>",
"    Substance P is released from sensory neurons following chemotherapy administration. Abundant NK1 receptors are found within the area postrema and the nucleus tractus solitarius, an important component of the anatomically indistinct emetic center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PREDICTIVE FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors have been identified which provide the clinician with the means of predicting the likelihood that CINV will develop in various situations. The most important is the intrinsic emetogenicity of the chemotherapy agent and its mode of administration. Other prognostic factors are related to the patient population and others are treatment-dependent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chemotherapy agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of CINV has been greatly facilitated by the development of classification schemes that reflect the likelihood of emesis developing following treatment with a particular agent. A 1997 classification scheme gained broad acceptance and was utilized as the basis for treatment recommendations by guideline panels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Chemotherapy agents were divided into five emetogenic levels, which were defined by the expected frequency of emesis in the absence of effective antiemetic prophylaxis.",
"   </p>",
"   <p>",
"    A modification of this schema was proposed at the 2004 Perugia Antiemetic Consensus Guideline meeting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/26\">",
"     26",
"    </a>",
"    ] and is still in widespread use. Chemotherapy agents were placed into four categories (",
"    <a class=\"graphic graphic_table graphicRef58756 \" href=\"mobipreview.htm?7/23/7549\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef65923 \" href=\"mobipreview.htm?26/53/27484\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High &mdash; &gt;90 percent risk of emesis",
"     </li>",
"     <li>",
"      Moderate &mdash; &gt;30 to 90 percent risk of emesis",
"     </li>",
"     <li>",
"      Low &mdash; 10 to 30 percent risk of emesis",
"     </li>",
"     <li>",
"      Minimal &mdash; &lt;10 percent risk of emesis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This schema is utilized in both the updated antiemetic guidelines of the Multinational Association of Supportive Care in Cancer (MASCC) and the American Society of Clinical Oncology (ASCO) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For any given drug, the route and rate of administration, as well as the dose, can also influence emetogenicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. For combination regimens, the emetogenic level is determined by identifying the most emetogenic agent in the combination and then assessing the relative contribution of the other agents. As an example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    are both moderately emetogenic agents, but when given together, the regimen is generally considered to be highly emetogenic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Patient-related factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of patient-related factors have been associated with an increased risk of CINV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/31-35\">",
"     31-35",
"    </a>",
"    ]. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Emesis with prior chemotherapy increases the risk of CINV. As an example, in a study of 1413 patients, the majority (72 percent) of patients reporting vomiting at the first treatment also reported subsequent vomiting; 31 percent of these patients experienced emesis at all remaining treatments [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/35\">",
"       35",
"      </a>",
"      ]. In contrast, 76 percent of patients who were emesis-free at the first treatment remained so for all later treatments.",
"     </li>",
"     <li>",
"      Women have an increased risk of CINV compared to men.",
"     </li>",
"     <li>",
"      Younger patients are more susceptible to CINV than older patients.",
"     </li>",
"     <li>",
"      Patients with a significant history of alcohol consumption are less susceptible to CINV than those without such a history.",
"     </li>",
"     <li>",
"      Rapid metabolizers of certain 5-HT3 receptor antagonists are more susceptible to severe CINV [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/36\">",
"       36",
"      </a>",
"      ], and certain polymorphisms in the 5-HT3 receptor can also confer a greater risk of CINV [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients who experience acute emesis with chemotherapy are significantly more likely to have",
"      <strong>",
"       delayed",
"      </strong>",
"      emesis.",
"     </li>",
"     <li>",
"      Anticipatory emesis occurs in patients who have had poor control of either acute or delayed emesis with prior chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/4,38\">",
"       4,38",
"      </a>",
"      ]. It has been suggested that a history of motion sickness may predispose to anticipatory emesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/57/19346?source=see_link\">",
"       \"Patient information: Nausea and vomiting with cancer treatment (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H588016308\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three distinct types of chemotherapy-induced nausea and vomiting (CINV) have been defined: acute, delayed, and anticipatory. Delayed emesis occurs most frequently after",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      but can also occur following other agents, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , anthracyclines, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of emesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are several potential sites at which chemotherapy is thought to exert its emetogenic effects (",
"      <a class=\"graphic graphic_figure graphicRef70638 \" href=\"mobipreview.htm?31/29/32213\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of factors have been identified that provide the clinician with the means of predicting the likelihood that CINV will develop in various situations, the most important of which is the intrinsic emetogenicity of the chemotherapy agent. Chemotherapy agents can be divided into four emetogenic levels, which were defined by the expected frequency of emesis in the absence of effective antiemetic prophylaxis (",
"      <a class=\"graphic graphic_table graphicRef58756 \" href=\"mobipreview.htm?7/23/7549\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef65923 \" href=\"mobipreview.htm?26/53/27484\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Chemotherapy agent'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      This schema is utilized in antiemetic guidelines of the Multinational Association of Supportive Care in Cancer (MASCC) and the American Society of Clinical Oncology (ASCO) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39894/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=see_link\">",
"       \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/1\">",
"      Kris MG, Gralla RJ, Clark RA, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985; 3:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/2\">",
"      Tavorath R, Hesketh PJ. Drug treatment of chemotherapy-induced delayed emesis. Drugs 1996; 52:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/3\">",
"      Hesketh PJ, Sanz-Altamira P, Bushey J, Hesketh AM. Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. Support Care Cancer 2012; 20:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/4\">",
"      Morrow GR, Roscoe JA, Kirshner JJ, et al. Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics. Support Care Cancer 1998; 6:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/5\">",
"      BORISON HL, WANG SC. Physiology and pharmacology of vomiting. Pharmacol Rev 1953; 5:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/6\">",
"      Borison HL. Area postrema: chemoreceptor circumventricular organ of the medulla oblongata. Prog Neurobiol 1989; 32:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/7\">",
"      Miller AD, Leslie RA. The area postrema and vomiting. Front Neuroendocrinol 1994; 15:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/8\">",
"      Fukuda H, Koga T. Non-respiratory neurons in the B&ouml;tzinger complex exhibiting appropriate firing patterns to generate the emetic act in dogs. Neurosci Res 1992; 14:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/9\">",
"      Koga T, Fukuda H. Neurons in the nucleus of the solitary tract mediating inputs from emetic vagal afferents and the area postrema to the pattern generator for the emetic act in dogs. Neurosci Res 1992; 14:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/10\">",
"      Carpenter DO. Neural mechanisms of emesis. Can J Physiol Pharmacol 1990; 68:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/11\">",
"      Miller AD, Wilson VJ. 'Vomiting center' reanalyzed: an electrical stimulation study. Brain Res 1983; 270:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/12\">",
"      Mitchelson F. Pharmacological agents affecting emesis. A review (Part I). Drugs 1992; 43:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/13\">",
"      Bountra C, Gale JD, Gardner CJ, et al. Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs. Oncology 1996; 53 Suppl 1:102.",
"     </a>",
"    </li>",
"    <li>",
"     Wang SC. Emetic and antiemetic drugs. In: Physiological pharmacology: A comprehensive treatise, Root WS, Hofmann FG (Eds), Academic Press, New York 1965. Vol Vol II, p.225.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/15\">",
"      Leslie RA. Neuroactive substances in the dorsal vagal complex of the medulla oblongata: nucleus of the tractus solitarius, area postrema, and dorsal motor nucleus of the vagus. Neurochem Int 1985; 7:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/16\">",
"      Andrews PL, Rapeport WG, Sanger GJ. Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci 1988; 9:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/17\">",
"      Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 1991; 83:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/18\">",
"      Saria A. The tachykinin NK1 receptor in the brain: pharmacology and putative functions. Eur J Pharmacol 1999; 375:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/19\">",
"      Watson JW, Gonsalves SF, Fossa AA, et al. The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor. Br J Pharmacol 1995; 115:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/20\">",
"      Hesketh PJ. Understanding the pathobiology of chemotherapy-induced nausea and vomiting. Providing a basis for therapeutic progress. Oncology (Williston Park) 2004; 18:9.",
"     </a>",
"    </li>",
"    <li>",
"     Rudd JA, Andrews PLR. Mechanisms of acute, delayed, and anticipatory emesis induced by anticancer therapies. In: Management of nausea and vomiting in cancer and cancer treatment, Hesketh PJ (Ed), Jones and Bartlett Publishers, Sudbury 2005. p.15.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/22\">",
"      Zagon A, Totterdell S, Jones RS. Direct projections from the ventrolateral medulla oblongata to the limbic forebrain: anterograde and retrograde tract-tracing studies in the rat. J Comp Neurol 1994; 340:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/23\">",
"      Saito R, Takano Y, Kamiya HO. Roles of substance P and NK(1) receptor in the brainstem in the development of emesis. J Pharmacol Sci 2003; 91:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/24\">",
"      Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15:103.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/26\">",
"      Grunberg SM, Warr D, Gralla RJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art. Support Care Cancer 2011; 19 Suppl 1:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/27\">",
"      Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011; 29:4189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/28\">",
"      Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010; 21 Suppl 5:v232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/29\">",
"      Olver IN, Simon RM, Aisner J. Antiemetic studies: a methodological discussion. Cancer Treat Rep 1986; 70:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/30\">",
"      Jordan NS, Schauer PK, Schauer A, et al. The effect of administration rate on cisplatin-induced emesis. J Clin Oncol 1985; 3:559.",
"     </a>",
"    </li>",
"    <li>",
"     Hesketh PJ, Plagge P, Bryson JC. Single dose ondansetron for the prevention of acute cisplatin-induced emesis: Analysis of efficacy and prognostic factors. In: Mechanisms and Control of Emesis, Bianchi L, Grelot AD, Miller GL (Eds), John Libby Eurotext Ltd, 1992. p.235.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/32\">",
"      Pollera CF, Giannarelli D. Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model. Cancer 1989; 64:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/33\">",
"      Pater J, Slamet L, Zee B, et al. Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting. Support Care Cancer 1994; 2:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/34\">",
"      Olver IN. Antiemetic study design: desirable objectives, stratifications and analyses. Br J Cancer Suppl 1992; 19:S30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/35\">",
"      Morrow GR, Roscoe JA, Hickok JT, et al. Initial control of chemotherapy-induced nausea and vomiting in patient quality of life. Oncology (Williston Park) 1998; 12:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/36\">",
"      Kaiser R, Sezer O, Papies A, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002; 20:2805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/37\">",
"      Tremblay PB, Kaiser R, Sezer O, et al. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 2003; 21:2147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/38\">",
"      Fallowfield LJ. Behavioural interventions and psychological aspects of care during chemotherapy. Eur J Cancer 1992; 28A Suppl 1:S39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39894/abstract/39\">",
"      Morrow GR. The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy. Cancer 1985; 55:2766.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1150 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-4F64B2DDF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_61_39894=[""].join("\n");
var outline_f38_61_39894=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H588016308\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF EMESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Acute emesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Delayed emesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Anticipatory emesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Neuroanatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neurotransmitters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PREDICTIVE FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chemotherapy agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Patient-related factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H588016308\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/1150\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/1150|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/29/32213\" title=\"figure 1\">",
"      Chemo emetic pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/1150|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/23/7549\" title=\"table 1\">",
"      Emetogenicity chemo drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/53/27484\" title=\"table 2\">",
"      Emetogenicity oral chemotherapy agents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16120?source=related_link\">",
"      Approach to the adult with nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19208?source=related_link\">",
"      Characteristics of antiemetic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/57/19346?source=related_link\">",
"      Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_61_39895="WHO length for age girls 0 to 24 months";
var content_f38_61_39895=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80511%7EPEDS%2F77249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80511%7EPEDS%2F77249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 587px\">",
"   <div class=\"ttl\">",
"    Length-for-age percentiles, girls 0 to 24 months, WHO growth standards",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 567px; height: 459px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WHO: World Health Organization.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Stature-for-age percentiles, girls, 2 to 20 years, CDC growth charts: United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 670px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From National Health Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_61_39895=[""].join("\n");
var outline_f38_61_39895=null;
var title_f38_61_39896="n-3 Long chain polyunsaturated fatty acids (LCPUFA) for preterm and term infants";
var content_f38_61_39896=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   n-3 Long chain polyunsaturated fatty acids (LCPUFA) for preterm and term infants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/61/39896/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/61/39896/contributors\">",
"     Christina J Valentine, MD, MS, RD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/61/39896/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/61/39896/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/61/39896/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/61/39896/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/61/39896/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/61/39896/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1325468725\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplementation of n-3 long chain polyunsaturated fatty acids (n-3 LCPUFAs) has been proposed to improve outcome in infants, particularly neurodevelopmental outcome. However, it remains uncertain whether there is benefit in supplemental dietary n-3 LCPUFAs (also referred to as omega-3 LCPUFAs) for term and preterm infants.",
"   </p>",
"   <p>",
"    This topic will review the evidence regarding whether or not dietary n-3 LCPUFAs supplementation for infants is beneficial. The risk and benefits of maternal intake of n-3 LCPUFAs through fish intake and the potential benefits of LCPUFAs consumed as dietary seafood or fish oil in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33273?source=see_link\">",
"     \"Risks and benefits of fish consumption and fish oil supplements during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36330?source=see_link\">",
"     \"Fish oil and marine omega-3 fatty acids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109751441\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174264629\">",
"    <span class=\"h2\">",
"     Metabolism and function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long chain polyunsaturated fatty acids (LCPUFAs) can be divided into n-6 and n-3 fatty acids. Arachidonic acid (AA) is an n-6 fatty acid (also referred to as omega-6) because of the placement of its first double bond from the methyl end at the C6 position [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/1\">",
"     1",
"    </a>",
"    ], whereas docosahexaenoic acid (DHA) is an n-3 fatty acid because of its first double bond at the third position [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/2\">",
"     2",
"    </a>",
"    ]. Both AA and DHA are biologically active end products of the essential fatty acids, linoleic (precursor for AA) and alpha-linoleic (precursor for DHA), which are exclusively attained from the diet. The LCPUFAs are synthesized in the liver endoplasmic reticulum and peroxisome by a series of desaturase and elongase enzymes, and the n-6 and n-3 LCPUFAs compete for these enzymes in their biosynthesis (",
"    <a class=\"graphic graphic_figure graphicRef87057 \" href=\"mobipreview.htm?19/46/20207\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Biosynthesis depends on precursor availability and enzyme activity which may be limiting in ill or preterm newborns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AA can be derived directly from meat sources and DHA from oily fish such as herring, tuna and salmon, and vegetarian fed chicken and their eggs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/7\">",
"     7",
"    </a>",
"    ]. In the United States, the ratio of n-6 to n-3 LCPUFA has shifted from a 1:1 ratio to one that favors n-6 LCPUFA due to the increased dietary intake of meat over fish. This shift may have implication on the balance between pro-inflammatory (AA) and anti-inflammatory prostaglandin (DHA and other n-3 LCPUFAs such as eicosapentaenoic acid) synthesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174264677\">",
"    <span class=\"h3\">",
"     Docosahexaenoic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;DHA is an integral component of the phospholipid membrane of brain and retinal cells, and also plays a role in anti-inflammatory prostaglandin synthesis, signaling events, gene expression, and cytokine expression. It is preferentially incorporated into the rapidly developing brain and retina during the last trimester of pregnancy and the first two years of infancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/8-11\">",
"     8-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autopsy analysis estimates that the fetus accumulates 50 to 60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of DHA during the third trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/5\">",
"     5",
"    </a>",
"    ]. It is estimated that the store of DHA at term birth is about 1050 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/12\">",
"     12",
"    </a>",
"    ]. Over the first six months of life, infants accumulate DHA at a rate of about 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and about one-half of all dietary DHA is incorporated into the brain.",
"   </p>",
"   <p>",
"    As a result, women who are pregnant or breastfeeding need to have sufficient dietary consumption of n-3 LCPUFA to ensure adequate DHA accretion in the fetus and breast milk. This can be achieved by a maternal diet that includes one to two weekly servings of fish that are high in n-3 LCPUFA but low in mercury (",
"    <a class=\"graphic graphic_table graphicRef53648 \" href=\"mobipreview.htm?16/25/16795\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33273?source=see_link&amp;anchor=H13#H13\">",
"     \"Risks and benefits of fish consumption and fish oil supplements during pregnancy\", section on 'Fish intake guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174264247\">",
"    <span class=\"h2\">",
"     Suggested dietary requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently, no societal or governmental recommended neonatal dietary intake of LCPUFA has been established due to the lack of complete, accurate information regarding DHA requirements for infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following are published suggested intakes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Food and Nutrition Board of the Institute of Medicine in The United States (IOM) has suggested that an advisable intake for infants up to six months of age include 4.4",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      of n-6 fatty acids and 0.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      of n-3 fatty acids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Committee on Nutrition for the European Society for Pediatric Gastroenterology and Nutrition suggests that the daily intake for a preterm infant include the following [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/15\">",
"       15",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Linoleic acid: 385 to 1540",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"     </li>",
"     <li>",
"      Linolenic acid: &gt;55",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"     </li>",
"     <li>",
"      Docosahexaenoic acid: 12 to 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"     </li>",
"     <li>",
"      Arachidonic acid: 18 to 42",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174264660\">",
"    <span class=\"h2\">",
"     LCPUFA content in milk",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174264684\">",
"    <span class=\"h3\">",
"     Human milk",
"    </span>",
"    &nbsp;&mdash;&nbsp;LCPUFA content varies in human milk and is dependent on maternal diet and body stores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/9,16,17\">",
"     9,16,17",
"    </a>",
"    ]. For example, DHA concentration compared with the other fatty acids ranges from 0.1 mol weight percent in a starving Sudanese woman to a 20-fold increase of 2 percent in a Chinese woman who consumes fish as a main dietary source [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, the average amount of DHA in human milk is about 0.35 mol weight percent, and a mother who consumes 100 mg per day of DHA will maintain this concentration in her breast milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/13\">",
"     13",
"    </a>",
"    ]. Term infants who consume 750 mL per day of human milk with a concentration of 0.35 mol weight percent will have an adequate daily DHA intake of 100 mg.",
"   </p>",
"   <p>",
"    Human milk sources with low DHA concentration are more concerning in preterm infants who are deprived of fetal DHA that normally accrues at an average rate of 50 to 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day during the last trimester of pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/8,19\">",
"     8,19",
"    </a>",
"    ]. In the United States, DHA concentrations in maternal and donor human milk used in neonatal intensive care units are low in concentration with reported mean values between 0.1 and 0.32 mol weight percent, which may not adequately meet the needs of premature infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/16,18,20,21\">",
"     16,18,20,21",
"    </a>",
"    ]. As an example, a DHA milk concentration of 0.1 mol weight percent only provides an inadequate dietary intake of 12",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for the preterm infant fed 150",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    enteral milk. Whereas, a milk concentration of 0.5 mol weight percent at the same volume would result in a sufficient intake of 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/4,22,23\">",
"     4,22,23",
"    </a>",
"    ]. A supplement of 1 g of DHA to a mother with an initial DHA milk concentration of 0.1 mol weight percent could raise it to 0.8 mol weight percent.",
"   </p>",
"   <p>",
"    The concentration of DHA in breast milk rises with increased maternal fish consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/24\">",
"     24",
"    </a>",
"    ]. However, excess mercury exposure in the infant is also a concern with increased maternal fish consumption. As a result, we suggest that breastfeeding mothers consume one to two weekly servings of fish that are high in n-3 LCPUFA but low in mercury to ensure adequate breast milk DHA content (",
"    <a class=\"graphic graphic_table graphicRef53648 \" href=\"mobipreview.htm?16/25/16795\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33273?source=see_link&amp;anchor=H13#H13\">",
"     \"Risks and benefits of fish consumption and fish oil supplements during pregnancy\", section on 'Fish intake guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174264691\">",
"    <span class=\"h3\">",
"     Formula",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 1980s and early 1990s, several studies demonstrated that n-3 LCPUFA concentration was lower in plasma and red blood cells of formula-fed infants compared with infants who received human milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Data were also being accumulated on DHA&rsquo;s role in brain and retinal cell structural development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. As a result, LCPUFAs were added in varying formulations and concentration to formulas for term and preterm infants. However, the majority of the studies used a concentration of 0.5 percent weight or less, which most likely provides insufficient amounts of DHA, particularly in preterm infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1356262\">",
"    <span class=\"h1\">",
"     RATIONALE FOR LCPUFA SUPPLEMENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is good evidence that breastfeeding compared with formula feeding improves cognition (ie, 3 to 5 points on cognitive tests) and, in preterm infants, visual acuity. It has been proposed that these results are due to differences in docosahexaenoic acid (DHA) content, which is present in human milk but not in bovine milk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/47/32505?source=see_link&amp;anchor=H23#H23\">",
"     \"Infant benefits of breastfeeding\", section on 'Neurodevelopmental outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been suggested that supplementation of bovine milk-based formula with long chain polyunsaturated fatty acids (LCPUFAs) would improve cognition and visual acuity. Addition of DHA to human milk via human milk fortifiers has also been suggested for preterm infants to compensate for the loss of accretion during the third trimester of pregnancy. However, as discussed below, clinical trials have not consistently shown that LCPUFA supplementation improves either cognition or visual acuity in preterm and term infants. (See",
"    <a class=\"local\" href=\"#H7495424\">",
"     'Clinical trials'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As of 2012, no agency within the United States such as the American Academy of Pediatrics or the Institute of Medicine has recommended LCPUFA supplementation for preterm and term infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7495424\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several clinical trials have been conducted to evaluate the effect of supplementation of long chain polyunsaturated fatty acids (LCPUFAs).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174265169\">",
"    <span class=\"h2\">",
"     Neurodevelopment and growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the clinical trials have evaluated the effect of LCPUFA supplementation on cognition, visual acuity, and growth. However, it is challenging to interpret the results from these trials because of significant variations in study design (eg, LCPUFA products, concentration and duration of supplementation, and outcome measures and assessment [timing and instruments used for assessments]). In addition, it may be the specific type of LCPUFAs (eg, DHA) that is the important component for neurodevelopmental outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75721490\">",
"    <span class=\"h3\">",
"     Formula-fed infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results from systematic reviews evaluating the effect of LCPUFA supplementation of formula are inconsistent regarding the benefit of supplementation for visual acuity and cognition in either preterm or term infants. Although results of these reviews do not demonstrate a consistent overall benefit of n-3 LCPUFA supplementation for both improved cognition and visual acuity in all infants, there is evidence that supplementation may improve neurodevelopmental outcome in very preterm infants and visual acuity for all infants. These analyses are limited by the large differences in study design including potential inadequate dosing and duration of supplementation (see",
"    <a class=\"local\" href=\"#H75721298\">",
"     'Limitations'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Two systematic reviews have focused on the effects of supplementation specifically for either preterm or term infants.",
"   </p>",
"   <p>",
"    The following findings of n-3 LCPUFA supplementation in",
"    <strong>",
"     preterm",
"    </strong>",
"    infants were noted in the first systematic review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Visual acuity &ndash; Visual acuity was assessed by a variety of methods including behavior (Teller and Lea acuity card) and visual evoked potential (VEP) methods, and electroretinogram. Meta-analysis could not be performed as results were expressed in log units. Nevertheless, most of the included studies did not find any differences in visual assessment between supplemented and control infants with the exception of one study that found VEP acuity was more mature in supplemented infants at two months post-term [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/29\">",
"       29",
"      </a>",
"      ]. A second study reported a subset of patients had improved VEP acuity at six months but not at three and 12 months post-term [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Development &ndash; Three out of seven studies reported improved neurodevelopmental outcome. However, a meta-analysis of studies that used Bayley Scales of Infant Development (BSID) for assessment found no effect of supplementation on neurodevelopmental outcome at 12 and 18 months of age of the total group effect. A subsequent study published after completion of this systematic review reported no significant difference in cognitive testing in patients who received n-3 LCPUFA supplementation and controls at 10 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/31\">",
"       31",
"      </a>",
"      ]. No subgroup analysis based on different gestational age was performed.",
"     </li>",
"     <li>",
"      Growth and side effects &ndash; Data are inconsistent regarding the effect of n-3 LCPUFA supplementation on growth in preterm infants. In this systematic review, 4 of 15 studies reported improved growth in infants who received supplementation at different postnatal ages, two other studies reported poorer growth in the supplemented group, and the remainder of the studies found no effect on growth. Meta-analyses demonstrated improved growth at two months post-term but not at 12 and 18 months post-term.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following findings of n-3 LCPUFA supplementation in",
"    <strong>",
"     term",
"    </strong>",
"    infants were noted in the second of these systematic reviews [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Visual acuity &ndash; Data are inconsistent regarding the effect of n-3 LCPUFA supplementation on visual acuity. Half of the included studies showed a positive effect in the supplemented group whereas the remaining studies reported no difference between supplemented and control groups. These studies varied by the means of assessment (behavior [Teller cards] and VEP measurements), timing of testing, and duration and content of supplementation. Limited pool analyses based on either timing of testing and type of assessment found no effect of n-3 LCPUFA supplementation with the exception of meta-analyses that showed improved VEP in supplemented infants at 4 and 12 months of age.",
"     </li>",
"     <li>",
"      Development &ndash; All meta-analyses and almost all of the included studies that assessed neurodevelopmental outcome by BSID demonstrated no effect of n-3 LCPUFA supplementation through an age range from three months to two years of age. The one exception was from a single group that reported higher scores for BSID physical developmental index for supplemented infants compared with controls at 18 months of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. There was also no difference between supplemented patients and controls using other methods of developmental testing except one report of improved problem solving in 10-month-old supplemented infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/35\">",
"       35",
"      </a>",
"      ] and another demonstrating better novelty preference measured by Fagan infant test at nine months. Finally, one study from the Netherlands reported no effect on n-3 LCPUFA supplementation on neurologic function at nine years of age for patients who had been formula-fed as infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Growth &ndash; The majority of studies did not find any beneficial or harmful effects of n-3 LCPUFA supplementation. A meta-analysis found that the supplemented group may have a lower but clinically insignificant lower weight at one year of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other systematic reviews are comprised of analyses that include",
"    <strong>",
"     both",
"    </strong>",
"    term and preterm infants and focused either on cognition or visual acuity. &nbsp;",
"   </p>",
"   <p>",
"    In the systematic review focused on cognition that involved 1802 preterm and term infants, there was no difference in BSID scores at one year of age between infants fed formula that was supplemented with n-3 LCPUFA and controls who received unsupplemented formula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/37\">",
"     37",
"    </a>",
"    ]. Stratified subgroup analysis did not demonstrate any association in cognitive function with supplementation in either preterm or term infants. Meta-regression analysis also did not demonstrate any dosing effect of docosahexaenoic acid (DHA) or arachidonic acid (AA). However, as noted by the authors, there was variation regarding outcome among the 12 trials; two of which reported significant improved cognition associated with n-3 LCPUFA supplementation, one with positive effects in some of the categories of the BSID test, and nine studies that showed no benefit. Another major limitation was that this review pooled studies with a wide range of dosing and sources for LCPUFA supplementation, which may have masked a potential benefit with higher DHA dosing. (See",
"    <a class=\"local\" href=\"#H75721298\">",
"     'Limitations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As an example of the potential positive effect of higher dosing, a subsequent British trial, which was not included in the above review, had DHA concentration that was higher at 0.5 and reported higher cognitive scores in preterm infants who received supplemented formula with DHA concentrations &ge;0.5 weight percent compared with those given unsupplemented preterm formula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/31\">",
"     31",
"    </a>",
"    ]. In infants who received maternal breast milk, there were no differences in cognitive scores between LCPUFA supplementation and nonsupplemented infants.",
"   </p>",
"   <p>",
"    A systematic review reported n-3 LCPUFA supplementation of formula improved visual acuity in both term and preterm infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/38\">",
"     38",
"    </a>",
"    ]. In this analysis, the primary outcome measured was the main difference in visual resolution acuity (measured in logarithm of minimum angle of resolution [logMAR]).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Visual evoked response (VEP) &ndash; A meta-analysis of 10 studies that measured visual acuity by VEP method showed benefit of n-3 LCPUFA supplementation at 2, 4, and 12 months of age.",
"     </li>",
"     <li>",
"      Behavioral method &ndash; A meta-analysis of 12 studies that measured visual acuity by behavioral methods demonstrated a positive effect of n-3 LCPUFA supplementation at two months of age but",
"      <strong>",
"       not",
"      </strong>",
"      at 4 or 12 months of age.",
"     </li>",
"     <li>",
"      Subgroup analysis of preterm infants:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Subgroup analysis of trials using VEP methods was only performed in preterm infants at four months of age and showed no difference in the effect of n-3 LCPUFA supplementation between preterm and term infants. There were insufficient data for subgroup analysis at 2 and 12 months of age.",
"     </li>",
"     <li>",
"      The results of subgroup analyses of trials using behavioral methods varied. At two months of age, n-3 LCPUFA was beneficial in term but not preterm infants. In contrast, at four months of age, there was a benefit of effect in preterm but not term infants. At 12 months of age, there was no positive effect for either group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dose &ndash; Secondary analysis failed to show any effect of DHA and AA dosing. There was also no association between varying DHA and AA ratio and visual acuity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75721384\">",
"    <span class=\"h3\">",
"     Human milk-fed preterm infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data are also inconclusive of the effect of n-3 LCPUFA supplementation in preterm infants who receive human milk.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a single center trial of 141 very low birth weight preterm infants (birth weight less than 1500 g), higher scores for recognition memory and problem-solving at six months of age were reported in infants who were randomly assigned to receive human milk supplemented with 32 mg of DHA and 31 mg of AA per 100 mL of human milk until discharged compared with controls without supplementation until discharged home [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, in the previously mentioned British trial, n-3 LCPUFA supplementation did not improve cognitive outcome in preterm infants who received maternal breast milk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/31\">",
"       31",
"      </a>",
"      ]. In this trial, the overall fat content was 4.5 g per 100 mL of milk with a DHA concentration of 0.5 weight percent (ie, g per 100 g fat) resulting in an overall content of DHA of 22.5 mg per 100 mL of milk, which is lower than used in the above trial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75721298\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inconsistent results from the above clinical trials may be due to variations in study design (eg, varying doses and source of DHA and AA, their relative ratio, and duration of supplementation), as noted above. Some experts in the field believe that the type of supplementation and the length of administration are important factors that affect cognitive outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/32,40\">",
"     32,40",
"    </a>",
"    ]. As an example, studies of term infants that showed a positive effect of supplementation on neurodevelopmental outcome at 18 months of age used high dose n-3 LCPUFA supplementation consisting of a consistent source of DHA (0.32 percent) from a single cell microalgae (Crypthecodinium cohnii) and AA from fungi (Morticierella alpine), which was given for at least one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. This DHA concentration of 0.32 percent was higher than most of the other studies, and was also the same concentration of DHA used in the trial in human milk-fed infants that reported a positive effect on cognition at six months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/39\">",
"     39",
"    </a>",
"    ]. The latter trial also included AA supplementation with a concentration of 0.31 percent of AA. (See",
"    <a class=\"local\" href=\"#H174265341\">",
"     'Knowledge gaps and future research'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174265204\">",
"    <span class=\"h2\">",
"     Other outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other suggested benefits for n-3 LCPUFA supplementation include decrease inflammation and enhanced immunologic response to infections.",
"   </p>",
"   <p>",
"    However, data are also limited and inconsistent as demonstrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial of preterm infants (gestational age less than 33 weeks) reported a reduced rate of bronchopulmonary dysplasia (BPD) in male patients and those with a birth weight less than 1250 g in patients who received breast milk from women who randomly assigned to high DHA diet compared to those whose mother received a low DHA diet [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/41\">",
"       41",
"      </a>",
"      ]. In addition, there was a reduced risk of hay fever in boys at 12 and 18 months of age. Further indirect evidence for DHA supplementation is provided by a study that found a decreased level of DHA in preterm infants (gestational age less than 30 weeks) was associated with an increased risk of BPD, and decreased arachidonic acid level with an increased risk of late-onset sepsis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a trial of infants at high risk of developing allergic disease found that there was no difference in the incidence of immunoglobulin E associated food allergies in the first year of life in infants whose mothers received n-3 LCPUFA supplementation during pregnancy compared with controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/43\">",
"       43",
"      </a>",
"      ]. However, the incidence of atopy and egg sensitization was lower in infants whose mothers received n-3 LCPUFA supplementation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33273?source=see_link&amp;anchor=H8#H8\">",
"       \"Risks and benefits of fish consumption and fish oil supplements during pregnancy\", section on 'Other outcomes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In adults, long-term consumption of adequate amounts of dietary n-3 LCPUFAs may reduce the risk of atherosclerosis and cardiovascular events. However, a randomized, double-blinded trial found no difference in cardiovascular or anthropometric measurements at nine years of age between children who received LCPUFA formula supplementation as infants (n = 145) born at term compared with those who received a standard non-LCPUFA supplemented formula (n = 159) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/44\">",
"       44",
"      </a>",
"      ]. Children who received human milk had marginally lower heart rate but had similar blood pressure and growth parameters to the formula-fed groups. In another study, girls who received n-3 LCPUFA supplementation as preterm infants were heavier at 10-year follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/45\">",
"       45",
"      </a>",
"      ]. Blood pressure appeared to correlate with body weight. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36330?source=see_link&amp;anchor=H3#H3\">",
"       \"Fish oil and marine omega-3 fatty acids\", section on 'Effects on cardiovascular risk factors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36330?source=see_link&amp;anchor=H13#H13\">",
"       \"Fish oil and marine omega-3 fatty acids\", section on 'Cardiovascular outcomes'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174265341\">",
"    <span class=\"h1\">",
"     KNOWLEDGE GAPS AND FUTURE RESEARCH",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously discussed, it remains inconclusive whether or not n-3 long chain polyunsaturated fatty acid (LCPUFA) supplementation in preterm and term infants is beneficial. Although one of the major factors that may have led to inconsistent results is the variation in study design (noted above), other factors that may contribute to the uncertainty of n-3 LCPUFA benefit include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sample size may have been inadequate as the benefit of n-3 LCPUFA supplementation may be more subtle than previously appreciated.",
"     </li>",
"     <li>",
"      Evaluation tools are not sensitive enough or have not been performed at an appropriate age. Most of the studies have utilized the Bayley Scales of Infant Toddler Development and testing has been done before or at two years of age. Several investigators have stated that this early developmental test is too broad and does not provide an analysis of independent cognitive process.",
"     </li>",
"     <li>",
"      Genetic variations in the fatty acid metabolism may moderate the effects of LCPUFA supplementation. For example, it has been speculated that the polymorphism of the fatty acid desaturase (FADS) 1 and FADS2 genes, which modify the encoding of delta-5 and delta-6 desaturase, may have a direct effect on the amount of n-3 LCPUFA available to the developing fetus and neonate. In addition, differential results relative to gender have also been noted.",
"     </li>",
"     <li>",
"      Inadequate docosahexanoic acid (DHA) dosing and duration of administration (see",
"      <a class=\"local\" href=\"#H75721298\">",
"       'Limitations'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result, it has been suggested that future trials should consider using high dose DHA (at least 0.32 percent) that is given for at least one year duration with an adequate sample size (at least 143 patients per arm) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/32,40\">",
"     32,40",
"    </a>",
"    ]. In addition, other proposed assessment measures include functional measures utilizing magnetic resonance imaging (MRI) and school performance, and the development of biomarkers that reflect DHA levels that can be correlated with outcome measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174266230\">",
"    <span class=\"h1\">",
"     OUR APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although, currently available data have been inconclusive regarding benefits of n-3 long chain polyunsaturated fatty acid (LCPUFA) supplementation for both term and preterm infants, there is good evidence that supplementation is safe without any adverse effects on growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/13,28\">",
"     13,28",
"    </a>",
"    ]. Support for supplementation is based on research that demonstrated n-3 LCPUFAs are important components of the developing brain and retina during the third trimester of pregnancy and the first six months of life. In addition, cognition is slightly better in infants fed human milk than those who receive bovine milk-based formula, which is deficient in n-3 LCPUFA content compared with human milk. Supplementation may be particularly beneficial in preterm infants who miss the important fetal accretion of n-3 LCPUFAs, such as docosahexaenoic acid (DHA), during all or some of the third trimester. (See",
"    <a class=\"local\" href=\"#H109751441\">",
"     'Background'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1356262\">",
"     'Rationale for LCPUFA supplementation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Until results from future research endeavors are available, the author, a proponent of LCPUFA supplementation, suggests the following approach to maintain adequate levels of n-3 LCPUFA for preterm and term infants based on the potential for benefits and the proven safety of supplementation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who are pregnant or breastfeeding should consume sufficient amounts of n-3 LCPUFAs to ensure adequate accretion of n-3 LCPUFAs for the fetus and in their breast milk. This can be achieved by consuming three sources of maternal DHA-rich foods per week or as a dietary supplement of 1 gram of DHA per day. In general, one to two weekly servings of oily fish, which is high in n-3 LCPUFA but low in mercury, is sufficient to maintain adequate fetal and breast milk DHA accretion (",
"      <a class=\"graphic graphic_table graphicRef53648 \" href=\"mobipreview.htm?16/25/16795\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33273?source=see_link&amp;anchor=H13#H13\">",
"       \"Risks and benefits of fish consumption and fish oil supplements during pregnancy\", section on 'Fish intake guidelines'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend that all infants should receive maternal breast milk. If maternal breast milk is not available, donor human milk should be provided. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/47/32505?source=see_link\">",
"       \"Infant benefits of breastfeeding\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23655?source=see_link&amp;anchor=H10#H10\">",
"       \"Human milk feeding and fortification of human milk for premature infants\", section on 'Preterm formula versus donor milk'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For term infants who are formula-fed, we suggest that the formula contain a concentration of DHA of 0.32.",
"     </li>",
"     <li>",
"      For preterm infants, we suggest that sufficient n-3 LCPUFA supplementation be given to either the breastfeeding mother or infant to achieve a dietary intake of DHA that achieves intrauterine accretion values of 50",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39896/abstract/4,46\">",
"       4,46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174266527\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Docosahexaenoic acid (DHA) is an n-3 long chain polyunsaturated fatty acid (LCPUFA) that is an integral component of the brain and retinal phospholipid membrane. It is preferentially incorporated into the rapidly developing brain and retina during the last trimester of pregnancy and the first two years of life. (See",
"      <a class=\"local\" href=\"#H174264677\">",
"       'Docosahexaenoic acid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is good evidence that breastfeeding compared with formula feeding slightly improves cognition by 3 to 5 points on neurodevelopmental tests. One theory to explain these results is differences in DHA content, which is present in human milk but not bovine milk. However, results are not clear and inconsistent from clinical trials that evaluated the effect of n-3 LCPUFA supplementation on neurodevelopmental outcome in formula-fed term and preterm infants, and in human milk-fed preterm infants. The inconsistency is thought to be due in part to the variations in study design including type of supplementation, and dosing and duration of supplementation. (See",
"      <a class=\"local\" href=\"#H1356262\">",
"       'Rationale for LCPUFA supplementation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H174265169\">",
"       'Neurodevelopment and growth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical trials have shown that n-3 LCPUFA supplementation has no adverse effects on growth.",
"     </li>",
"     <li>",
"      Data are insufficient to determine whether n-3 LCPUFA supplementation is effective in decreasing inflammation and enhancing immunologic response. (See",
"      <a class=\"local\" href=\"#H174265204\">",
"       'Other outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Future trials are needed to fill the knowledge gaps regarding the potential benefits of n-3 LCPUFA supplementation. Future trials should consider using higher doses of DHA, duration of therapy for at least one year, and an adequate sample size. (See",
"      <a class=\"local\" href=\"#H174265341\">",
"       'Knowledge gaps and future research'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Until further data are available, we use the following approach regarding dietary n-3 LCPUFA for preterm and term infants:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest that women who are pregnant or breastfeeding eat a diet of at least one to two servings per week of oily fish that is low in mercury (",
"      <a class=\"graphic graphic_table graphicRef53648 \" href=\"mobipreview.htm?16/25/16795\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest that pregnant or breastfeeding women who do not consume this much fish take a dietary supplement of 1 gram of DHA per day (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33273?source=see_link&amp;anchor=H13#H13\">",
"       \"Risks and benefits of fish consumption and fish oil supplements during pregnancy\", section on 'Fish intake guidelines'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36330?source=see_link&amp;anchor=H27#H27\">",
"       \"Fish oil and marine omega-3 fatty acids\", section on 'Dose and form'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend that all infants receive maternal breast milk, if available (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We recommend infants receive donor human milk rather than formula if maternal breast milk is unavailable (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/47/32505?source=see_link\">",
"       \"Infant benefits of breastfeeding\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23655?source=see_link&amp;anchor=H2#H2\">",
"       \"Human milk feeding and fortification of human milk for premature infants\", section on 'Advantages of human milk'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23655?source=see_link&amp;anchor=H10#H10\">",
"       \"Human milk feeding and fortification of human milk for premature infants\", section on 'Preterm formula versus donor milk'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For term infants who are formula-fed, it remains uncertain what the optimal concentration of DHA should be. The author suggests that a formula contain a minimum concentration of DHA of 0.32 percent. (See",
"      <a class=\"local\" href=\"#H174264660\">",
"       'LCPUFA content in milk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For preterm infants, we suggest that sufficient n-3 LCPUFA supplementation be given to either the breastfeeding mother or infant to achieve a dietary intake of DHA that achieves intrauterine accretion values of 50",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H174264660\">",
"       'LCPUFA content in milk'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/1\">",
"      Innis SM. Essential fatty acid transfer and fetal development. Placenta 2005; 26 Suppl A:S70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/2\">",
"      The nomenclature of lipids (recommendations 1976). IUPAC-IUB Commission on Biochemical Nomenclature. J Lipid Res 1978; 19:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/3\">",
"      German JB, Dillard CJ. Composition, structure and absorption of milk lipids: a source of energy, fat-soluble nutrients and bioactive molecules. Crit Rev Food Sci Nutr 2006; 46:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/4\">",
"      Valentine CJ. Maternal dietary DHA supplementation to improve inflammatory outcomes in the preterm infant. Adv Nutr 2012; 3:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/5\">",
"      Clandinin MT, Chappell JE, Heim T, et al. Fatty acid utilization in perinatal de novo synthesis of tissues. Early Hum Dev 1981; 5:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/6\">",
"      Mayes C, Burdge GC, Bingham A, et al. Variation in [U-13C] alpha linolenic acid absorption, beta-oxidation and conversion to docosahexaenoic acid in the pre-term infant fed a DHA-enriched formula. Pediatr Res 2006; 59:271.",
"     </a>",
"    </li>",
"    <li>",
"     Souci SW, Fachmann W, Kraut H. Food Composition and Nutrition Tables, 7th ed, MedPharm Scientific Publishers, Stuttgart, Germany 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/8\">",
"      Kuipers RS, Luxwolda MF, Offringa PJ, et al. Fetal intrauterine whole body linoleic, arachidonic and docosahexaenoic acid contents and accretion rates. Prostaglandins Leukot Essent Fatty Acids 2012; 86:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/9\">",
"      Innis SM. Perinatal biochemistry and physiology of long-chain polyunsaturated fatty acids. J Pediatr 2003; 143:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/10\">",
"      Martinez M. Tissue levels of polyunsaturated fatty acids during early human development. J Pediatr 1992; 120:S129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/11\">",
"      Lewin GA, Schachter HM, Yuen D, et al. Effects of omega-3 fatty acids on child and maternal health. Evid Rep Technol Assess (Summ) 2005; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/12\">",
"      Cunnane SC, Francescutti V, Brenna JT, Crawford MA. Breast-fed infants achieve a higher rate of brain and whole body docosahexaenoate accumulation than formula-fed infants not consuming dietary docosahexaenoate. Lipids 2000; 35:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/13\">",
"      Innis SM. Omega-3 Fatty acids and neural development to 2 years of age: do we know enough for dietary recommendations? J Pediatr Gastroenterol Nutr 2009; 48 Suppl 1:S16.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine of the National Academies. Dietary Reference Intakes (DRIs): For Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein and Amino Acids, The National Academies Press, Washington, DC 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/15\">",
"      Agostoni C, Buonocore G, Carnielli VP, et al. Enteral nutrient supply for preterm infants: commentary from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition. J Pediatr Gastroenterol Nutr 2010; 50:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/16\">",
"      Brenna JT, Varamini B, Jensen RG, et al. Docosahexaenoic and arachidonic acid concentrations in human breast milk worldwide. Am J Clin Nutr 2007; 85:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/17\">",
"      Brenna JT. Animal studies of the functional consequences of suboptimal polyunsaturated fatty acid status during pregnancy, lactation and early post-natal life. Matern Child Nutr 2011; 7 Suppl 2:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/18\">",
"      Jensen RG. Lipids in human milk. Lipids 1999; 34:1243.",
"     </a>",
"    </li>",
"    <li>",
"     Valentine CJ, Morrow G, Morrow AL. Promoting Pasteurized Donor Human Milk Use in the Neonatal Intensive Care Unit (NICU) as an adjunct to care and to Prevent Necrotizing Enterocolitis and shorten length of stay, F. a. D. A. Division of Dockets Management (HFA-305) (Ed), Rockville, MD 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/20\">",
"      Valentine CJ, Morrow G, Fernandez S, et al. Docosahexaenoic Acid and Amino Acid Contents in Pasteurized Donor Milk are Low for Preterm Infants. J Pediatr 2010; 157:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/21\">",
"      Baack ML, Norris AW, Yao J, Colaizy T. Long-chain polyunsaturated fatty acid levels in US donor human milk: meeting the needs of premature infants? J Perinatol 2012; 32:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/22\">",
"      Makrides M, Neumann MA, Gibson RA. Effect of maternal docosahexaenoic acid (DHA) supplementation on breast milk composition. Eur J Clin Nutr 1996; 50:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/23\">",
"      Lapillonne A, Eleni dit Trolli S, Kermorvant-Duchemin E. Postnatal docosahexaenoic acid deficiency is an inevitable consequence of current recommendations and practice in preterm infants. Neonatology 2010; 98:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/24\">",
"      Quinn EA, Kuzawa CW. A dose-response relationship between fish consumption and human milk DHA content among Filipino women in Cebu City, Philippines. Acta Paediatr 2012; 101:e439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/25\">",
"      Ponder DL, Innis SM, Benson JD, Siegman JS. Docosahexaenoic acid status of term infants fed breast milk or infant formula containing soy oil or corn oil. Pediatr Res 1992; 32:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/26\">",
"      Putnam JC, Carlson SE, DeVoe PW, Barness LA. The effect of variations in dietary fatty acids on the fatty acid composition of erythrocyte phosphatidylcholine and phosphatidylethanolamine in human infants. Am J Clin Nutr 1982; 36:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/27\">",
"      Makrides M, Neumann M, Simmer K, et al. Are long-chain polyunsaturated fatty acids essential nutrients in infancy? Lancet 1995; 345:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/28\">",
"      Schulzke SM, Patole SK, Simmer K. Long-chain polyunsaturated fatty acid supplementation in preterm infants. Cochrane Database Syst Rev 2011; :CD000375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/29\">",
"      Uauy RD, Birch DG, Birch EE, et al. Effect of dietary omega-3 fatty acids on retinal function of very-low-birth-weight neonates. Pediatr Res 1990; 28:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/30\">",
"      O'Connor DL, Hall R, Adamkin D, et al. Growth and development in preterm infants fed long-chain polyunsaturated fatty acids: a prospective, randomized controlled trial. Pediatrics 2001; 108:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/31\">",
"      Isaacs EB, Ross S, Kennedy K, et al. 10-year cognition in preterms after random assignment to fatty acid supplementation in infancy. Pediatrics 2011; 128:e890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/32\">",
"      Simmer K, Patole SK, Rao SC. Long-chain polyunsaturated fatty acid supplementation in infants born at term. Cochrane Database Syst Rev 2011; :CD000376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/33\">",
"      Birch EE, Hoffman DR, Uauy R, et al. Visual acuity and the essentiality of docosahexaenoic acid and arachidonic acid in the diet of term infants. Pediatr Res 1998; 44:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/34\">",
"      Birch EE, Carlson SE, Hoffman DR, et al. The DIAMOND (DHA Intake And Measurement Of Neural Development) Study: a double-masked, randomized controlled clinical trial of the maturation of infant visual acuity as a function of the dietary level of docosahexaenoic acid. Am J Clin Nutr 2010; 91:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/35\">",
"      Willatts P, Forsyth JS, DiModugno MK, et al. Effect of long-chain polyunsaturated fatty acids in infant formula on problem solving at 10 months of age. Lancet 1998; 352:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/36\">",
"      de Jong C, Kikkert HK, Fidler V, Hadders-Algra M. The Groningen LCPUFA study: no effect of postnatal long-chain polyunsaturated fatty acids in healthy term infants on neurological condition at 9 years. Br J Nutr 2010; 104:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/37\">",
"      Qawasmi A, Landeros-Weisenberger A, Leckman JF, Bloch MH. Meta-analysis of long-chain polyunsaturated fatty acid supplementation of formula and infant cognition. Pediatrics 2012; 129:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/38\">",
"      Qawasmi A, Landeros-Weisenberger A, Bloch MH. Meta-analysis of LCPUFA supplementation of infant formula and visual acuity. Pediatrics 2013; 131:e262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/39\">",
"      Henriksen C, Haugholt K, Lindgren M, et al. Improved cognitive development among preterm infants attributable to early supplementation of human milk with docosahexaenoic acid and arachidonic acid. Pediatrics 2008; 121:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/40\">",
"      Meldrum SJ, Smith MA, Prescott SL, et al. Achieving definitive results in long-chain polyunsaturated fatty acid supplementation trials of term infants: factors for consideration. Nutr Rev 2011; 69:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/41\">",
"      Manley BJ, Makrides M, Collins CT, et al. High-dose docosahexaenoic acid supplementation of preterm infants: respiratory and allergy outcomes. Pediatrics 2011; 128:e71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/42\">",
"      Martin CR, Dasilva DA, Cluette-Brown JE, et al. Decreased postnatal docosahexaenoic and arachidonic acid blood levels in premature infants are associated with neonatal morbidities. J Pediatr 2011; 159:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/43\">",
"      Palmer DJ, Sullivan T, Gold MS, et al. Effect of n-3 long chain polyunsaturated fatty acid supplementation in pregnancy on infants' allergies in first year of life: randomised controlled trial. BMJ 2012; 344:e184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/44\">",
"      de Jong C, Boehm G, Kikkert HK, Hadders-Algra M. The Groningen LCPUFA study: No effect of short-term postnatal long-chain polyunsaturated fatty acids in healthy term infants on cardiovascular and anthropometric development at 9 years. Pediatr Res 2011; 70:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/45\">",
"      Kennedy K, Ross S, Isaacs EB, et al. The 10-year follow-up of a randomised trial of long-chain polyunsaturated fatty acid supplementation in preterm infants: effects on growth and blood pressure. Arch Dis Child 2010; 95:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39896/abstract/46\">",
"      Sauerwald UC, Fink MM, Demmelmair H, et al. Effect of different levels of docosahexaenoic acid supply on fatty acid status and linoleic and &alpha;-linolenic acid conversion in preterm infants. J Pediatr Gastroenterol Nutr 2012; 54:353.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83231 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-AB4CE9AEE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_61_39896=[""].join("\n");
var outline_f38_61_39896=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H174266527\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1325468725\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109751441\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174264629\">",
"      Metabolism and function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H174264677\">",
"      - Docosahexaenoic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174264247\">",
"      Suggested dietary requirements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174264660\">",
"      LCPUFA content in milk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H174264684\">",
"      - Human milk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H174264691\">",
"      - Formula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1356262\">",
"      RATIONALE FOR LCPUFA SUPPLEMENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7495424\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174265169\">",
"      Neurodevelopment and growth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H75721490\">",
"      - Formula-fed infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H75721384\">",
"      - Human milk-fed preterm infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H75721298\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174265204\">",
"      Other outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H174265341\">",
"      KNOWLEDGE GAPS AND FUTURE RESEARCH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H174266230\">",
"      OUR APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H174266527\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/83231\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/83231|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/46/20207\" title=\"figure 1\">",
"      Pathway of the biosynthesis of DHA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/83231|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/25/16795\" title=\"table 1\">",
"      Seafood advisory for pregnant women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36330?source=related_link\">",
"      Fish oil and marine omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23655?source=related_link\">",
"      Human milk feeding and fortification of human milk for premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/47/32505?source=related_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33273?source=related_link\">",
"      Risks and benefits of fish consumption and fish oil supplements during pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_61_39897="Treatment and surveillance of non-metastatic carcinoid tumors";
var content_f38_61_39897=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and surveillance of non-metastatic carcinoid tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/61/39897/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/61/39897/contributors\">",
"     Stephen E Goldfinger, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/61/39897/contributors\">",
"     Jonathan R Strosberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/61/39897/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/61/39897/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/61/39897/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/61/39897/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/61/39897/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/61/39897/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;carcinoid&rdquo; is generally applied to neuroendocrine tumors originating in the digestive tract, lungs, or rare primary sites such as kidneys or ovaries. Use of the term &ldquo;carcinoid&rdquo; usually implies well-differentiated histology, but the term can be applied to the rare high-grade or poorly differentiated neuroendocrine tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/40/6794?source=see_link&amp;anchor=H440387068#H440387068\">",
"     \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\", section on 'Pathology, tumor classification, and nomenclature'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    &ldquo;Carcinoid syndrome&rdquo; is the term applied to a constellation of symptoms mediated by various humoral factors that are elaborated by some carcinoid tumors (",
"    <a class=\"graphic graphic_table graphicRef79329 \" href=\"mobipreview.htm?34/59/35771\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/1\">",
"     1",
"    </a>",
"    ]. Two of the most common manifestations are flushing and diarrhea (",
"    <a class=\"graphic graphic_table graphicRef63079 \" href=\"mobipreview.htm?37/54/38763\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9206?source=see_link\">",
"     \"Clinical features of the carcinoid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most carcinoids are associated with carcinoid syndrome only when they have metastasized to the liver. Exceptions are bronchial and ovarian carcinoids, which can release hormones directly into the systemic circulation, thereby producing symptoms without metastases (",
"    <a class=\"graphic graphic_table graphicRef56015 \" href=\"mobipreview.htm?17/7/17531\">",
"     table 3",
"    </a>",
"    ). When it occurs, carcinoid syndrome associated with foregut tumors such as bronchial carcinoids is often atypical with episodes of flushing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diaphoresis, occasionally accompanied by other symptoms such as lacrimation, salivation and edema. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9206?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical features of the carcinoid syndrome\", section on 'Bronchial carcinoid variant syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, the basic principles of evaluation and management of patients with carcinoid tumors include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Radiographic staging and tumor localization",
"      </strong>",
"      &ndash; Common imaging modalities include CT or MRI scans as well as somatostatin-receptor scintigraphy (SRS; OctreoScan&reg;). Upper and lower endoscopy (with attention to the terminal ileum) should be performed for the evaluation of metastatic carcinoid with an unknown primary site. CT enterography can also be used for this purpose. While video capsule endoscopy allows for evaluation of the entire small intestine, routine use of capsule endoscopy cannot be recommended due to the risk of bowel obstruction from retention of the capsule at the site of an intestinal carcinoid. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41174?source=see_link&amp;anchor=H3#H3\">",
"       \"Neuroendocrine cancer of unknown primary site\", section on 'Well-differentiated neuroendocrine tumor'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Mesenteric masses are usually indicative of a primary tumor located in the small intestine. Radiographic staging and tumor localization of carcinoid tumors is addressed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11400?source=see_link\">",
"       \"Diagnosis of the carcinoid syndrome and tumor localization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pathologic assessment of tumor differentiation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      grade (assessment of mitotic rate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      Ki-67 index,",
"      <span class=\"nowrap\">",
"       presence/absence",
"      </span>",
"      of necrosis and pleomorphism). This subject is addressed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/40/6794?source=see_link&amp;anchor=H440387068#H440387068\">",
"       \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\", section on 'Pathology, tumor classification, and nomenclature'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Removal of the tumor if all disease is surgically resectable, even if liver metastases are present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/30/43496?source=see_link&amp;anchor=H691390#H691390\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Surgical options'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Control of carcinoid symptoms, if present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16888?source=see_link\">",
"       \"Treatment of the carcinoid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Judicious use of antitumor therapy for unresectable metastatic disease. One of the key principles underlying selection of appropriate therapy for advanced disease is the indolent nature of most well-differentiated carcinoids and their prolonged natural history; this must be weighed against the toxicity of available antitumor regimens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will provide an overview of treatment of localized carcinoid tumors, focusing on treatment of digestive tract primary sites. Antitumor treatment, prognosis and biochemical monitoring of patients with advanced or metastatic carcinoid, diagnosis and treatment of the carcinoid syndrome, radiologic staging, tumor localization, and histologic assessment of carcinoid tumors, and management of bronchial and thymic carcinoid tumors are discussed in detail elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/30/43496?source=see_link\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6665?source=see_link\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11400?source=see_link\">",
"       \"Diagnosis of the carcinoid syndrome and tumor localization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16888?source=see_link\">",
"       \"Treatment of the carcinoid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11400?source=see_link\">",
"       \"Diagnosis of the carcinoid syndrome and tumor localization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/40/6794?source=see_link\">",
"       \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/55/9082?source=see_link\">",
"       \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/28/21962?source=see_link\">",
"       \"Thymic neuroendocrine (carcinoid) tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT OF LOCALIZED CARCINOID TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of choice for a patient who has a localized carcinoid tumor is usually surgery. The extent of the surgical resection depends on the site of origin and size of the primary tumor. A detailed discussion of the clinical presentation of carcinoid tumors arising in specific organs is available elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/60/969?source=see_link\">",
"     \"Clinical characteristics of carcinoid tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Appendix",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of appendiceal carcinoids is best predicted by tumor size. In many series, tumors less than 2 cm in diameter (found in approximately 95 percent of patients) have a low likelihood of metastases at diagnosis (",
"    <a class=\"graphic graphic_table graphicRef82306 \" href=\"mobipreview.htm?14/6/14444\">",
"     table 4",
"    </a>",
"    ). In contrast, up to 30 percent of larger tumors have already metastasized at diagnosis, mostly to regional nodes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36074?source=see_link&amp;anchor=H3#H3\">",
"     \"Cancer of the appendix and pseudomyxoma peritonei\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A TNM staging system is available for appendiceal carcinoids (",
"    <a class=\"graphic graphic_table graphicRef50547 \" href=\"mobipreview.htm?4/18/4397\">",
"     table 5",
"    </a>",
"    ) that is distinct from the TNM staging system for carcinoids arising at other sites within the gastrointestinal tract and lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36074?source=see_link&amp;anchor=H4#H4\">",
"     \"Cancer of the appendix and pseudomyxoma peritonei\", section on 'Staging and prognosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/55/9082?source=see_link&amp;anchor=H17350165#H17350165\">",
"     \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\", section on 'Staging system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Optimal surgical management for appendiceal carcinoids is subject to some debate. Because most are discovered incidentally in an appendectomy specimen done for other reasons, a decision must be made whether or not to return the patient to the operating room for a right colectomy. Unlike simple appendectomy, colectomy removes the draining lymph nodes of the appendix and any residual disease that might remain at the base of the appendix or in the mesoappendix.",
"   </p>",
"   <p>",
"    Because of the association of tumor size with prognosis, a right hemicolectomy has been traditionally recommended for tumors greater than 2 cm or those with mesoappendiceal invasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/3\">",
"     3",
"    </a>",
"    ]. On the other hand, whether or not a colectomy should be performed in some patients with smaller tumors is unclear; there is limited evidence on which to base clear indications for hemicolectomy. Some clinicians pursue completion right colectomy for tumors &lt;2 cm only if there is evidence of mesoappendiceal invasion or positive or unclear margins, while others disagree and consider that appendectomy alone is adequate for tumors &lt;2 cm, even with mesoappendiceal invasion. There is general agreement that tumors less than 1 cm can usually be treated by simple appendectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These issues are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36074?source=see_link&amp;anchor=H5#H5\">",
"     \"Cancer of the appendix and pseudomyxoma peritonei\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Small intestine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoid tumors of the small intestine are most commonly found in the ileum, within 60 cm of the ileocecal valve. Small intestinal carcinoids have the potential to metastasize, irrespective of size (",
"    <a class=\"graphic graphic_table graphicRef82306 \" href=\"mobipreview.htm?14/6/14444\">",
"     table 4",
"    </a>",
"    ). The TNM staging system for jejunoileal carcinoids, which is distinct from that used for appendiceal carcinoids, is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef58532 \" href=\"mobipreview.htm?41/15/42236\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/31/18938?source=see_link&amp;anchor=H17#H17\">",
"     \"Epidemiology, clinical features, and types of small bowel neoplasms\", section on 'Carcinoid tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with nonmetastatic tumors should be treated with resection of the involved segment and small bowel mesentery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/8/21642?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of small bowel neoplasms\", section on 'Carcinoid tumors'",
"    </a>",
"    .) Because multiple carcinoids are present in nearly 26 percent of cases, the remainder of the small bowel should be examined at the time of surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/4\">",
"     4",
"    </a>",
"    ]. Although this is a controversial area, resection of the primary tumor may be advised even in patients with known distant metastases in order to reduce the potential for bowel obstruction, bleeding, or to palliate abdominal pain related to the primary tumor.",
"   </p>",
"   <p>",
"    The prognosis depends upon disease stage (",
"    <a class=\"graphic graphic_table graphicRef58532 \" href=\"mobipreview.htm?41/15/42236\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/5\">",
"     5",
"    </a>",
"    ]. However, even among patients with distant metastasis, five year overall survival rates range from 40 to 85 percent; ten year survival rates of 40 to 60 percent are reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]; the five, ten, and fifteen-year outcomes for a large series of 135 surgically-treated small bowel carcinoids are illustrated in the table (",
"    <a class=\"graphic graphic_table graphicRef62793 \" href=\"mobipreview.htm?40/63/41980\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19140597\">",
"     'Stage and site of origin'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5647503\">",
"    <span class=\"h2\">",
"     Ampulla of Vater",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ampullary carcinoids are rare. The TNM staging system is the same as that used for small bowel carcinoids (",
"    <a class=\"graphic graphic_table graphicRef58532 \" href=\"mobipreview.htm?41/15/42236\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There is a high likelihood of nodal metastases, even with tumor size &lt;2 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Pancreaticoduodenectomy has been advocated for resectable cases regardless of size due to relatively high risk of occult nodal metastases. However, these recommendations are based on very small case series and treatment decisions may need to be individualized based on precise location of tumors, histologic grade, depth of invasion, and patient suitability for aggressive surgery. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Rectum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most rectal carcinoid tumors are small, localized, and mucosal or submucosal in location [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/13\">",
"     13",
"    </a>",
"    ]. As with rectal adenocarcinomas, transrectal endoscopic ultrasound (TEUS) is often useful for assessment of tumor size, depth of invasion and lymph node involvement in rectal carcinoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/60/969?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical characteristics of carcinoid tumors\", section on 'Rectum'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28967?source=see_link\">",
"     \"Endoscopic ultrasound in rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The TNM staging system that is used for carcinoid tumors of the rectum is outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef53191 \" href=\"mobipreview.htm?2/22/2413\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/5\">",
"     5",
"    </a>",
"    ]. Tumors that are smaller than 1 cm and confined to the mucosa or submucosa (T1) can be treated by local endoscopic excision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/13,16-19\">",
"     13,16-19",
"    </a>",
"    ]. Multiple techniques have been described for endoscopic resection of submucosal tumors, including endoscopic submucosal dissection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], band snare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/22\">",
"     22",
"    </a>",
"    ], band ligation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/23\">",
"     23",
"    </a>",
"    ], and aspiration lumpectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/24\">",
"     24",
"    </a>",
"    ]. The risk of recurrence is exceptionally small for stage I tumors that are &lt;1 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/25\">",
"     25",
"    </a>",
"    ] (although not zero [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/13\">",
"     13",
"    </a>",
"    ]). The reported five-year survival rate was 97 percent in an analysis derived from the Surveillance, Epidemiology and End Results (SEER) database [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal treatment for tumors that are larger than 1 cm but smaller than 2 cm is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/27\">",
"     27",
"    </a>",
"    ]. The metastatic risk is estimated to be between 10 and 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/28\">",
"     28",
"    </a>",
"    ]. Transanal excision can be performed in patients with intermediate sized tumors (1 to 2 cm) that are confined to the submucosa (ie, T1 (",
"    <a class=\"graphic graphic_table graphicRef53191 \" href=\"mobipreview.htm?2/22/2413\">",
"     table 8",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients whose tumors invade the muscularis propria (T2) in whom lymph node metastases are excluded by TEUS can also be managed with transanal excision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/29\">",
"     29",
"    </a>",
"    ]. Transanal endoscopic microsurgery (TEM) is another option for tumors of intermediate size and invasiveness, particularly in the proximal rectum. It can be used to resect tumors that are difficult to excise using conventional techniques or as a salvage option in patients with residual positive margins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tumors larger than 2 cm and those that invade into or beyond the muscularis propria (ie,",
"    <span class=\"nowrap\">",
"     T3/4",
"    </span>",
"    tumors) or have regional lymph node metastases have usually been treated by low anterior resection or abdominoperineal resection (APR) depending on the distance from the anal verge, similar to treatment for rectal adenocarcinomas. APR is generally required for very distal rectal tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prognosis is mainly dependent on tumor size and depth of invasion, as reflected by the T-stage classification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/7\">",
"     7",
"    </a>",
"    ]. The relationship between size and metastatic propensity is depicted in the table (",
"    <a class=\"graphic graphic_table graphicRef82306 \" href=\"mobipreview.htm?14/6/14444\">",
"     table 4",
"    </a>",
"    ). In a SEER database series, the five-year survival rates for localized, regional, or distant disease involving the rectum or rectosigmoid junction over the last decade were 90, 49, and 26 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432448\">",
"    <span class=\"h2\">",
"     Colon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoid tumors of the colon tend to be more aggressive than those arising in the rectum; in one large series derived from the SEER database, five-year survival rates were only 62 percent across all stages (compared to 88 percent for rectal carcinoids) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/32\">",
"     32",
"    </a>",
"    ]. Colonic carcinoids are frequently right sided and may be clinically occult until locally advanced; approximately two-thirds have evidence of nodal or distant metastases at the time of diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/60/969?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical characteristics of carcinoid tumors\", section on 'Colon'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given that most tumors are &gt;2 cm",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    invasive through the muscularis propria, patients with nonmetastatic carcinoid tumors of the colon should be managed with formal partial colectomy and regional lymphadenectomy, similar to treatment of colonic adenocarcinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/49/30489?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the management of primary colon cancer\", section on 'Surgical resection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16762?source=see_link&amp;anchor=H125358593#H125358593\">",
"     \"Surgical oncologic principles for the resection of colon cancer\", section on 'Surgical procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prognosis is dependent on stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/7\">",
"     7",
"    </a>",
"    ]. The TNM staging system that includes carcinoid tumors of the colon is outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef53191 \" href=\"mobipreview.htm?2/22/2413\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Colonic NETs have the worst prognosis of any gastrointestinal tract NET [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/18,32,35,36\">",
"     18,32,35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Stomach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric carcinoids are subdivided into three categories, with differing biologic behavior and prognoses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 1, which represent 70 to 80 percent of all gastric carcinoids, are associated with chronic atrophic gastritis. In this condition, serum gastrin rises in response to gastric achlorhydria. The elevated gastrin, in turn, simulates neuroendocrine cell hyperplasia in the stomach and development of multifocal polypoid carcinoid tumors. The clinical behavior of these tumors is usually indolent. Most are grade 1 tumors with stage I disease and no mortality with prolonged follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Type 2, which represent approximately 5 percent of gastric carcinoid tumors, also occur as a result of elevated serum gastrin levels stimulating multifocal gastric carcinoid tumors. The underlying cause of type 2 gastric carcinoids is a pancreatic or duodenal gastrinoma (Zollinger-Ellison syndrome). The clinical behavior is usually indolent. &nbsp;",
"     </li>",
"     <li>",
"      Type 3 gastric carcinoids (sporadic carcinoids) occur in the absence of atrophic gastritis or the Zollinger-Ellison syndrome. They account for 20 percent of gastric carcinoids and are the most aggressive; local or hepatic metastases are present in up to 65 percent of patients who come to resection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Definitions and a more complete discussion of characteristics of the different types of gastric carcinoids are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/60/969?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical characteristics of carcinoid tumors\", section on 'Stomach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The TNM staging system that includes carcinoid tumors of the stomach is outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef65045 \" href=\"mobipreview.htm?40/55/41852\">",
"     table 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management depends on the type of gastric carcinoid:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 3 (sporadic) gastric carcinoids are treated by partial or total gastrectomy with local lymph node resection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/38-40\">",
"       38-40",
"      </a>",
"      ]. The risk of nodal metastases is dependent on tumor size and depth, and some have suggested that endoscopic resection alone may represent adequate therapy for intraepithelial tumors &lt;2 cm and perhaps for tumors &lt;1 cm invading the lamina propria or submucosa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/41\">",
"       41",
"      </a>",
"      ]. However, this is not a standard approach.",
"      <br/>",
"      <br/>",
"      For type 1 and 2 gastric carcinoids smaller than 1 to 2 cm, endoscopic resection represents adequate therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. Subsequent endoscopic surveillance is needed every 6 to 12 months since these patients continue to exhibit mucosal changes and hyperplasia of enterochromaffin-like cells (ECL) due to sustained hypergastrinemia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Posttreatment follow-up'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Progression to a malignant phenotype or disease-related death is rare with small tumors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/44\">",
"       44",
"      </a>",
"      ]. Metastases occur in less than 10 percent of tumors &le;2 cm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/45\">",
"       45",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Antrectomy is a reasonable option for type 1 gastric carcinoids if there are numerous progressive tumors. Antrectomy reduces hypergastrinemia by reducing the gastrin-producing cell mass in the antrum of the stomach; in most cases, this leads to tumor regression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/43,46-49\">",
"       43,46-49",
"      </a>",
"      ]. The success of this approach was shown in a series of 51 patients with type I carcinoids, 10 of whom had antrectomy (eight in conjunction with endoscopic removal of the largest tumor) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/43\">",
"       43",
"      </a>",
"      ]. Seven of the eight with residual disease became endoscopically tumor-free, and one progressed and died of metastatic disease. In all, 9 of the 10 patients treated with antrectomy remained tumor-free for an average of 65 months.",
"     </li>",
"     <li>",
"      More aggressive surgical therapy is rarely needed for type 1 gastric carcinoids, unless there is extensive tumor involvement of the gastric wall (which increases the risk for a coexisting adenocarcinoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/50\">",
"       50",
"      </a>",
"      ]), tumor size &gt;2 cm (which increases the risk for metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/45\">",
"       45",
"      </a>",
"      ]), poorly differentiated histology, or for emergent bleeding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of medical rather than surgical therapy (anti-gastrin maneuvers such as acidification by diet or dilute oral hydrochloric acid, or somatostatin analog therapy) for type 1 tumors is debated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/38,48,52,53\">",
"     38,48,52,53",
"    </a>",
"    ]. Gastrin levels may or may not decrease, and continued endoscopic surveillance is necessary. Such therapy is best restricted to patients who are not suitable for surgical treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lung",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred treatment for bronchial carcinoids is surgical resection. The clinical features, diagnosis, and treatment of bronchial carcinoid tumors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/55/9082?source=see_link\">",
"     \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     POSTTREATMENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence from which to make recommendations for follow-up after resection of a carcinoid tumor. For all resected well-differentiated small intestinal and colonic carcinoid tumors, and for rectal, gastric, and appendiceal carcinoids &gt;2 cm, in our practice we focus on long-term (rather than frequent) surveillance given the fact that distant relapses can occur beyond five years after surgery, particularly with small bowel primary tumors. For example, in patients with resected small intestinal carcinoids, we generally recommend surveillance with triple-phase CT scans or MRI of the abdomen and pelvis, urine 5-HIAA, and CgA every six months for the first one to two years after surgery, annually for the next four years; and then every two years until approximately 10 years after surgery. For surveillance of carcinoid tumors at other sites, we generally follow the same strategy, but eliminate urinary 5-HIAA.",
"   </p>",
"   <p>",
"    We do not recommend posttreatment surveillance for appendiceal tumors &lt;2 cm and rectal tumors &lt;1 cm in size given the exceptionally low risks of recurrence.",
"   </p>",
"   <p>",
"    However, clinical practice is variable, particularly with respect to the use of serum tumor markers as a component of posttreatment surveillance. There are no data addressing the benefit of tumor markers in the posttreatment follow-up of carcinoid tumors. Urinary 5-HIAA is only useful as a tumor marker for midgut carcinoids (ie, those arising in small bowel or the proximal large bowel). &nbsp;",
"   </p>",
"   <p>",
"    When they are performed, assays for serum and urine biomarkers need to be interpreted in context. As an example, the use of proton pump inhibitors can falsely elevate serum CgA levels, and measurement of 24 hour urine 5-HIAA requires strict adherence to dietary restrictions during urine collection. Urine 5-HIAA measurements are not recommended for surveillance of tumors that are unlikely to produce serotonin, ie, carcinoid tumors of the hindgut (distal colon and rectum), or foregut (lungs, stomach, duodenum). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11400?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis of the carcinoid syndrome and tumor localization\", section on 'Chromogranin concentration'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11400?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnosis of the carcinoid syndrome and tumor localization\", section on 'Urinary excretion of 5-HIAA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8526341\">",
"    <span class=\"h2\">",
"     Recommendations from expert groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our recommendations are consistent with those of the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    , which are relatively non-specific after treatment of all resected small intestinal and colonic carcinoid tumors and for rectal, gastric, and appendiceal carcinoids &gt;2 cm:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       3 to 12 months postresection",
"      </strong>",
"      : History and physical examination, consider",
"      <span class=\"nowrap\">",
"       abdominal/pelvic",
"      </span>",
"      CT or MRI, consider urine 5-HIAA, consider assay of serum chromogranin A (CgA).",
"     </li>",
"     <li>",
"      <strong>",
"       &gt;1 year postresection",
"      </strong>",
"      : History and physical examination, consider urine 5-HIAA, consider assay of serum CGA, imaging studies as clinically indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Posttreatment surveillance is not recommended by the NCCN for appendiceal tumors &lt;2 cm and rectal tumors &lt;1 cm in size given the exceptionally low risks of recurrence. For rectal tumors 1 to 2 cm in size, the only surveillance recommended is proctoscopy at 6 and 12 months. We agree with this position. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36074?source=see_link&amp;anchor=H6#H6\">",
"     \"Cancer of the appendix and pseudomyxoma peritonei\", section on 'Posttreatment follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The NCCN guidelines for posttreatment surveillance of type I and II gastric carcinoids &le;2 cm include history and physical examination with esophagogastroduodenoscopy (EGD) every 6 to 12 months for three years and annually thereafter; imaging studies only as clinically indicated. We agree with this position.",
"   </p>",
"   <p>",
"    Our recommendations are also consistent with those of the North American Neuroendocrine Tumor Society (NANETS), although they also recommend posttreatment surveillance for appendiceal tumors between 1 and 2 cm in size if other poor prognosis factors such as lymphovascular invasion, mesoappendiceal invasion, intermediate or high-grade, or features of mixed histology are present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consensus-based follow-up guidelines are also available from the European Neuroendocrine Tumor Society (ENETS), and unlike other guidelines, specific recommendations are stratified according to risk of tumor recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/55\">",
"     55",
"    </a>",
"    ]. However, in our view, these posttreatment surveillance guidelines are overly complex and confusing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prognosis depends primarily on tumor stage, histologic",
"    <span class=\"nowrap\">",
"     grade/differentiation,",
"    </span>",
"    and site of origin. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19140597\">",
"    <span class=\"h2\">",
"     Stage and site of origin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognostic validity of tumor stage for well differentiated NETs of the luminal GI tract is supported by several studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/7,56-58\">",
"     7,56-58",
"    </a>",
"    ]. However, at least some data suggest that there are no significant difference in outcomes between stage I and II midgut (jejunal and ileocecal) carcinoids (five-year overall survival 100 percent for both), and heterogeneous outcomes in patients with stage IIIB (node-positive) disease depending on whether disease was resected (five-year overall survival 95 percent) or unresectable (five-year overall survival 78 percent) (",
"    <a class=\"graphic graphic_table graphicRef58532 \" href=\"mobipreview.htm?41/15/42236\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/58\">",
"     58",
"    </a>",
"    ]. The staging systems in use for well differentiated NETs of the GI tract (both those of the European Neuroendocrine Tumor Society and the AJCC staging system) do not acknowledge a distinction between resected and microscopically involved versus large and unresectable mesenteric lymph nodes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/40/6794?source=see_link&amp;anchor=H13525387#H13525387\">",
"     \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\", section on 'Staging system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Site also determines prognosis. As a general principle, well-differentiated tumors originating in the midgut (small intestine, proximal colon) are more prone to metastasize than are well-differentiated tumors of the foregut (lung, stomach) or hindgut (distal colon, rectum) (",
"    <a class=\"graphic graphic_table graphicRef56015 \" href=\"mobipreview.htm?17/7/17531\">",
"     table 3",
"    </a>",
"    ). However, they also progress more slowly once they do metastasize, and as a result, median survival durations are longer among patients with metastatic (stage IV) carcinoid tumors of the small intestine compared to metastatic carcinoid tumors originating in other sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/6\">",
"     6",
"    </a>",
"    ]. Prognosis is particularly poor for colonic carcinoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differing prognosis according to stage and site of origin can be illustrated by an analysis of the SEER database that evaluated the impact of primary tumor site and stage (localized, locally advanced, metastatic) in 35,618 patients with carcinoid tumors (",
"    <a class=\"graphic graphic_table graphicRef70558 \" href=\"mobipreview.htm?0/12/205\">",
"     table 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/35\">",
"     35",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19140604\">",
"    <span class=\"h2\">",
"     Tumor differentiation and grade",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World health Organization (WHO) classification system for neuroendocrine tumors (NETs) of the digestive system separates these tumors into two major categories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Well-differentiated NETs, which show a solid, trabecular, gyriform, or glandular pattern, with fairly uniform nuclei, salt-and-pepper chromatin, and finely granular cytoplasm.",
"     </li>",
"     <li>",
"      Poorly differentiated neuroendocrine carcinomas, which are high-grade carcinomas that resemble small cell or large cell neuroendocrine carcinoma of the lung (",
"      <a class=\"graphic graphic_picture graphicRef74630 \" href=\"mobipreview.htm?26/10/26794\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/43/22201?source=see_link&amp;anchor=H1176454#H1176454\">",
"       \"Pathology of lung malignancies\", section on 'Neuroendocrine tumors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Poorly differentiated neuroendocrine carcinomas are often associated with a rapid clinical course. Well-differentiated NETs, on the other hand, generally have a much better prognosis, even if metastatic. Issues of tumor classification are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/40/6794?source=see_link&amp;anchor=H799311#H799311\">",
"     \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to level of differentiation (the extent to which the neoplastic cells resemble their normal, nonneoplastic counterparts), grade, which reflects an assessment of the inherent biologic aggressiveness of the tumor, is also of prognostic significance. All poorly differentiated gastroenteropancreatic NETs are high-grade (grade 3), while well-differentiated NETs can be either low-grade (grade 1) or intermediate-grade (grade 2).",
"   </p>",
"   <p>",
"    Multiple studies have evaluated the impact of tumor grade (defined primarily by mitotic rate per 10 HPF",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Ki-67 labeling) on prognosis of gastroenteropancreatic neuroendocrine tumors. In one institutional study, five-year survival rates for metastatic gastrointestinal carcinoid tumors of low, intermediate, or high-grade histologic differentiation were 87, 38, and 0 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The guidelines for distinguishing low, intermediate, and high-grade tumors based upon mitotic rate (per 10 HPF) and Ki-67 index (percent), as defined by the American Joint Committee on cancer (AJCC), are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef53740 \" href=\"mobipreview.htm?27/28/28107\">",
"     table 11",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/5\">",
"     5",
"    </a>",
"    ]. It is important, however, to note that the grading cutoff points established by the AJCC are somewhat arbitrary and subject to change based on evolving data. Issues related to grading of gastroenteropancreatic NETs are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/40/6794?source=see_link&amp;anchor=H800434#H800434\">",
"     \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\", section on 'Issues related to assessing grade'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19140611\">",
"    <span class=\"h2\">",
"     Other prognostic factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Tumor burden &ndash;",
"      </strong>",
"      Among patients with liver metastases, burden is an important prognostic factor. In one institutional study of 301 patients with metastatic carcinoid tumors of the small intestine, five-year survival rates for those with &lt;5 and &ge;5 metastases were 79 and 47 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/62\">",
"       62",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Carcinoid heart disease -",
"      </strong>",
"      Presence of clinically significant valvular damage represents an important adverse prognostic factor. In a report of 146 patients with metastatic midgut carcinoid tumors, five-year survival rates were 75 percent for the entire cohort, while they were only 45 percent among the 23 patients (16 percent) with carcinoid heart disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12472?source=see_link\">",
"       \"Carcinoid heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Hormone production &ndash;",
"      </strong>",
"      There is no compelling evidence that functioning tumors (ie, those associated with the carcinoid syndrome) have a worse prognosis than nonfunctioning tumors among patients with metastatic disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19140618\">",
"    <span class=\"h2\">",
"     Survival trends",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies, based upon population registries as well as institutional data, have documented a trend towards improved survival for carcinoid tumors over the past three decades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/35,63,64\">",
"     35,63,64",
"    </a>",
"    ]. As an example, an analysis of the SEER database observed a dramatic increase in median survival among patients diagnosed between 1988 and 2004 versus 1973 and 1987 (138 versus 95 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/35\">",
"     35",
"    </a>",
"    ]. The introduction of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    in 1987 was hypothesized to be a potential factor explaining the apparent improvement in survival; however, earlier diagnosis may also be an explanatory factor.",
"   </p>",
"   <p>",
"    The prognosis of patients with carcinoid heart disease has also improved significantly over the past 20 years, possibly due to increasing valve replacement surgeries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39897/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12472?source=see_link&amp;anchor=H17#H17\">",
"     \"Carcinoid heart disease\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The basic principles of evaluation and management of patients with carcinoid tumors consists of localization and staging of tumors, pathologic assessment of the histologic grade and differentiation, surgical removal of tumor(s) if the disease is surgically resectable, control of symptoms of carcinoid syndrome, if present, and judicious use of antitumor therapy for unresectable metastatic disease. A key principle underlying selection of appropriate therapy for advanced disease is the indolent nature of most well-differentiated carcinoids and their prolonged natural history. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a localized carcinoid tumor, we recommend resection, the extent of which depends upon the site of origin and size of the primary tumor (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Resection of the primary tumor may be advised even in patients with known distant metastases in order to reduce the potential for bowel obstruction, bleeding, or to palliate abdominal pain related to the primary tumor. This is a controversial area, and decision-making must be individualized. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment of localized carcinoid tumors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14320540\">",
"    <span class=\"h2\">",
"     Management by site",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following represents our approach to specific sites:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Simple appendectomy is sufficient for tumors &lt;2 cm that do not invade the mesoappendix. A right hemicolectomy has been traditionally recommended for tumors &gt;2 cm or those with mesoappendiceal invasion but this is controversial. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Appendix'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with small bowel carcinoids should undergo resection of the involved segment and small bowel mesentery. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Small intestine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ampulla of Vater carcinoid tumors may be more aggressive than other duodenal carcinoid tumors. Pancreaticoduodenectomy has been advocated for resectable cases regardless of size. However, these recommendations are based on very small case series and treatment decisions need to be individualized. (See",
"      <a class=\"local\" href=\"#H5647503\">",
"       'Ampulla of Vater'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rectal carcinoids that are smaller than 1 cm and confined to the mucosa or submucosa (T1) can be treated by local endoscopic excision. The management of tumors between 1 and 2 cm that are confined to the mucosa or submucosa is controversial. Tumors larger than 2 cm and those that invade into or beyond the muscularis propria or have regional lymph node metastases are treated by low anterior resection (LAR) or abdominoperineal resection (APR). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Rectum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with nonmetastatic colonic carcinoid tumors should be managed with formal partial colectomy and regional lymphadenectomy. (See",
"      <a class=\"local\" href=\"#H432448\">",
"       'Colon'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Local management for gastric carcinoids depends on the type (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Stomach'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Type 3 (sporadic) gastric carcinoids are treated by partial or total gastrectomy with local lymph node resection.",
"     </li>",
"     <li>",
"      For type 1 and 2 gastric carcinoids smaller than 1 to 2 cm, endoscopic resection is the treatment of choice. Antrectomy is a reasonable option for type 1 gastric carcinoids if there are numerous progressive tumors.",
"     </li>",
"     <li>",
"      More aggressive surgical therapy is rarely needed for type 1 gastric carcinoids, unless there is extensive tumor involvement of the gastric wall (which increases the risk for a coexisting adenocarcinoma), tumor size &gt;2 cm, or for emergent bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14320532\">",
"    <span class=\"h2\">",
"     Posttreatment followup",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Given the long-natural history and the propensity for small bowel carcinoid tumors to metastasize, we recommend surveillance with triple-phase CT scans or MRI of the abdomen and pelvis, urine 5-HIAA, and assay for serum chromogranin A (CgA) every six months for the first one to two years after surgery; annually for the next four years; and then every two years until approximately 10 years after surgery for all resected small intestinal and colonic carcinoid tumors, and for rectal, gastric, and appendiceal carcinoids &gt;2 cm. (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Posttreatment follow-up'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Posttreatment surveillance is not recommended for appendiceal tumors &lt;2 cm and rectal tumors &lt;1 cm in size. For superficial rectal tumors 1 to 2 cm in size, the only surveillance recommended is proctoscopy at 6 and 12 months.",
"     </li>",
"     <li>",
"      For gastric carcinoids &le;2 cm, we recommend history and physical examination with esophagogastroduodenoscopy (EGD) every 6 to 12 months for three years and annually thereafter; imaging studies only as clinically indicated.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/1\">",
"      Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999; 340:858.",
"     </a>",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th ed, Edge, SB, Byrd, DR, Compton, CC, et al (Eds), Springer, New York 2010. p.133.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/3\">",
"      Pape UF, Perren A, Niederle B, et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012; 95:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/4\">",
"      Yantiss RK, Odze RD, Farraye FA, Rosenberg AE. Solitary versus multiple carcinoid tumors of the ileum: a clinical and pathologic review of 68 cases. Am J Surg Pathol 2003; 27:811.",
"     </a>",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th ed, Edge, SB, Byrd, DR, Compton, CC, et al (Eds), Springer, New York 2010. p.181.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/6\">",
"      Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology 2009; 89:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/7\">",
"      Jann H, Roll S, Couvelard A, et al. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 2011; 117:3332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/8\">",
"      Landerholm K, Zar N, Andersson RE, et al. Survival and prognostic factors in patients with small bowel carcinoid tumour. Br J Surg 2011; 98:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/9\">",
"      Poultsides GA, Frederick WA. Carcinoid of the ampulla of Vater: morphologic features and clinical implications. World J Gastroenterol 2006; 12:7058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/10\">",
"      Carter JT, Grenert JP, Rubenstein L, et al. Neuroendocrine tumors of the ampulla of Vater: biological behavior and surgical management. Arch Surg 2009; 144:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/11\">",
"      Clements WM, Martin SP, Stemmerman G, Lowy AM. Ampullary carcinoid tumors: rationale for an aggressive surgical approach. J Gastrointest Surg 2003; 7:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/12\">",
"      Makhlouf HR, Burke AP, Sobin LH. Carcinoid tumors of the ampulla of Vater: a comparison with duodenal carcinoid tumors. Cancer 1999; 85:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/13\">",
"      Kwaan MR, Goldberg JE, Bleday R. Rectal carcinoid tumors: review of results after endoscopic and surgical therapy. Arch Surg 2008; 143:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/14\">",
"      Fujishima H, Misawa T, Maruoka A, et al. Rectal carcinoid tumor: endoscopic ultrasonographic detection and endoscopic removal. Eur J Radiol 1993; 16:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/15\">",
"      Kobayashi K, Katsumata T, Yoshizawa S, et al. Indications of endoscopic polypectomy for rectal carcinoid tumors and clinical usefulness of endoscopic ultrasonography. Dis Colon Rectum 2005; 48:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/16\">",
"      Mani S, Modlin IM, Ballantyne G, et al. Carcinoids of the rectum. J Am Coll Surg 1994; 179:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/17\">",
"      Park CH, Cheon JH, Kim JO, et al. Criteria for decision making after endoscopic resection of well-differentiated rectal carcinoids with regard to potential lymphatic spread. Endoscopy 2011; 43:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/18\">",
"      Caplin M, Sundin A, Nillson O, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology 2012; 95:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/19\">",
"      Onozato Y, Kakizaki S, Iizuka H, et al. Endoscopic treatment of rectal carcinoid tumors. Dis Colon Rectum 2010; 53:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/20\">",
"      Ono A, Fujii T, Saito Y, et al. Endoscopic submucosal resection of rectal carcinoid tumors with a ligation device. Gastrointest Endosc 2003; 57:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/21\">",
"      Fujishiro M, Yahagi N, Nakamura M, et al. Successful outcomes of a novel endoscopic treatment for GI tumors: endoscopic submucosal dissection with a mixture of high-molecular-weight hyaluronic acid, glycerin, and sugar. Gastrointest Endosc 2006; 63:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/22\">",
"      Berkelhammer C, Jasper I, Kirvaitis E, et al. \"Band-snare\" resection of small rectal carcinoid tumors. Gastrointest Endosc 1999; 50:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/23\">",
"      Okamoto Y, Fujii M, Tateiwa S, et al. Treatment of multiple rectal carcinoids by endoscopic mucosal resection using a device for esophageal variceal ligation. Endoscopy 2004; 36:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/24\">",
"      Imada-Shirakata Y, Sakai M, Kajiyama T, et al. Endoscopic resection of rectal carcinoid tumors using aspiration lumpectomy. Endoscopy 1997; 29:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/25\">",
"      Murray SE, Sippel RS, Lloyd R, Chen H. Surveillance of small rectal carcinoid tumors in the absence of metastatic disease. Ann Surg Oncol 2012; 19:3486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/26\">",
"      Landry CS, Brock G, Scoggins CR, et al. A proposed staging system for rectal carcinoid tumors based on an analysis of 4701 patients. Surgery 2008; 144:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/27\">",
"      Naunheim KS, Zeitels J, Kaplan EL, et al. Rectal carcinoid tumors--treatment and prognosis. Surgery 1983; 94:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/28\">",
"      Shields CJ, Tiret E, Winter DC, International Rectal Carcinoid Study Group. Carcinoid tumors of the rectum: a multi-institutional international collaboration. Ann Surg 2010; 252:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/29\">",
"      Schindl M, Niederle B, H&auml;fner M, et al. Stage-dependent therapy of rectal carcinoid tumors. World J Surg 1998; 22:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/30\">",
"      Kinoshita T, Kanehira E, Omura K, et al. Transanal endoscopic microsurgery in the treatment of rectal carcinoid tumor. Surg Endosc 2007; 21:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/31\">",
"      Tsai BM, Finne CO, Nordenstam JF, et al. Transanal endoscopic microsurgery resection of rectal tumors: outcomes and recommendations. Dis Colon Rectum 2010; 53:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/32\">",
"      Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/33\">",
"      Rosenberg JM, Welch JP. Carcinoid tumors of the colon. A study of 72 patients. Am J Surg 1985; 149:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/34\">",
"      Ballantyne GH, Savoca PE, Flannery JT, et al. Incidence and mortality of carcinoids of the colon. Data from the Connecticut Tumor Registry. Cancer 1992; 69:2400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/35\">",
"      Yao JC, Hassan M, Phan A, et al. One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26:3063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/36\">",
"      Maggard MA, O'Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg 2004; 240:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/37\">",
"      Thomas D, Tsolakis AV, Grozinsky-Glasberg S, et al. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. Eur J Endocrinol 2013; 168:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/38\">",
"      Gilligan CJ, Lawton GP, Tang LH, et al. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol 1995; 90:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/39\">",
"      Pl&ouml;ckinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/40\">",
"      Delle Fave G, Kwekkeboom DJ, Van Cutsem E, et al. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology 2012; 95:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/41\">",
"      Saund MS, Al Natour RH, Sharma AM, et al. Tumor size and depth predict rate of lymph node metastasis and utilization of lymph node sampling in surgically managed gastric carcinoids. Ann Surg Oncol 2011; 18:2826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/42\">",
"      Sj&ouml;blom SM, Sipponen P, J&auml;rvinen H. Gastroscopic follow up of pernicious anaemia patients. Gut 1993; 34:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/43\">",
"      Borch K, Ahr&eacute;n B, Ahlman H, et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005; 242:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/44\">",
"      Schindl M, Kaserer K, Niederle B. Treatment of gastric neuroendocrine tumors: the necessity of a type-adapted treatment. Arch Surg 2001; 136:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/45\">",
"      Soga J. Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases. Cancer 2005; 103:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/46\">",
"      Hirschowitz BI, Griffith J, Pellegrin D, Cummings OW. Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology 1992; 102:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/47\">",
"      Higham AD, Dimaline R, Varro A, et al. Octreotide suppression test predicts beneficial outcome from antrectomy in a patient with gastric carcinoid tumor. Gastroenterology 1998; 114:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/48\">",
"      Dakin GF, Warner RR, Pomp A, et al. Presentation, treatment, and outcome of type 1 gastric carcinoid tumors. J Surg Oncol 2006; 93:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/49\">",
"      Ozao-Choy J, Buch K, Strauchen JA, et al. Laparoscopic antrectomy for the treatment of type I gastric carcinoid tumors. J Surg Res 2010; 162:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/50\">",
"      Gladdy RA, Strong VE, Coit D, et al. Defining surgical indications for type I gastric carcinoid tumor. Ann Surg Oncol 2009; 16:3154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/51\">",
"      Jordan PH Jr, Barroso A, Sweeney J. Gastric carcinoids in patients with hypergastrinemia. J Am Coll Surg 2004; 199:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/52\">",
"      Ferraro G, Annibale B, Marignani M, et al. Effectiveness of octreotide in controlling fasting hypergastrinemia and related enterochromaffin-like cell growth. J Clin Endocrinol Metab 1996; 81:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/53\">",
"      Granberg D, Wilander E, Stridsberg M, et al. Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids. Gut 1998; 43:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/54\">",
"      Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas 2010; 39:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/55\">",
"      Arnold R, Chen YJ, Costa F, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology 2009; 90:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/56\">",
"      Pape UF, Jann H, M&uuml;ller-Nordhorn J, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008; 113:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/57\">",
"      Dolcetta-Capuzzo A, Villa V, Albarello L, et al. Gastroenteric neuroendocrine neoplasms classification: comparison of prognostic models. Cancer 2013; 119:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/58\">",
"      Strosberg JR, Weber JM, Feldman M, et al. Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol 2013; 31:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/59\">",
"      Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010; 39:707.",
"     </a>",
"    </li>",
"    <li>",
"     Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours of the Digestive System, 4th ed, Bosman TF, Carneiro F, Hruban RH, Theise ND (Eds), International Agency for Research on cancer (IARC), Lyon 2010. p.13.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/61\">",
"      Strosberg J, Nasir A, Coppola D, et al. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol 2009; 40:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/62\">",
"      Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997; 8:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/63\">",
"      Tomassetti P, Campana D, Piscitelli L, et al. Endocrine tumors of the ileum: factors correlated with survival. Neuroendocrinology 2006; 83:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/64\">",
"      Zar N, Garmo H, Holmberg L, et al. Long-term survival of patients with small intestinal carcinoid tumors. World J Surg 2004; 28:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39897/abstract/65\">",
"      M&oslash;ller JE, Pellikka PA, Bernheim AM, et al. Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation 2005; 112:3320.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2615 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.147-71980919F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_61_39897=[""].join("\n");
var outline_f38_61_39897=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT OF LOCALIZED CARCINOID TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Appendix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Small intestine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5647503\">",
"      Ampulla of Vater",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H432448\">",
"      Colon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Stomach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      POSTTREATMENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8526341\">",
"      Recommendations from expert groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19140597\">",
"      Stage and site of origin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19140604\">",
"      Tumor differentiation and grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19140611\">",
"      Other prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19140618\">",
"      Survival trends",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14320540\">",
"      Management by site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14320532\">",
"      Posttreatment followup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2615\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2615|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/10/26794\" title=\"picture 1\">",
"      Histologic appearance of neuroendocrine tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2615|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/59/35771\" title=\"table 1\">",
"      Products of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/54/38763\" title=\"table 2\">",
"      Carcinoid symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/7/17531\" title=\"table 3\">",
"      Characteristics of carcinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/6/14444\" title=\"table 4\">",
"      Incidence mets carcinoid size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/18/4397\" title=\"table 5\">",
"      TNM stage append carcinoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/15/42236\" title=\"table 6\">",
"      TNM gastrointest carcinoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/63/41980\" title=\"table 7\">",
"      Survival small bowel carcinoid tumor by stage and resection type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/22/2413\" title=\"table 8\">",
"      TNM staging CRC carcinoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/55/41852\" title=\"table 9\">",
"      TNM stage gastric carcinoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/12/205\" title=\"table 10\">",
"      Carcinoid survival by stage and site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/28/28107\" title=\"table 11\">",
"      AJCC criteria for histologic grade of neuroendocrine tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/55/9082?source=related_link\">",
"      Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36074?source=related_link\">",
"      Cancer of the appendix and pseudomyxoma peritonei",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12472?source=related_link\">",
"      Carcinoid heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/60/969?source=related_link\">",
"      Clinical characteristics of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11400?source=related_link\">",
"      Diagnosis of the carcinoid syndrome and tumor localization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28967?source=related_link\">",
"      Endoscopic ultrasound in rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/31/18938?source=related_link\">",
"      Epidemiology, clinical features, and types of small bowel neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/30/43496?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6665?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41174?source=related_link\">",
"      Neuroendocrine cancer of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/49/30489?source=related_link\">",
"      Overview of the management of primary colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/43/22201?source=related_link\">",
"      Pathology of lung malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/40/6794?source=related_link\">",
"      Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16762?source=related_link\">",
"      Surgical oncologic principles for the resection of colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/28/21962?source=related_link\">",
"      Thymic neuroendocrine (carcinoid) tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/8/21642?source=related_link\">",
"      Treatment of small bowel neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16888?source=related_link\">",
"      Treatment of the carcinoid syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_61_39898="Systemic treatment for advanced hepatocellular carcinoma";
var content_f38_61_39898=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Systemic treatment for advanced hepatocellular carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/61/39898/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/61/39898/contributors\">",
"     Keith E Stuart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/61/39898/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/61/39898/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/61/39898/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/61/39898/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/61/39898/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocellular carcinoma (HCC) is an aggressive tumor that frequently occurs in the setting of chronic liver disease and cirrhosis. It is typically diagnosed late in the course of patients with chronic liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/1\">",
"     1",
"    </a>",
"    ]. The patient's hepatic reserve, as indicated by the Child-Pugh classification, often dictates therapeutic options (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Treatment options for HCC are divided into surgical therapies (ie, resection, cryoablation, and liver transplantation) and nonsurgical therapies, which may be liver-directed (ie, percutaneous ethanol injection, radiofrequency ablation, transarterial chemoembolization, radiation and radioembolization) or systemic (chemotherapy, molecularly targeted therapy, hormone therapy). A general approach to the treatment of HCC is shown in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef57014 \" href=\"mobipreview.htm?40/37/41567\">",
"     algorithm 1",
"    </a>",
"    ). An alternative treatment algorithm has been proposed by the Barcelona group (",
"    <a class=\"graphic graphic_algorithm graphicRef69566 \" href=\"mobipreview.htm?11/36/11855\">",
"     algorithm 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Attempts to generate algorithmic approaches to the treatment of HCC are difficult since new treatments and indications for various treatments are evolving rapidly. Furthermore, therapeutic approaches tend to vary based upon the available expertise as well as variability in the criteria for hepatic resection and liver transplantation. These issues and a general approach to treatment of HCC are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43063?source=see_link\">",
"     \"Overview of treatment approaches for hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Here we will discuss systemic treatment approaches for patients with advanced, unresectable HCC for whom liver-directed therapy is not appropriate. Surgical treatment, liver-directed nonsurgical therapies, and the epidemiology, clinical manifestations, and diagnosis of HCC are reviewed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palliative chemotherapy has not been used routinely for patients with advanced HCC for a number of reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HCC has been considered to be a relatively chemotherapy-refractory tumor. This may be in part due to the high rate of expression of drug resistance genes, including p-glycoprotein, glutathione-S-transferase, heat shock proteins, and mutations in p53.",
"     </li>",
"     <li>",
"      It can be difficult to gauge survival benefits from a systemic therapy regimen in patients with advanced HCC since survival is often determined not by tumor aggressiveness or the impact of a systemic treatment, but by the degree of hepatic dysfunction. Systemic chemotherapy is usually not well tolerated by patients with significant underlying hepatic dysfunction.",
"     </li>",
"     <li>",
"      Clinical investigations of chemotherapy in advanced HCC have been undertaken in diverse patient populations. As an example, patients in Asian studies tend to be significantly younger, with well compensated cirrhosis due to chronic hepatitis B or C, while North American or European patients with HCC are typically over 60, with alcoholic cirrhosis and comorbid illnesses. Not only does this interfere with chemotherapy tolerance, dose, and the reported side effect profile, but in studies applying strict entry criteria, the results may be applicable only to the small minority of Western patients who have well preserved hepatic function. Moreover, chemotherapy may have less efficacy in patients with significant cirrhosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There has been a resurgence of interest and enthusiasm for systemic therapy of HCC with the emergence of data showing that single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    improves survival over best supportive care alone. These results established sorafenib monotherapy as the new reference standard systemic treatment for advanced HCC and formed the basis for approval of sorafenib for unresectable HCC in the United States. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Sorafenib'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, there still may be a role for cytotoxic chemotherapy in selected medically appropriate patients who fail or are intolerant of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    , and who have adequate hepatic function and a reasonable remaining life expectancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Estimating life expectancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several staging or prognostic systems have been developed to guide the prognosis and treatment of patients with HCC. These include the American Joint Committee on Cancer (AJCC) TNM, Okuda, CLIP (Cancer of the Liver Italian Program), CUPI (Chinese University Prognostic Index), GETCH (Groupe d&rsquo;Etude et de Traitement du Carcinome Hepatocellulaire) and the BCLC (Barcelona Clinic) staging systems. These systems were developed based upon both surgical and nonsurgical patients, and they generally aim to classify patients with HCC broadly into those with early, intermediate, and advanced stage disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25992?source=see_link\">",
"     \"Staging and prognostic factors in hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with advanced HCC are a heterogeneous group. There are substantial differences in overall survival that are due to factors not captured within the subgroups identified by these staging systems, and it is not clear that any of these staging systems provides meaningful prognostic discrimination among those with advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there is some evidence that outcomes of nonsurgical HCC can be predicted by both patient and tumor characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. As an example, a prognostic scoring system for patients with advanced HCC not amenable to locoregional therapy has been proposed (the ALCPS, Advanced Liver Cancer Prognostic System), which allows a separation of three prognostic groups with significantly different three-month survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/5\">",
"     5",
"    </a>",
"    ]. The stratification is based upon the assignment of a weighted point value to 11 different patient and tumor characteristics, with the total number of points corresponding to an estimated likelihood of three month survival (",
"    <a class=\"graphic graphic_table graphicRef57772 \" href=\"mobipreview.htm?27/56/28557\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    While a prognostic scoring system such as this can objectively help clinicians to select appropriate candidates for evaluation of treatment efficacy in clinical trials of new agents, there are no prospective data addressing its ability to predict which patients might benefit from any form of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Response assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventionally, treatment response of HCC to systemic therapy has been assessed by radiologic imaging using conventional response criteria such as that of the World Health Organization or RECIST (Response Evaluation Criteria in Solid Tumors) (",
"    <a class=\"graphic graphic_table graphicRef74693 \" href=\"mobipreview.htm?41/48/42764\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. However, criteria such as these may not accurately reflect response to treatment or tumor viability, particularly in the era of targeted therapy with agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    that are cytostatic rather than cytotoxic. It is not uncommon to observe patients without a significant radiographic response who have evidence of reduced tumor viability or even a pathologic complete response in a resected specimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Furthermore, in patients with HCC treated with sorafenib, tumor necrosis may initially be manifested as an enlarging rather than a shrinking lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An HCC expert consensus proposed the use of modified RECIST criteria, which mainly measure tumor viability in assessing response for patients with HCC treated with targeted agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef58792 \" href=\"mobipreview.htm?27/46/28396\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/2,12,13\">",
"     2,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, guidelines from the European Association for Study of the Liver (EASL) suggest that estimated reduction in viable tumor burden using dynamic imaging techniques be incorporated into definitions for response for patients receiving local ablation therapies for HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/14\">",
"     14",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36138?source=see_link&amp;anchor=H3#H3\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\", section on 'Assessing response to locoregional therapies'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete response (CR) &mdash; Absence of enhanced tumor areas, reflecting complete necrosis",
"     </li>",
"     <li>",
"      Partial response (PR) &mdash; A &gt;50 percent decrease in enhanced areas, reflecting partial tissue necrosis",
"     </li>",
"     <li>",
"      Progressive disease (PD) &mdash; An increase &gt;25 percent in the size of &ge;1 measurable lesion or appearance of a new lesion",
"     </li>",
"     <li>",
"      Stable disease &mdash; Any tumor response between PR and PD",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although not used widely for patients receiving systemic chemotherapy, response monitoring using functional criteria such as the EASL criteria or modified RECIST may provide a more accurate reflection of vital tumor burden and treatment benefit than standard RECIST, particularly for cytostatic treatments targeting angiogenesis, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/2,11,13,15\">",
"     2,11,13,15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Sorafenib'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Serial measurements of the serum tumor marker alpha fetoprotein (AFP) appear to be a valid surrogate endpoint for the identification of patients who would derive benefit from systemic chemotherapy, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. In one study, AFP responders (arbitrarily defined as patients whose serum AFP decreased by more than 20 percent after a minimum of two cycles of chemotherapy) had better median survival than did nonresponders (13.5 versus 5.6 months), and AFP response was strongly associated with radiographic response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/16\">",
"     16",
"    </a>",
"    ]. Furthermore, an AFP response was frequently observed in patients with radiographically stable disease, and served to identify a subgroup of these patients with better survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SYSTEMIC CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy has not been used routinely for patients with advanced HCC for a number of reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HCC has been considered a relatively chemotherapy refractory tumor. This may be in part due to the high rate of expression of drug resistance genes, including p-glycoprotein, glutathione-S-transferase, heat shock proteins, and mutations in p53 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/20-22\">",
"       20-22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It can be difficult to gauge benefit from chemotherapy in patients with advanced HCC since survival is often determined not by tumor aggressiveness or the impact of a systemic treatment, but by the degree of hepatic dysfunction. Systemic chemotherapy is usually not well tolerated by patients with significant underlying hepatic dysfunction.",
"     </li>",
"     <li>",
"      Clinical investigations of chemotherapy in advanced HCC have been undertaken in diverse patient populations. As an example, patients in Asian studies tend to be significantly younger, with well-compensated cirrhosis due to chronic hepatitis B or C, while North American or European patients with HCC are typically over 60, with alcoholic cirrhosis and comorbid illnesses. Not only does this interfere with chemotherapy tolerance, dose, and the reported side effect profile, but in studies applying strict entry criteria, the results may be applicable only to the small minority of Western patients who have well preserved hepatic function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Furthermore, chemotherapy may be less effective overall in patients with significant cirrhosis. This was illustrated in an evaluation of predictive factors among 147 patients receiving chemotherapy for HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/23\">",
"     23",
"    </a>",
"    ]. There were no objective responses among patients with a poor performance status, ascites, portal vein tumor thrombus, or serum bilirubin &gt;2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35286487\">",
"    <span class=\"h2\">",
"     Monotherapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Doxorubicin and mitoxantrone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    has been the most studied chemotherapy agent for advanced HCC. Although an early trial in 1975 reported dramatic clinical activity and a 79 percent response rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/24\">",
"     24",
"    </a>",
"    ], subsequent work suggests that the true objective response rate with doxorubicin monotherapy is 20 percent or less with doses of 75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/25-30\">",
"     25-30",
"    </a>",
"    ]. Lower doses (&le;60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per cycle) are associated with even lower objective response rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the modest objective response rate, at least two controlled trials involving 106 and 445 patients, respectively, suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    is associated with a small survival advantage compared to either best supportive care alone (median survival 10.6 versus 7.5 weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/28\">",
"     28",
"    </a>",
"    ] or nolatrexed (median survival 32 versus 22 weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/32\">",
"     32",
"    </a>",
"    ]. The reason for the disparate survival outcomes in these two trials is unclear, but patient selection may have played a role.",
"   </p>",
"   <p>",
"    A limited number of phase III studies note higher response rates but no survival benefit with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    monotherapy compared to non-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    5-FU-based regimens and single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/29,33,34\">",
"     29,33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    have an approximately similar level of antitumor efficacy as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (response rates 10 to 25 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. In contrast, the single agent activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    (PLD) is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Combination regimens containing PLD are discussed below. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Gemcitabine-based'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    High-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    may potentiate the antitumor effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/42\">",
"     42",
"    </a>",
"    ]. In an open-label trial in which 38 patients with advanced HCC received doxorubicin plus tamoxifen (120",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day), 12 (32 percent) achieved a response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/43\">",
"     43",
"    </a>",
"    ]. However, the median progression free survival was only seven months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Fluoropyrimidines",
"    </span>",
"    &nbsp;&mdash;&nbsp;5-Fluorouracil (5-FU) has acceptably low toxicity and broad antitumor efficacy. Although there is extensive hepatic metabolism, adequate doses can usually be administered in the setting of hepatic dysfunction or jaundice.",
"   </p>",
"   <p>",
"    Response rates with 5-FU monotherapy have been low. However, when given in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    , response rates as high as 28 percent have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/44\">",
"     44",
"    </a>",
"    ], although lower rates have been noted by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Single agent treatment with the orally active fluoropyrimidine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/46\">",
"     46",
"    </a>",
"    ] was associated with an objective response in nine of 37 patients (25 percent) in one study, including one complete response. However, a lower objective response rate (three partial responses among 50 treated patients) was noted in a subsequent phase II study evaluating the same dose of capecitabine in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (130",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H35286534\">",
"     'Oxaliplatin-based'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Gemcitabine, irinotecan, and thalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    has modest activity at best. In one report, 5 of 28 patients with locally advanced or metastatic disease who received gemcitabine (1250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    once weekly) had a partial response of short duration (median 13 weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/48\">",
"     48",
"    </a>",
"    ]. However, two other trials were disappointing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]; one showed no objective responses in 30 patients treated with gemcitabine 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    although nine achieved stable disease for a median of 7.4 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     Irinotecan",
"    </a>",
"    monotherapy resulted in one partial response for seven months among 14 patients with advanced HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/51\">",
"     51",
"    </a>",
"    ]. A second trial in 29 patients documented no objective partial responses but 12 disease stabilizations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In early reports,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , an agent with antiangiogenic activity, [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/53-55\">",
"     53-55",
"    </a>",
"    ] has been associated with low rates of objective antitumor activity but disease stabilization in up to one-third of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Combination chemotherapy regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple combination cytotoxic regimens have been tested in patients with advanced HCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Cisplatin-based",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    -based combination regimens appear to result in higher objective response rates than non-cisplatin-containing regimens, although it is not clear that any regimen confers a survival benefit. Response rates with several two and three-drug regimens are approximately the same:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      &ndash; Response rates 18 and 49 percent in two studies, one conducted in children (with predominantly HCC rather than the more chemosensitive hepatoblastoma) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      , and continuous infusion 5-FU &ndash; Objective response rate 24 and 27 percent in two different studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      and infusional 5-FU &ndash; Response rate 15 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/60\">",
"       60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      &ndash; Response rate 24 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/61\">",
"       61",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Sequential low-dose infusional",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus infusional 5-FU &ndash; Response rate 47 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/62\">",
"       62",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      &ndash; Response rate 6 and 20 percent in two studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/63,64\">",
"       63,64",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Gemcitabine-based",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      &nbsp;and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      &ndash; In one phase II study, the combination of gemcitabine (1250",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 8) and cisplatin (70",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1 of every 21-day cycle) was associated with an overall response rate of 20 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/65\">",
"       65",
"      </a>",
"      ]. Grade 3 to 4 toxicities included anemia (37 percent), neutropenia (13 percent), thrombocytopenia (7 percent), transaminitis and mucositis (3 percent each). A second trial using a slightly different dosing regimen (cisplatin 25",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 8, gemcitabine 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 8) reported a more favorable toxicity profile but a lower response rate (one partial response among 15 patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"       pegylated liposomal doxorubicin",
"      </a>",
"      &ndash; Pegylated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"       liposomal doxorubicin",
"      </a>",
"      (PLD) in combination with gemcitabine is modestly active. In a phase II trial, 41 patients received gemcitabine (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1 and 8) plus pegylated liposomal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1) every 28 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/67\">",
"       67",
"      </a>",
"      ]. There were three complete and seven partial responses (overall response rate 24 percent), the median TTP was 5.8 months, and median overall survival was 22.5 months. Treatment was well tolerated, with grade 3 to 4 toxicity limited to neutropenia (17 percent) and thrombocytopenia (2 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35286534\">",
"    <span class=\"h3\">",
"     Oxaliplatin-based",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combinations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    or a fluoropyrimidine are active in patients with advanced HCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35286602\">",
"    <span class=\"h4\">",
"     GEMOX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activity has been suggested for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (GEMOX), a regimen that lacks substantial renal and hepatic toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. In a phase II study involving 32 cirrhotics with previously untreated advanced HCC (lung metastases in 10, multifocal liver disease in 18, the rest node-positive), gemcitabine (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    by fixed dose rate infusion) on day 1 was followed by oxaliplatin (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    on day 2, with both drugs repeated every two weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/68\">",
"     68",
"    </a>",
"    ]. Grade 3 or 4 toxicities included thrombocytopenia (27 percent), neutropenia (24 percent with two cases of febrile neutropenia), anemia (9 percent) and neuropathy (9 percent). The objective response rate was 18 percent, and an additional 58 percent had disease stabilization. Median survival was 11.5 months. For unclear reasons, treatment seemed to be more effective in patients with nonalcoholic rather than alcoholic cirrhosis. Combinations of GEMOX with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    are discussed below. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Molecularly targeted therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35286632\">",
"    <span class=\"h4\">",
"     XELOX",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a phase II study evaluating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for 14 of every 21 days) in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (130",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks), there were only three partial responses among 50 treated patients (objective response rate 6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/47\">",
"     47",
"    </a>",
"    ]. However, 29 additional patients had stable disease, and the disease control rate was 72 percent. Median overall and progression-free survival were 9.3 and 4.1 months, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41195279\">",
"    <span class=\"h4\">",
"     FOLFOX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regimens containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    plus short-term infusional 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    are most commonly used in the treatment of advanced colorectal cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Modified FOLFOX4 (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 5",
"    </a>",
"    ) was directly compared to single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks) in an Asian trial of 371 patients with advanced or metastatic HCC, 90 percent of whom had HBV infection as the underlying etiology of cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/70\">",
"     70",
"    </a>",
"    ]. In a preliminary report of the most mature data (after 305 events had occurred), which were presented in an oral abstract session of the 2010 ASCO annual meeting, the median survival in the FOLFOX arm, although significantly better than that with doxorubicin monotherapy, was short (6.5 versus 4.9 months, p = .00425). FOLFOX was also associated with significantly better median PFS (3 versus 1.8 months), objective response rate (9 versus 3 percent), and disease control rate (partial response plus stable disease, 53 versus 33 percent). Although the rate of sensory neuropathy was higher in the FOLFOX group (15 versus 0.6 percent), most cases were mild, and there were no significant differences in the rate of grade 3 or 4 toxicities (either hematologic or nonhematologic) between the groups.",
"   </p>",
"   <p>",
"    Interpretation of these results is hampered by the use of a relatively low dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    in the control arm. Furthermore, whether these results can be extrapolated to American patients, who have alcohol or HCV rather than HBV as the underlying cause of cirrhosis, is unclear. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of cytotoxic chemotherapy is modest in patients with HCC, and in general, the duration of benefit is limited. No single regimen has emerged as superior to any other, although few randomized trials have been conducted. Despite objective responses that are occasionally complete, median survival in all of these studies has been short (4.4 to 11.6 months), with the exception of those in which",
"    <span class=\"nowrap\">",
"     resection/transplantation",
"    </span>",
"    is attempted after chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Interferon alfa and chemoimmunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;IFNa is an immunomodulatory cytokine that has demonstrated activity in preclinical models against several tumor types including HCC. At least three controlled trials have evaluated IFNa monotherapy for patients with advanced HCC, with conflicting results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An early Chinese randomized trial of 75 patients suggested superior response rates and better tolerability of IFNa compared to single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A possible survival benefit for IFNa compared to BSC was suggested in a second trial in which 75 patients with inoperable HCC were randomly assigned to receive IFNa (50",
"      <span class=\"nowrap\">",
"       mU/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IM three times weekly) or no antitumor therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/72\">",
"       72",
"      </a>",
"      ]. Objective responses were noted in 11 of 35 patients (31 percent) and median survival was significantly improved in the IFNa treated group (14.5 versus 7.5 weeks, respectively). Treatment was surprisingly well tolerated; dose reduction was required in only 34 percent, predominantly because of fatigue.",
"     </li>",
"     <li>",
"      In contrast, these results were not confirmed in a second trial in which 58 patients were randomly assigned to IFNa (3 mU three times weekly for one year) or symptomatic treatment only [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/73\">",
"       73",
"      </a>",
"      ]. Only two of 30 evaluable patients (6.6 percent) achieved a partial response, and the survival at one and two years was not different between the two groups (58 and 38 percent versus 36 and 12 percent, respectively). Despite the markedly lower dose than in the previous study, IFNa was associated with side effects in 23 of 30 patients (77 percent), leading to discontinuation in 13.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Combinations of chemotherapy with interferon-alfa (IFNa) appear active.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     The PIAF regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    , IFNa,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and infusional 5-FU (PIAF) is an active, albeit toxic, combination regimen for advanced HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/9,74,75\">",
"     9,74,75",
"    </a>",
"    ]. In one uncontrolled study, for example, PIAF was associated with an objective response in 13 of 50 patients (26 percent) with advanced HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/9\">",
"     9",
"    </a>",
"    ]. Furthermore, histologic examination revealed no evidence of tumor cells in four of nine patients (44 percent) who underwent surgical resection after achieving a partial response. Overall median survival of the entire population was nine months, and eight of the resected patients remained in complete remission from eight to 26 months. Toxicity was mainly myelosuppression and mucositis, and there were two treatment-related deaths from neutropenic sepsis.",
"   </p>",
"   <p>",
"    Whether results with PIAF are better than with single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    was the subject of a multinational trial in which 188 unselected patients with chemotherapy-naive unresectable HCC were randomly assigned to doxorubicin monotherapy (60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks) or PIAF (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 through 4, IFNa 5",
"    <span class=\"nowrap\">",
"     MU/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    subcutaneously on days 1 through 4, doxorubicin 40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1, and 5-FU 400",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 through 4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/30\">",
"     30",
"    </a>",
"    ]. While objective response rates were higher with PIAF (21 versus 11 percent), this difference was not statistically significant, nor was the difference in median survival duration (8.7 versus 6.8 months, p = 0.83). Not surprisingly, treatment-related toxicity was more pronounced with PIAF (neutropenia 82 versus 63 percent grade 3 or 4, thrombocytopenia 57 versus 24 percent grade 3 or 4, hypokalemia 7 versus 0 percent grade 3 or 4).",
"   </p>",
"   <p>",
"    One potential explanation for a failure to show a survival benefit in this trial may have been the lack of patient selection. The importance of baseline liver function to outcomes with the PIAF regimen was illustrated in a series of 149 patients with unresectable HCC who were treated with PIAF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/74\">",
"     74",
"    </a>",
"    ]. The objective response rate was significantly higher in patients with a normal bilirubin and a non-cirrhotic liver compared to those with cirrhosis and a serum bilirubin &gt;0.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (50 versus 6 percent). Of note, eight of 16 patients with a partial response to PIAF who underwent surgical exploration had a complete pathologic response.",
"   </p>",
"   <p>",
"    The place of the PIAF regimen in the treatment of unresectable HCC remains uncertain. However, due to its toxicity profile, it should be considered only for fit patients with a good performance status and minimal hepatic dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     5-FU plus IFNa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of combining IFNa with just 5-FU alone is unclear; some data suggest that efficacy is schedule-dependent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report in which 43 patients (nine with the fibrolamellar variant of HCC) received infusional 5-FU (200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for 21 of every 28 days) plus IFNa (4",
"      <span class=\"nowrap\">",
"       MU/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      three times weekly), an objective response was demonstrated in 14 (33 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/76\">",
"       76",
"      </a>",
"      ]. Two of four patients with HCC who were subsequently resected had a complete histologic response. Despite the presence of cirrhosis in 71 percent of the patients with HCC, toxicity was moderate, with grade 3 or 4 stomatitis, fatigue, and hematologic toxicity in 33, 5, and 9 percent of patients, respectively.",
"      <br/>",
"     </li>",
"     <li>",
"      A similar level of benefit (objective response rates between 33 and 50 percent, one-third to one-half complete) has been seen with combinations of systemic IFNa with intrahepatic arterial 5-FU in patients with advanced HCC and major portal vein thrombus (a contraindication to transhepatic arterial chemoembolization) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/77-79\">",
"       77-79",
"      </a>",
"      ]. Overall survival and chemotherapy response have been significantly correlated with tumor expression of the type I interferon receptor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/78,79\">",
"       78,79",
"      </a>",
"      ]. Transhepatic arterial chemoembolization for HCC is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/9/41114?source=see_link&amp;anchor=H1248650293#H1248650293\">",
"       \"Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization\", section on 'Transarterial embolization'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In contrast, less favorable results were noted in a small series of 10 patients receiving systemic 5-FU 750",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly plus IFNa (9 MU three times weekly); treatment was associated with substantial toxicity and no sustained antitumor responses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above data suggest that combination chemotherapy may play a minor role in the treatment of advanced HCC. However, there are insufficient data to routinely recommend any standard regimen, and no drug or regimen has been approved for the treatment of HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/81\">",
"     81",
"    </a>",
"    ]. Newer data on the efficacy of molecularly targeted agents for HCC have brought these agents, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    , to the forefront of therapy. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Molecularly targeted therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Nevertheless, systemic chemotherapy may still be considered for patients whose tumors progress while on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    and whose performance status and baseline liver function are sufficient to tolerate it. The side effect profile of any chemotherapy regimen should be considered carefully in patients with advanced liver disease and a short life expectancy. Pending the results of several ongoing phase II clinical trials, we recommend that cytotoxic therapy be reserved for medically appropriate patients with adequate hepatic function and preferably administered within the context of a clinical trial.",
"   </p>",
"   <p>",
"    For patients who are not eligible for clinical trials or if they are not available, we usually recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    for fit patients. Cisplatin, interferon alpha,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and 5-FU (PIAF) or infusional doxorubicin and cisplatin are reasonable choices for young and healthy patients if more aggressive therapy is desired [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/82\">",
"     82",
"    </a>",
"    ]. Weekly low-dose doxorubicin is an acceptable option for older or more frail patients as is oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    or weekly high-dose 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    for sick or jaundiced individuals.",
"   </p>",
"   <p>",
"    Reactivation of viral hepatitis may occur in patients with HCC who are undergoing intensive systemic chemotherapy, so it is important to maintain antiviral medications. This topic and the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    to prevent reactivation of hepatitis B during chemotherapy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=see_link&amp;anchor=H8#H8\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Impact of preexisting liver disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/24/6538?source=see_link&amp;anchor=H27#H27\">",
"     \"Lamivudine monotherapy for chronic hepatitis B virus infection\", section on 'With immunosuppression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MOLECULARLY TARGETED THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment approaches that are directed against a specific molecular defect are termed \"molecularly targeted therapies\". While the molecular pathogenesis of HCC remains poorly understood, the following results have been noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several lines of evidence point to a possible role for the epidermal growth factor receptor",
"      <span class=\"nowrap\">",
"       (EGFR)/EGF",
"      </span>",
"      (HER1) signaling pathway in the carcinogenesis and proliferative behavior of HCC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/83-91\">",
"       83-91",
"      </a>",
"      ]. These data have led to the exploration of agents that inhibit the EGFR, such as the small molecule tyrosine kinase inhibitor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      and the anti-EGFR monoclonal antibody",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      HCCs are highly vascular tumors, and high levels of expression of vascular endothelial growth factor (VEGF) have been observed, raising the possibility that agents targeting VEGF",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the VEGF receptor (VEGFR) might be of therapeutic value.",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       Raf/MAP",
"      </span>",
"      kinase-ERK kinase",
"      <span class=\"nowrap\">",
"       (MEK)/extracellular",
"      </span>",
"      signal regulated kinase (ERK) pathway has been implicated in HCC tumorigenesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/92\">",
"       92",
"      </a>",
"      ]. Raf (receptor activation factor) kinase is an essential component of the MAP kinase pathway, which is a key signaling mechanism that regulates many cellular functions such as growth, transformation, and apoptosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/93\">",
"       93",
"      </a>",
"      ]. ERK is the downstream enzyme of the MAP kinase pathway that is directly activated by Raf kinase to phosphorylated ERK.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overexpression of activated MEK1 in HCC cell lines enhances tumor growth and survival by preventing apoptosis. Furthermore, the core proteins of hepatitis C virus (HCV), a major risk factor for HCC, elicit high basal levels of Raf-1 activity in hepatocytes, increasing the risk of neoplastic transformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. Taken together, these data suggest therapeutic potential for drugs that inhibit Raf kinase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Sorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     Sorafenib",
"    </a>",
"    (Nexavar) is a multi-targeted orally active small molecule tyrosine kinase inhibitor (TKI) that inhibits Raf kinase and the vascular endothelial growth factor receptor (VEGFR) intracellular kinase pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/95\">",
"     95",
"    </a>",
"    ]. Efficacy in HCC was initially suggested by a phase I trial in which a single patient with HCC had an objective partial response, as assessed by standard RECIST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/96\">",
"     96",
"    </a>",
"    ]. Subsequent phase II and III studies did not confirm a high level of objective measurable antitumor activity as measured using standard RECIST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/11,97\">",
"     11,97",
"    </a>",
"    ]; however, results from the phase III SHARP trial suggest a survival benefit compared to best supportive care alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/97\">",
"     97",
"    </a>",
"    ]. Considerations for response assessment in patients receiving molecularly targeted agents such as sorafenib are discussed above. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Response assessment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the phase II trial of 137 chemotherapy-naive patients with inoperable HCC and Child-Pugh A or B cirrhosis treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      (400 mg twice daily), there were only three objective responses (2.2 percent), eight minor responses (5.8 percent), and 46 (34 percent) with stable disease for at least 16 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/11\">",
"       11",
"      </a>",
"      ]. The median time to tumor progression (TTP) was 5.5 months and median overall survival, 9.2 months.",
"     </li>",
"     <li>",
"      The multicenter European SHARP trial randomly assigned 602 patients with inoperable HCC and Child-Pugh A cirrhosis to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      (400 mg twice daily) or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/97\">",
"       97",
"      </a>",
"      ]. Overall survival, the primary endpoint, was significantly longer in the sorafenib-treated patients (10.7 versus 7.9 months), as was time to radiologic progression (5.5 versus 2.8 months). Similar to the phase II trial described above, objective response rates were low, according to RECIST (7 partial responses [2 percent]). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Response assessment'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Treatment was well tolerated with manageable side effects. The only grade 3 or 4 adverse effects that occurred significantly more often in the treated group were diarrhea (8 versus 2 percent) and hand-foot skin reaction (8 versus &lt;1 percent). There were no differences in liver dysfunction or bleeding. The overall incidence of sorafenib-related side effects (particularly dermatologic) was low compared to that reported by others [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/98\">",
"       98",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=see_link&amp;anchor=H10#H10\">",
"       \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\", section on 'Hand-foot skin reaction'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      These results established sorafenib monotherapy as the new reference standard systemic treatment for advanced HCC and formed the basis for approval of sorafenib for unresectable HCC in the United States.",
"     </li>",
"     <li>",
"      The efficacy of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      in Asian patients was the subject of a second placebo-controlled phase III trial in which 226 patients with Child-Pugh A cirrhosis and no prior systemic therapy for HCC received sorafenib 400 mg twice daily or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/99\">",
"       99",
"      </a>",
"      ]. Patients receiving sorafenib had significantly better median overall survival (6.5 versus 4.2 months) and TTP (2.8 versus 1.4 months). Grade 3 or 4 side effects included hand-foot skin reaction (11 percent), diarrhea (6 percent) and fatigue (3 percent).",
"      <br/>",
"      <br/>",
"      The magnitude of benefit was markedly less in this trial than seen in the SHARP trial. In fact, the treated group in the Asian trial had a shorter survival duration than the control group in the SHARP trial (6.5 versus 7.9 months), despite the fact that both trials used the same entry criteria. Nevertheless, patients accrued to the Asian study were more ill at the start of therapy than those in the SHARP trial, with a generally worse performance status and more advanced stage of disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/100\">",
"       100",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An important unanswered question is whether there are differences in response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    based upon the etiology of the HCC. Asian patients have a higher prevalence of infection with hepatitis B virus (HBV) as compared to Western populations; 73 percent of the patients enrolled to the Asian trial had HBV infection versus 18 percent of those enrolled to SHARP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/97,99\">",
"     97,99",
"    </a>",
"    ]. At least some exploratory analyses suggest that patients with HCV infection as the etiology of their cirrhosis may have a better response to sorafenib as compared to those with other underlying causes of cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. As an example, in an exploratory analysis of the phase III SHARP trial, although a survival benefit was seen in all subgroups treated with sorafenib, the difference in median overall survival between sorafenib and placebo-treated patients was highest in those with HCV-related cirrhosis (6.6 months, 14 versus 7.4 months); it was 3.6 months (9.7 versus 6.1 months) in patients with HBV-related cirrhosis, and 2.3 months (10.3 versus 8 months) in those with underlying alcohol-related liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/102\">",
"     102",
"    </a>",
"    ]. These differences in outcome according to hepatitis virus type could potentially explain some of the survival differences between the SHARP and Asian trials of sorafenib. However, the available data are scant, and further study is needed to establish the influence of underlying liver disease on sorafenib treatment responsiveness.",
"   </p>",
"   <p>",
"    Taken together, these findings underscore the differences in prognosis of HCC depending on ethnicity and cause of cirrhosis, and have led some to question the role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    as mandatory standard therapy in all patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Safety in patients with liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patients enrolled in the above trials had predominantly (over 95 percent) Child-Pugh A cirrhosis. However, the majority of patients with HCC have underlying cirrhosis, and therefore, competing causes of death from progressive HCC versus worsening cirrhosis. In a systematic review of 118 studies of patients with cirrhosis and no HCC, the one- and two-year survival rates for patients with Child-Pugh A, B, or C cirrhosis were 95 and 90, 80 and 70, and 45 and 38 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/103\">",
"     103",
"    </a>",
"    ]. &nbsp;Death from cirrhosis could potentially mask treatment-related antitumor effect.",
"   </p>",
"   <p>",
"    Despite the specific population studied in the SHARP trial, the original FDA approval of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    for HCC in the United States did not specify the underlying cirrhosis state. However, there is only limited clinical experience and few published data regarding the safety and efficacy of sorafenib in patients with Child's Pugh B or C cirrhosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report consisted of a subset analysis of 38 patients with Child Pugh B cirrhosis and 98 patients with Child Pugh A cirrhosis who were enrolled in the phase II",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      trial described above [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/104\">",
"       104",
"      </a>",
"      ]. Drug pharmacokinetics were similar in both groups, as were rates of drug discontinuation and dose reduction. Despite a more than 50 percent shorter course of therapy in the Child Pugh B patients (median duration of therapy 1.8 versus 4 months), outcomes were similar.",
"      <br/>",
"      <br/>",
"      However, outcomes were poorer in the Child-Pugh B group (median overall survival 3.2 versus 9.5 months in those with Child-Pugh A cirrhosis). &nbsp;Furthermore, certain adverse effects were more common in those with Child-Pugh B cirrhosis (grade 3 or 4 elevated bilirubin in 53 versus 14 percent, grade 3 or 4 encephalopathy in 13 versus 3 percent), which could have been drug related or due to disease progression.",
"     </li>",
"     <li>",
"      A similar conclusion was reached in a retrospective report of experience with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      in 59 patients with HCC, 26 with Child-Pugh A, 29 with Child-Pugh B, and 10 with Child-Pugh C cirrhosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/105\">",
"       105",
"      </a>",
"      ]. The median survival time in the three groups was 8.3, 4.3, and 1.5 months, respectively. These data support the view that sorafenib is unlikely to benefit patients with Child-Pugh C cirrhosis.",
"     </li>",
"     <li>",
"      The safety and efficacy of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      in patients with liver dysfunction was also addressed in an analysis of 1586 patients receiving sorafenib and registered in the international GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib) prospective database [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/106\">",
"       106",
"      </a>",
"      ]. In a preliminary report presented at the 2011 ASCO meeting, the safety profile of sorafenib was similar in patients with Child-Pugh A and B cirrhosis, but a greater percentage of Child-Pugh B patients discontinued therapy due to adverse effects; they also had a higher rate of deaths during treatment up to 30 days from the last sorafenib dose (34 versus 15 percent) and a shorter overall median survival (5 versus 10.5 months).",
"      <br/>",
"      <br/>",
"      The analysis also highlighted interspecialty differences in treating HCC with sorafenib. Hepatologists and gastroenterologists were more likely to use full starting doses of sorafenib and to treat patients for a longer period of time. Despite this variation in treatment practice, toxicity rates (hand-foot syndrome, hematologic toxicities) were similar among all three specialties.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Underlying cirrhosis also makes it more difficult to clear drugs for which there is significant hepatic metabolism, like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    . There is controversy as to whether the initial dose of sorafenib needs to be modified in patients with hepatic dysfunction, as evidenced by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The safety of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      in patients with elevated transaminase levels was studied in a subgroup analysis of data from the SHARP trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/107\">",
"       107",
"      </a>",
"      ]. Patients with mild or moderate liver dysfunction (&ge;1.8 times the upper limit of normal) did not experience increased hepatic or other toxicity. Although median overall survival was diminished in both placebo and sorafenib-treated patients with moderate liver dysfunction, median TTP and overall survival favored the sorafenib group regardless of transaminase levels. The authors concluded that treatment was safe and effective, even in patients with mild or moderately elevated baseline transaminase levels and that hepatic function remained stable over the course of sorafenib therapy.",
"     </li>",
"     <li>",
"      On the other hand, results from a phase I study suggest that dose reduction to 200 mg twice a day is required in patients with a bilirubin 1.5 to 3 times the upper limit of normal and that the drug cannot be tolerated with more severe hyperbilirubinemia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=see_link&amp;anchor=H48#H48\">",
"       \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Sorafenib'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The manufacturer recommends no dose adjustment for Child-Pugh class B impairment, and makes no recommendation for Child-Pugh class C cirrhosis (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 1",
"    </a>",
"    ). Nevertheless, we recommend an initial dose reduction to 200 mg twice daily in patients with a total bilirubin 1.5 to 3 times the upper limit of normal and that the drug not be administered to patients with more severe degrees of hyperbilirubinemia. For other patients with Child-Pugh B cirrhosis, standard dosing from the onset with dose modification as needed is appropriate.",
"   </p>",
"   <p>",
"    Given the poor prognosis of patients with HCC and Child-Pugh C cirrhosis, the associated significantly abnormal liver function, and the high risk of treatment-related toxicity, most physicians would not prescribe",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    to these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3776918\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects of antiangiogenic TK inhibitors such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    may include hypertension, renal toxicity, arterial thromboembolism, bleeding, cardiotoxicity, thyroid dysfunction, hand-foot skin reaction, rash, pruritus, alopecia, problems with wound healing, hepatotoxicity, and muscle wasting (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=see_link&amp;anchor=H9#H9\">",
"     \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\", section on 'Sorafenib and sunitinib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with other antiangiogenic TK inhibitors, hypertension has been associated with treatment benefit in HCC, but this has not been seen in all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H30695629#H30695629\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Association with antitumor efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     Sorafenib",
"    </a>",
"    has been associated with potentially fatal liver toxicity, which is characterized predominantly by a hepatocellular pattern of liver damage with significant increases in transaminases; uncommonly elevations in the international normalized ratio (INR) or hyperbilirubinemia may occur. Liver function tests should be monitored regularly during treatment. The US FDA-approved labeling for",
"    <a class=\"external\" href=\"file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b50667e4-5ebc-4968-a646-d605058dbef0\">",
"     sorafenib",
"    </a>",
"    recommends that if transaminases are &ldquo;significantly increased&rdquo; without alternative explanation, such as viral hepatitis or progressing underlying malignancy, that the drug be discontinued. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=see_link&amp;anchor=H48#H48\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Sorafenib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional details about side effect profile of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    and management strategies are available elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=see_link&amp;anchor=H9#H9\">",
"     \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\", section on 'Sorafenib and sunitinib'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Sorafenib plus doxorubicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    was studied in a phase II trial in which all patients received doxorubicin (60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every 21 days), and they were randomly assigned to sorafenib 400 twice daily for a maximum of six cycles or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/110\">",
"     110",
"    </a>",
"    ]. Combination therapy was associated with a similarly low objective response rate (4 versus 2 percent with doxorubicin alone), but a significantly longer time to tumor progression (6.4 versus 2.8 months) and median overall survival duration (13.7 versus 6.5 months). The side effect profile was not significantly worse with combined therapy, although one in five patients receiving sorafenib plus doxorubicin had a decrease in left ventricular ejection fraction.",
"   </p>",
"   <p>",
"    The degree to which this improvement represents synergism between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    remains to be defined. Before this approach can be considered standard, this combination must be compared to sorafenib alone in a large-scale phase III trial, which is ongoing (Cancer and Leukemia Group B [CALGB] trial 80802) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other agents targeting VEGF",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    (Avastin, a monoclonal antibody [MoAb] directed against VEGF) alone is active in HCC. Efficacy was shown in a trial in which 46 patients with nonmetastatic HCC received single agent bevacizumab at a dose of either 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    doses once every other week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/112\">",
"     112",
"    </a>",
"    ]. An objective response was documented in six (13 percent, one complete), and the median progression-free survival was 6.9 months. The most common grade 3 or 4 toxicities were hypertension (15 percent), thrombosis (6 percent) and major bleeding (11 percent).",
"   </p>",
"   <p>",
"    A similar level of efficacy was seen in a second trial, reported in abstract form only [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/113\">",
"     113",
"    </a>",
"    ]. Using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    5 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 14 days, there were three partial responses and 13 disease stabilizations among 30 patients; six had to discontinue therapy because of variceal bleeding.",
"   </p>",
"   <p>",
"    The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (GEMOX) was safe and moderately effective in a small phase II trial in which 30 patients received gemcitabine (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    followed by oxaliplatin (85",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    on days 2 and 16, plus bevacizumab (10",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1 of the first cycle and thereafter, on days 1 and 15 of each cycle) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/114\">",
"     114",
"    </a>",
"    ]. The objective response rate was 20 percent, the six-month progression-free survival rate was 48 percent, and median overall survival was 9.6 months. However, whether these results are superior to GEMOX alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/68\">",
"     68",
"    </a>",
"    ] or bevacizumab alone can only be determined in a randomized trial. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Combination chemotherapy regimens'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    is also tolerable and modestly active [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. Whether any combination regimens are better than bevacizumab alone or the chemotherapy regimen alone will require a randomized trial. The combination of bevacizumab plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Sunitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     Sunitinib",
"    </a>",
"    (Sutent) is another orally active TKI that targets a variety of TKs in addition to VEGFR, including platelet-derived growth factor receptors (PDGFRs), KIT, RET, and FLT3. Experience with sunitinib is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial phase II study included 37 patients with unresectable HCC who were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      (50 mg daily for four of every six weeks) and assessed by monthly CT scans [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/117\">",
"       117",
"      </a>",
"      ]. There was one confirmed partial response, and 35 percent had stable disease for over three months. However, grade 3 to 4 toxicity was prominent (thrombocytopenia, neutropenia, asthenia and hand-foot skin reaction in 38, 24, 14, and 11 percent, respectively). Four patients had a fatal treatment-related adverse event (renal failure, bleeding, thrombocytopenia, and hepatic encephalopathy). A similarly high rate of treatment-related toxicity, including worsening of liver functional reserve, was reported in a second trial using this same dose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/118\">",
"       118",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two other phase II studies administered a lower dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      (37.5 mg daily for four of every six weeks) to 34 and 45 patients, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/119,120\">",
"       119,120",
"      </a>",
"      ]. In both studies, there was only one objective response, but about 40 to 45 percent of patients achieved stable disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/119\">",
"       119",
"      </a>",
"      ]. Fewer grade 3 or 4 toxicities were reported than in the prior study (there were no grade 5 toxicities).",
"      <br/>",
"      <br/>",
"      A phase III trial directly compared this lower daily dose of sunitinib versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      in 1073 previously untreated patients with advanced HCC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/121\">",
"       121",
"      </a>",
"      ]. In a preliminary report of an interim analysis presented at the 2011 meeting of the American Society of Clinical Oncology (ASCO), sunitinib was associated with an inferior median survival (8.1 versus 10 months) and more frequent treatment-related toxicity. An Independent Data Monitoring and Safety Committee recommended closure of the study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these data,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    cannot be considered an appropriate alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    for initial systemic treatment of advanced HCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Anti EGFR strategies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Small molecule TK inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited activity for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    (Tarceva), a small molecule TKI with specificity for EGFR, has been suggested in phase II studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 38 patients with unresectable or metastatic HCC, one-half of whom had previously received cytotoxic chemotherapy,",
"      <span class=\"nowrap\">",
"       EGFR/HER1",
"      </span>",
"      expression was found in 88 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/122\">",
"       122",
"      </a>",
"      ]. Twelve patients (32 percent) were progression-free at six months, while three had a radiographic partial response that lasted for two, 10, and 11 months, respectively. The median survival of the entire cohort was 13 months.",
"     </li>",
"     <li>",
"      A second trial included 40 patients with previously untreated unresectable HCC who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      150 mg daily as monotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/123\">",
"       123",
"      </a>",
"      ]. There were no objective responses, but 17 achieved stable disease with 16 weeks of continuous therapy. The median overall survival was 11 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional studies with other receptor TKIs, both as monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/11\">",
"     11",
"    </a>",
"    ] and in combination with cytotoxic chemotherapy are ongoing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Erlotinib plus bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antitumor activity for a unique combination of agents that modify growth factor signaling was suggested in a phase II trial in which 59 patients with advanced HCC not amenable to surgical or regional therapies were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every two weeks) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    (150 mg orally daily, continuously), with assessment of antitumor response at the end of 16 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/124\">",
"     124",
"    </a>",
"    ]. There were 14 objective partial responses (response rate 24 percent), and 33 other patients (56 percent) had stable disease. The median progression-free and overall survival durations were 7.2 and 13.7 months, respectively.",
"   </p>",
"   <p>",
"    However, antitumor activity with this same regimen could not be confirmed in a second multi-institutional phase II trial that enrolled 27 patients with advanced HCC, an ECOG performance status of 0 or 1, Child-Pugh A or B cirrhosis, and no more than one prior systemic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/125\">",
"     125",
"    </a>",
"    ]. There was only one confirmed objective partial response, time to disease progression was only three months, and median overall survival was 9.5 months.",
"   </p>",
"   <p>",
"    The efficacy of this regimen is uncertain. Particularly in view of the substantial cost of this regimen (over $10,000 per month), randomized trials will be needed to confirm the superiority of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    over other systemic regimens. Such a trial is underway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/126\">",
"     126",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Sorafenib'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Cetuximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    (Erbitux) is a MoAb that binds to the EGFR of both tumor and normal cells, competitively inhibiting ligand binding and inducing receptor dimerization and internalization. Early results suggest activity for cetuximab in combination with GEMOX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/127\">",
"     127",
"    </a>",
"    ]. In a preliminary report of 44 patients who received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1 and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 2 every 14 days, in combination with cetuximab (400",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    initially, then 250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly), there were eight partial responses, and the total disease control rate (partial response plus stable disease) was 65 percent. Treatment was well tolerated with only one grade 4 toxicity (thrombocytopenia) and no grade 5 toxicities. Grade 2 and 3 neurotoxicity occurred in 16 and 5 percent of patients, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13506074\">",
"    <span class=\"h2\">",
"     Investigational approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newer molecularly targeted approaches that show promise in early studies include inhibitors of the mammalian target of rapamycin (mTOR), such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/128-130\">",
"     128-130",
"    </a>",
"    ], and inhibitors of hepatocyte growth",
"    <span class=\"nowrap\">",
"     factor/c-Met,",
"    </span>",
"    such as tivantinib and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/22/7526?source=see_link\">",
"     cabozantinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/131,132\">",
"     131,132",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     HORMONE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several hormone agents have been studied in advanced HCC, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , megestrol,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/34/7717?source=see_link\">",
"     lanreotide",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Tamoxifen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since estrogen receptors (ERs) are present in approximately one-third of HCCs, these tumors could potentially benefit from ER blockade with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . Several prospective randomized trials and a systematic review of tamoxifen in patients with advanced HCC have failed to show a survival benefit or improved functional status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/133-137\">",
"     133-137",
"    </a>",
"    ]. One possible reason for the lack of efficacy may be the presence of variant ERs in some of these tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/138,139\">",
"     138,139",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    may also function as a potential inhibitor of p-glycoprotein, the MDR (multidrug resistance) gene product, and this has led to trials of tamoxifen combined with various chemotherapeutic agents. Unfortunately, these studies have also failed to demonstrate any benefit for the addition of tamoxifen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/43,140-142\">",
"     43,140-142",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Doxorubicin and mitoxantrone'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Megestrol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modest benefit has been suggested for megestrol in uncontrolled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/138,143,144\">",
"     138,143,144",
"    </a>",
"    ], but the results of two randomized trials are conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of 24 patients with advanced HCC who were randomly assigned to megestrol (160 mg daily) or supportive care only, median survival was significantly better with megestrol (18 versus 7 months) despite no objective responses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/138\">",
"       138",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On the other hand, a survival benefit could not be shown in a larger placebo-controlled trial of megestrol 320 mg per day in 200 patients with treatment-na&iuml;ve HCC; in fact, there was a trend towards worse overall survival in the treated group (median 1.88 versus 2.14 months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/145\">",
"       145",
"      </a>",
"      ]. The markedly different survival durations in the placebo group compared to the supportive care arm of the previously described trial (2 versus 7 months) suggests that therapeutic outcomes may be strongly dependent on factors such as baseline liver function and performance status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Octreotide and lanreotide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification of somatostatin receptors in liver tissue from patients with HCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/146,147\">",
"     146,147",
"    </a>",
"    ] provided the rationale for a controlled trial in which 58 patients with advanced HCC were randomized to the somatostatin analog",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (250 micrograms twice daily subcutaneously) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/148\">",
"     148",
"    </a>",
"    ]. Treated patients had significantly better median survival (13 versus 4 months), but no objective responses. Efficacy did not correlate with the tissue somatostatin receptor concentration.",
"   </p>",
"   <p>",
"    These results could not be confirmed in two subsequent placebo-controlled randomized trials using a long-acting form of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (Sandostatin LAR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/149,150\">",
"     149,150",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/34/7717?source=see_link\">",
"     Lanreotide",
"    </a>",
"    is a long acting somatostatin analog that is available in a depot formulation that has comparable efficacy to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    when injected intramuscularly two to three times per month. Although limited antitumor activity has been suggested in nonrandomized studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/147,151\">",
"     147,151",
"    </a>",
"    ], a randomized trial of lanreotide versus placebo in 272 patients with advanced HCC failed to show any advantage for drug treatment in terms of progression-free or overall survival, and treatment was associated with worse quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/61/39898/abstract/152\">",
"     152",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, routine administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/34/7717?source=see_link\">",
"     lanreotide",
"    </a>",
"    cannot be recommended, particularly in view of the high cost of these drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H254793\">",
"    <span class=\"h1\">",
"     HEPATITIS B REACTIVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive therapy is a risk factor for reactivation of hepatitis B virus infection (HBV).&nbsp;Issues related to screening and prophylaxis are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the management of hepatitis B and case examples\", section on 'Who should be tested'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/42/44706?source=see_link\">",
"       \"Patient information: Liver cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocellular carcinoma (HCC) is an aggressive tumor that frequently occurs in the setting of chronic liver disease and cirrhosis. Hepatic reserve, as indicated by Child-Pugh class (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 1",
"    </a>",
"    ), often dictates the therapeutic options. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Systemic therapy is appropriate for patients with advanced unresectable disease who are unsuitable for locoregional therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/6/14442?source=see_link\">",
"     \"Surgical management of potentially resectable hepatocellular carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=see_link\">",
"     \"Liver transplantation for hepatocellular carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36138?source=see_link\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systemic therapy for HCC is an evolving field. In general, efficacy with conventional cytotoxic chemotherapy is modest at best, and the duration of benefit is limited. Although few randomized trials have been conducted, no single regimen has emerged as superior to any other, and no drug or regimen has been unequivocally shown to improve survival. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Systemic chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Newer data on the efficacy of molecularly targeted agents has brought these agents, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    , to the forefront of therapy for advanced HCC. Molecularly targeted therapy offers the potential for prolonged survival, although objective tumor remissions are rare. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Sorafenib'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following represents our recommended approach to these patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Our preferred approach is participation in an ongoing clinical trial testing new therapeutic strategies.",
"     </li>",
"     <li>",
"      For patients who are not eligible for a clinical trial or for whom protocol therapy is not feasible, we recommend initiating therapy with the orally active tyrosine kinase inhibitor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      400 mg twice daily (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Sorafenib'",
"      </a>",
"      above.) To improve early tolerability, we typically start at 200 mg twice a day and increase the daily dose in 200 mg increments approximately every five days until the target dose is reached. We recommend against initiating sorafenib in patients with Child-Pugh C cirrhosis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Safety in patients with liver disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic chemotherapy is an option for patients whose tumors progress while on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      and whose performance status and liver function are sufficient to tolerate it. The best regimen is not established. The side effect profile of each individual regimen must be carefully considered in patients who have advanced liver disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a short life expectancy.",
"      <br/>",
"      <br/>",
"      We prefer that eligible patients be enrolled on clinical trials testing new treatment strategies, if possible. For patients who are not eligible for clinical trials or if they are not available, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      for fit patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Acceptable alternatives include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      plus cisplatin, or gemcitabine plus either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"       pegylated liposomal doxorubicin",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      Weekly low-dose doxorubicin may be preferred for older or more frail patients, and oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      or weekly high-dose 5-FU and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      are appropriate choices for sick or jaundiced individuals. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Systemic chemotherapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The safety and benefit of combining molecularly targeted therapy (sorafenib or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      ) and cytotoxic chemotherapy is not yet definitively established, and we suggest not pursuing these strategies outside of the context of a clinical trial (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Molecularly targeted therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       Tamoxifen",
"      </a>",
"      is ineffective as monotherapy or in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      . Likewise, routine administration of octreotide or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/34/7717?source=see_link\">",
"       lanreotide",
"      </a>",
"      cannot be recommended outside of the context of a clinical trial. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Hormone therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/1\">",
"      A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/2\">",
"      Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/3\">",
"      Cabibbo G, Enea M, Attanasio M, et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010; 51:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/4\">",
"      Huitzil-Melendez FD, Capanu M, O'Reilly EM, et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol 2010; 28:2889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/5\">",
"      Yau T, Yao TJ, Chan P, et al. A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials. Cancer 2008; 113:2742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/6\">",
"      Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/7\">",
"      Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/8\">",
"      Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/9\">",
"      Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999; 5:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/10\">",
"      Lau WY, Leung TW, Lai BS, et al. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann Surg 2001; 233:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/11\">",
"      Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24:4293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/12\">",
"      Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/13\">",
"      Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012; 118:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/14\">",
"      Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/15\">",
"      Spira D, Fenchel M, Lauer UM, et al. Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. Acad Radiol 2011; 18:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/16\">",
"      Chan SL, Mo FK, Johnson PJ, et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 2009; 27:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/17\">",
"      Vora SR, Zheng H, Stadler ZK, et al. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist 2009; 14:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/18\">",
"      Shao YY, Lin ZZ, Hsu C, et al. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 2010; 116:4590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/19\">",
"      Yau T, Yao TJ, Chan P, et al. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist 2011; 16:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/20\">",
"      Soini Y, Virkaj&auml;rvi N, Raunio H, P&auml;&auml;kk&ouml; P. Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis. J Clin Pathol 1996; 49:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/21\">",
"      Huang CC, Wu MC, Xu GW, et al. Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 1992; 84:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/22\">",
"      Caruso ML, Valentini AM. Overexpression of p53 in a large series of patients with hepatocellular carcinoma: a clinicopathological correlation. Anticancer Res 1999; 19:3853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/23\">",
"      Nagahama H, Okada S, Okusaka T, et al. Predictive factors for tumor response to systemic chemotherapy in patients with hepatocellular carcinoma. Jpn J Clin Oncol 1997; 27:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/24\">",
"      Olweny CL, Toya T, Katongole-Mbidde E, et al. Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication. Cancer 1975; 36:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/25\">",
"      Chlebowski RT, Brzechwa-Adjukiewicz A, Cowden A, et al. Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rep 1984; 68:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/26\">",
"      Ihde DC, Kane RC, Cohen MH, et al. Adriamycin therapy in American patients with hepatocellular carcinoma. Cancer Treat Rep 1977; 61:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/27\">",
"      Nerenstone SR, Ihde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 1988; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/28\">",
"      Lai CL, Wu PC, Chan GC, et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988; 62:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/29\">",
"      Choi TK, Lee NW, Wong J. Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy. Cancer 1984; 53:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/30\">",
"      Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/31\">",
"      Sciarrino E, Simonetti RG, Le Moli S, Pagliaro L. Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients. Cancer 1985; 56:2751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/32\">",
"      Gish RG, Porta C, Lazar L, et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 2007; 25:3069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/33\">",
"      Falkson G, Moertel CG, Lavin P, et al. Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer 1978; 42:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/34\">",
"      Melia WM, Johnson PJ, Williams R. Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin. Cancer 1983; 51:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/35\">",
"      Hochster HS, Green MD, Speyer J, et al. 4'Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma. J Clin Oncol 1985; 3:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/36\">",
"      Pohl J, Zuna I, Stremmel W, Rudi J. Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma. Chemotherapy 2001; 47:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/37\">",
"      Colleoni M, Buzzoni R, Bajetta E, et al. A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma. Cancer 1993; 72:3196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/38\">",
"      Dunk AA, Scott SC, Johnson PJ, et al. Mitozantrone as single agent therapy in hepatocellular carcinoma. A phase II study. J Hepatol 1985; 1:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/39\">",
"      Halm U, Etzrodt G, Schiefke I, et al. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann Oncol 2000; 11:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/40\">",
"      Schmidinger M, Wenzel C, Locker GJ, et al. Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. Br J Cancer 2001; 85:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/41\">",
"      Lind PA, Naucler G, Holm A, et al. Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. Acta Oncol 2007; 46:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/42\">",
"      Cheng AL, Chuang SE, Fine RL, et al. Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochem Pharmacol 1998; 55:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/43\">",
"      Cheng AL, Yeh KH, Fine RL, et al. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma. Hepatogastroenterology 1998; 45:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/44\">",
"      Porta C, Moroni M, Nastasi G, Arcangeli G. 5-Fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase II study. Oncology 1995; 52:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/45\">",
"      Tetef M, Doroshow J, Akman S, et al. 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. Cancer Invest 1995; 13:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/46\">",
"      Patt YZ, Hassan MM, Aguayo A, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004; 101:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/47\">",
"      Boige V, Raoul JL, Pignon JP, et al. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer 2007; 97:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/48\">",
"      Yang TS, Lin YC, Chen JS, et al. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2000; 89:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/49\">",
"      Kubicka S, Rudolph KL, Tietze MK, et al. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 2001; 48:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/50\">",
"      Fuchs CS, Clark JW, Ryan DP, et al. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2002; 94:3186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/51\">",
"      O'Reilly EM, Stuart KE, Sanz-Altamira PM, et al. A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer 2001; 91:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/52\">",
"      Boige V, Ta&iuml;eb J, Hebbar M, et al. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. Eur J Cancer 2006; 42:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/53\">",
"      Lin AY, Brophy N, Fisher GA, et al. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 2005; 103:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/54\">",
"      Hsu C, Chen CN, Chen LT, et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 2003; 65:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/55\">",
"      Patt YZ, Hassan MM, Lozano RD, et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer 2005; 103:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/56\">",
"      Lee J, Park JO, Kim WS, et al. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol 2004; 54:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/57\">",
"      Czauderna P, Mackinlay G, Perilongo G, et al. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol 2002; 20:2798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/58\">",
"      Yang TS, Chang HK, Chen JS, et al. Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases. J Gastroenterol 2004; 39:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/59\">",
"      Ikeda M, Okusaka T, Ueno H, et al. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer 2005; 103:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/60\">",
"      Boucher E, Corbinais S, Brissot P, et al. Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol 2002; 50:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/61\">",
"      Park SH, Lee Y, Han SH, et al. Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer 2006; 6:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/62\">",
"      Rai K, Tsuji A, Morita S, et al. Continuous infusion of 5-FU and low-dose consecutive CDDP therapy in advanced hepatocellular carcinoma: a phase II study (abstract). Proc Am Soc Clin Oncol 2002; 21:164a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/63\">",
"      Shim JH, Park JW, Nam BH, et al. Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 2009; 63:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/64\">",
"      Lee JO, Lee KW, Oh DY, et al. Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann Oncol 2009; 20:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/65\">",
"      Parikh PM, Fuloria J, Babu G, et al. A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma. Trop Gastroenterol 2005; 26:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/66\">",
"      Chia WK, Ong S, Toh HC, et al. Phase II trial of gemcitabine in combination with cisplatin in inoperable or advanced hepatocellular carcinoma. Ann Acad Med Singapore 2008; 37:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/67\">",
"      Lombardi G, Zustovich F, Farinati F, et al. Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study. Cancer 2011; 117:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/68\">",
"      Louafi S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007; 109:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/69\">",
"      Mir O, Coriat R, Boudou-Rouquette P, et al. Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib. Med Oncol 2012; 29:2793.",
"     </a>",
"    </li>",
"    <li>",
"     Qin S, Bai Y, Ye J, et al. Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients (abstract 4008). J Clin Oncol 2010; 28:303s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/71\">",
"      Lai CL, Wu PC, Lok AS, et al. Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Br J Cancer 1989; 60:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/72\">",
"      Lai CL, Lau JY, Wu PC, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993; 17:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/73\">",
"      Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000; 31:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/74\">",
"      Leung TW, Tang AM, Zee B, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002; 94:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/75\">",
"      Lau WY, Ho SK, Yu SC, et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg 2004; 240:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/76\">",
"      Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003; 21:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/77\">",
"      Sakon M, Nagano H, Dono K, et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/78\">",
"      Ota H, Nagano H, Sakon M, et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 2005; 93:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/79\">",
"      Nagano H, Miyamoto A, Wada H, et al. Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. Cancer 2007; 110:2493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/80\">",
"      Stuart K, Tessitore J, Huberman M. 5-Fluorouracil and alpha-interferon in hepatocellular carcinoma. Am J Clin Oncol 1996; 19:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/81\">",
"      Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer 2004; 40:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/82\">",
"      Ortega JA, Krailo MD, Haas JE, et al. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Childrens Cancer Study Group. J Clin Oncol 1991; 9:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/83\">",
"      Huether A, H&ouml;pfner M, Sutter AP, et al. Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol 2005; 43:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/84\">",
"      Hung WC, Chuang LY, Tsai JH, Chang CC. Effects of epidermal growth factor on growth control and signal transduction pathways in different human hepatoma cell lines. Biochem Mol Biol Int 1993; 30:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/85\">",
"      Yamaguchi K, Carr BI, Nalesnik MA. Concomitant and isolated expression of TGF-alpha and EGF-R in human hepatoma cells supports the hypothesis of autocrine, paracrine, and endocrine growth of human hepatoma. J Surg Oncol 1995; 58:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/86\">",
"      Miyaki M, Sato C, Sakai K, et al. Malignant transformation and EGFR activation of immortalized mouse liver epithelial cells caused by HBV enhancer-X from a human hepatocellular carcinoma. Int J Cancer 2000; 85:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/87\">",
"      Schiffer E, Housset C, Cacheux W, et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 2005; 41:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/88\">",
"      H&ouml;pfner M, Sutter AP, Huether A, et al. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol 2004; 41:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/89\">",
"      Wu BW, Wu Y, Wang JL, et al. Study on the mechanism of epidermal growth factor-induced proliferation of hepatoma cells. World J Gastroenterol 2003; 9:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/90\">",
"      Ito Y, Takeda T, Sakon M, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 2001; 84:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/91\">",
"      Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005; 23:8093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/92\">",
"      Huynh H, Nguyen TT, Chow KH, et al. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 2003; 3:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/93\">",
"      Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006; 33:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/94\">",
"      Giambartolomei S, Covone F, Levrero M, Balsano C. Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein. Oncogene 2001; 20:2606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/95\">",
"      Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66:11851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/96\">",
"      Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/97\">",
"      Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/98\">",
"      Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010; 15:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/99\">",
"      Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25.",
"     </a>",
"    </li>",
"    <li>",
"     Raoul J, Santoro A, Beaugrand M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: a subanalysis from the SHARP trial (abstract). J Clin Oncol 2008; 26:234s.",
"    </li>",
"    <li>",
"     Bolondi L, Caspary W, Bennouna J, et al. Clinical benefit of sorafenib in hepatitis C patients with hepatocellular carcinoma (HCC): subgroup analysis of the SHARP trial (abstract). Data presented at the 2008 ASCO Gastrointestinal Cancers Symposium, Orlando, FL, January 25-27, 2008. (abstract 129).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/102\">",
"      Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012; 57:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/103\">",
"      D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/104\">",
"      Abou-Alfa GK, Amadori D, Santoro A, et al. Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. Gastrointest Cancer Res 2011; 4:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/105\">",
"      Pinter M, Sieghart W, Graziadei I, et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009; 14:70.",
"     </a>",
"    </li>",
"    <li>",
"     Marrero JA, Lencioni R, Kudo M,  et al. Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) second interim analysis in more than 1500 patients: Clinical findings in patients with liver dysfunction (Abstract 4001). J Clin Oncol 2011; 29:256s. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=83600 (Accessed on July 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/107\">",
"      Raoul JL, Bruix J, Greten TF, et al. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol 2012; 56:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/108\">",
"      Otsuka T, Eguchi Y, Kawazoe S, et al. Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol Res 2012; 42:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/109\">",
"      Estfan B, Byrne M, Kim R. Sorafenib in Advanced Hepatocellular Carcinoma: Hypertension as a Potential Surrogate Marker for Efficacy. Am J Clin Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/110\">",
"      Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010; 304:2154.",
"     </a>",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/show/NCT01015833?term=sorafenib+and+doxorubicin+and+hepatocellular+cancer&amp;rank=3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/112\">",
"      Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008; 26:2992.",
"     </a>",
"    </li>",
"    <li>",
"     Malka D, Dromain C, Farace F, et al. Bevacizumab in patients with advanced hepatocellular carcinoma (HCC): preliminarhy results of a phase II study with circulating endothelial cell (CEC) monitoring (abstract). J Clin Oncol 2007; 25:215s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/114\">",
"      Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/115\">",
"      Hsu CH, Yang TS, Hsu C, et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 2010; 102:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/116\">",
"      Sun W, Sohal D, Haller DG, et al. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer 2011; 117:3187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/117\">",
"      Faivre S, Raymond E, Boucher E, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009; 10:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/118\">",
"      Barone C, Basso M, Biolato M, et al. A phase II study of sunitinib in advanced hepatocellular carcinoma. Dig Liver Dis 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/119\">",
"      Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009; 27:3027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/120\">",
"      Koeberle D, Montemurro M, Samaras P, et al. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist 2010; 15:285.",
"     </a>",
"    </li>",
"    <li>",
"     Cheng A, Kang Y, Lin D, et al. Phase III trial of sunitinib versus sorafenib in advanced hepatocellular carcinoma (HCC) (Abstract 4000). J Clin Oncol 2011; 29:256s. (Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=78796 (Accessed on July 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/122\">",
"      Philip PA, Mahoney MR, Allmer C, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005; 23:6657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/123\">",
"      Thomas MB, Chadha R, Glover K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007; 110:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/124\">",
"      Kaseb AO, Garrett-Mayer E, Morris JS, et al. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology 2012; 82:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/125\">",
"      Philip PA, Mahoney MR, Holen KD, et al. Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. Cancer 2012; 118:2424.",
"     </a>",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/show/NCT00881751?term=NCT00881751&amp;rank=1 (Accessed on November 11, 2011).",
"    </li>",
"    <li>",
"     Louafi S, et al. Gemcitabine, oxaliplatin (GEMOX) and cetuximab for treatment of hepatocellular carcinoma (HCC): results of the phase II study ERGO (abstract). J Clin Oncol 2007; 25:221s.",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/show/NCT01035229?term=HCC+and+everolimus+and+phase+III+trial&amp;rank=1 (Accessed on June 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/129\">",
"      Zhu AX, Abrams TA, Miksad R, et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 2011; 117:5094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/130\">",
"      Shiah HS, Chen CY, Dai CY, et al. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. Aliment Pharmacol Ther 2013; 37:62.",
"     </a>",
"    </li>",
"    <li>",
"     Verslype C, Cohn AL, Kelley RK, et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma: results from a phase II randomized discontinuation trial. J Clin Oncol 30, 2012 (suppl; abstract 4007). file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=95343 (Accessed on June 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/132\">",
"      Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013; 14:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/133\">",
"      Castells A, Bruix J, Br&uacute; C, et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995; 109:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/134\">",
"      Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme). Lancet 1998; 352:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/135\">",
"      Chow PK, Tai BC, Tan CK, et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology 2002; 36:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/136\">",
"      Nowak A, Findlay M, Culjak G, Stockler M. Tamoxifen for hepatocellular carcinoma. Cochrane Database Syst Rev 2004; :CD001024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/137\">",
"      Barbare JC, Bouch&eacute; O, Bonnetain F, et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 2005; 23:4338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/138\">",
"      Villa E, Ferretti I, Grottola A, et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer 2001; 84:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/139\">",
"      Villa E, Dugani A, Fantoni E, et al. Type of estrogen receptor determines response to antiestrogen therapy. Cancer Res 1996; 56:3883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/140\">",
"      Cheng AL, Chen YC, Yeh KH, et al. Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. Cancer 1996; 77:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/141\">",
"      Raderer M, Pidlich J, M&uuml;ller C, et al. A phase I/II trial of epirubicin and high dose tamoxifen as a potential modulator of multidrug resistance in advanced hepatocellular carcinoma. Eur J Cancer 1996; 32A:2366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/142\">",
"      Melia WM, Johnson PJ, Williams R. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treat Rep 1987; 71:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/143\">",
"      Farinati F, Gianni S, De Giorgio M, Fiorentini S. Megestrol treatment in patients with hepatocellular carcinoma. Br J Cancer 2001; 85:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/144\">",
"      Chao Y, Chan WK, Wang SS, et al. Phase II study of megestrol acetate in the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/145\">",
"      Chow PK, Machin D, Chen Y, et al. Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma. Br J Cancer 2011; 105:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/146\">",
"      Bl&auml;ker M, Schmitz M, Gocht A, et al. Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. J Hepatol 2004; 41:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/147\">",
"      Cebon J, Findlay M, Hargreaves C, et al. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer 2006; 95:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/148\">",
"      Kouroumalis E, Skordilis P, Thermos K, et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998; 42:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/149\">",
"      Yuen MF, Poon RT, Lai CL, et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002; 36:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/150\">",
"      Becker G, Allgaier HP, Olschewski M, et al. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 2007; 45:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/151\">",
"      Raderer M, Hejna MH, Muller C, et al. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int J Oncol 2000; 16:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/61/39898/abstract/152\">",
"      Barbare JC, Bouch&eacute; O, Bonnetain F, et al. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. Eur J Cancer 2009; 45:1788.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2486 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-425BDFC11D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_61_39898=[""].join("\n");
var outline_f38_61_39898=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Estimating life expectancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Response assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SYSTEMIC CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35286487\">",
"      Monotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Doxorubicin and mitoxantrone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Fluoropyrimidines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Gemcitabine, irinotecan, and thalidomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Combination chemotherapy regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Cisplatin-based",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Gemcitabine-based",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35286534\">",
"      - Oxaliplatin-based",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H35286602\">",
"      GEMOX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H35286632\">",
"      XELOX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H41195279\">",
"      FOLFOX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Interferon alfa and chemoimmunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - The PIAF regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - 5-FU plus IFNa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MOLECULARLY TARGETED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Sorafenib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Safety in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3776918\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Sorafenib plus doxorubicin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other agents targeting VEGF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Sunitinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Anti EGFR strategies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Small molecule TK inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Erlotinib plus bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Cetuximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13506074\">",
"      Investigational approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      HORMONE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Megestrol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Octreotide and lanreotide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H254793\">",
"      HEPATITIS B REACTIVATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2486\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2486|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?40/37/41567\" title=\"algorithm 1\">",
"      Treatment algorithm for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?11/36/11855\" title=\"algorithm 2\">",
"      Barcelona Rx algorithm HCC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2486|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/21/8540\" title=\"table 1\">",
"      Child Pugh classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/56/28557\" title=\"table 2\">",
"      Progn strat adv HCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/48/42764\" title=\"table 3\">",
"      RECIST response criteria solid tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/46/28396\" title=\"table 4\">",
"      Modified RECIST for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/20/5454\" title=\"table 5\">",
"      Chemo regimens met CRC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=related_link\">",
"      Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=related_link\">",
"      Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/24/6538?source=related_link\">",
"      Lamivudine monotherapy for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36362?source=related_link\">",
"      Liver transplantation for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36138?source=related_link\">",
"      Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/9/41114?source=related_link\">",
"      Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43063?source=related_link\">",
"      Overview of treatment approaches for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/42/44706?source=related_link\">",
"      Patient information: Liver cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/24/25992?source=related_link\">",
"      Staging and prognostic factors in hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/6/14442?source=related_link\">",
"      Surgical management of potentially resectable hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_61_39899="Predictors shunt outcome";
var content_f38_61_39899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F80958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F80958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Predictors of improvement after shunting",
"    <br>",
"     for normal pressure hydrocephalus",
"    </br>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Favorable indicators*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Early appearance of gait disorder",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gait disorder most prominent symptom",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Shorter duration of symptoms (&lt;6 months)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Identified etiology of NPH",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Positive findings on diagnostic tests:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       High resistance on CSF infusion test",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Clinical response to CSF removal (Tap test, Lumbar drain)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       B-waves comprising &gt;50 percent of tracing on continuous ICP monitoring",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Unfavorable indicators*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Early appearance of dementia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Moderate to severe dementia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dementia present for more than two years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gait disorder absent or appearing after dementia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alcoholism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       MRI findings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Marked white matter disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Diffuse sulcal enlargement",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Medial temporal atrophy",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Any one factor is not decisive in selecting patients for surgery.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_61_39899=[""].join("\n");
var outline_f38_61_39899=null;
var title_f38_61_39900="Potential uses of IVIG";
var content_f38_61_39900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F82262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F82262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disorders in which IVIG may be used",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Primary congenital hypogammaglobulinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary agammaglobulinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Common variable immunodeficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        X-linked agammaglobulinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe combined immune deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyper IgM syndromes, X-linked and others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgG subclass deficiencies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Secondary acquired antibody deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic lymphocytic leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parvovirus B19 infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allogeneic bone marrow transplantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Autoimmune disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Hematologic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Immune (ideopathic) thrombocytopenic purpura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Autoimmune neutropenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Autoimmune hemolytic anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Platelet alloimmunization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Heparin-associated thrombocytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Post-transfusion purpura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Neonatal isoimmune thrombocytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Autoimmune von Willebrand disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anti-factor VIII autoantibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Renal and vasculitic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Membranous nephropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        IgA nephropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        HUS-TTP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lupus nephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Granulomatosis with polyangiitis (Wegener's)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Kawasaki disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Neuromuscular disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Polymyositis and dermatomyositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Inclusion body myositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Guillain-Barre syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Myasthenia gravis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chronic idiopathic demyelinating polyneuropathy (CIDP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sensitization to HLA antigens prior to transplantation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_61_39900=[""].join("\n");
var outline_f38_61_39900=null;
var title_f38_61_39901="Contents: Bullous disease";
var content_f38_61_39901=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?2/59/3006\">",
"       Dermatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Bullous disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Bullous disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/11/22714\">",
"           Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/34/35369\">",
"           Dermatitis herpetiformis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/58/15273\">",
"           Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/47/4858\">",
"           Epidermolysis bullosa acquisita",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/38/42601\">",
"           Initial management of pemphigus vulgaris and pemphigus foliaceus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/36/14922\">",
"           Linear IgA bullous dermatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/43/3770\">",
"           Management and prognosis of bullous pemphigoid",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/39/39544\">",
"           Management of mucous membrane pemphigoid",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/12/26825\">",
"           Management of refractory pemphigus vulgaris and pemphigus foliaceus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/2/4138\">",
"           Ocular cicatricial pemphigoid",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/44/18121\">",
"           Paraneoplastic pemphigus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/44/19146\">",
"           Pathogenesis, clinical manifestations, and diagnosis of pemphigus",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-2007E5292C-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f38_61_39901=[""].join("\n");
var outline_f38_61_39901=null;
var title_f38_61_39902="Dilated cardiomyopathy short axis echocardiogram";
var content_f38_61_39902=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/68493/shaxdicm_conv.mp4?title=Dilated+cardiomyopathy+short+axis+echocardiogram\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dilated cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 271px; height: 207px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Short axis view from a 2-D echocardiogram of a dilated cardiomyopathy shows marked left dilatation of the left ventricle which is diffusely hypokinetic.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_61_39902=[""].join("\n");
var outline_f38_61_39902=null;
var title_f38_61_39903="Oriental cholangiohep ERCP";
var content_f38_61_39903=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Recurrent pyogenic cholangitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cholangiogram obtained during ERCP showing a massively dilated left hepatic system and common bile duct both of which are filled with stones (appearing as round lucencies).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hannah M Lee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_61_39903=[""].join("\n");
var outline_f38_61_39903=null;
